<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="review-article" dtd-version="2.3" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Oncol.</journal-id>
<journal-title>Frontiers in Oncology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Oncol.</abbrev-journal-title>
<issn pub-type="epub">2234-943X</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fonc.2024.1307839</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Oncology</subject>
<subj-group>
<subject>Review</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Targeting the DNA damage response in hematological malignancies</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>De Mel</surname>
<given-names>Sanjay</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<xref ref-type="author-notes" rid="fn001">
<sup>*</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/612138"/>
<role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lee</surname>
<given-names>Ainsley Ryan</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1706786"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Tan</surname>
<given-names>Joelle Hwee Inn</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Tan</surname>
<given-names>Rachel Zi Yi</given-names>
</name>
<xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Poon</surname>
<given-names>Li Mei</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Chan</surname>
<given-names>Esther</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lee</surname>
<given-names>Joanne</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Chee</surname>
<given-names>Yen Lin</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lakshminarasappa</surname>
<given-names>Satish R.</given-names>
</name>
<xref ref-type="aff" rid="aff5">
<sup>5</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/2583454"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Jaynes</surname>
<given-names>Patrick William</given-names>
</name>
<xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Jeyasekharan</surname>
<given-names>Anand D.</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref>
<xref ref-type="author-notes" rid="fn001">
<sup>*</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
</contrib-group>
<aff id="aff1">
<sup>1</sup>
<institution>Department of Haematology-Oncology, National University Cancer Institute, Singapore, National University Health System</institution>, <addr-line>Singapore</addr-line>, <country>Singapore</country>
</aff>
<aff id="aff2">
<sup>2</sup>
<institution>Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore</institution>, <addr-line>Singapore</addr-line>, <country>Singapore</country>
</aff>
<aff id="aff3">
<sup>3</sup>
<institution>NUS Center for Cancer Research (N2CR), Yong Loo Lin School of Medicine, National University Singapore</institution>, <addr-line>Singapore</addr-line>, <country>Singapore</country>
</aff>
<aff id="aff4">
<sup>4</sup>
<institution>Cancer Science Institute of Singapore, National University of Singapore</institution>, <addr-line>Singapore</addr-line>, <country>Singapore</country>
</aff>
<aff id="aff5">
<sup>5</sup>
<institution>Department of Anatomy, Yong Loo Lin School of Medicine, National University of Singapore</institution>, <addr-line>Singapore</addr-line>, <country>Singapore</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>Edited by: Mario I. Vega, University of California, Los Angeles, United States</p>
</fn>
<fn fn-type="edited-by">
<p>Reviewed by: Marla Weetall, PTC Therapeutics, United States</p>
<p>Francesca Cottini, The Ohio State University, United States</p>
</fn>
<fn fn-type="corresp" id="fn001">
<p>*Correspondence: Sanjay De Mel, <email xlink:href="mailto:sanjay_widanalage@nuhs.edu.sg">sanjay_widanalage@nuhs.edu.sg</email>; Anand D. Jeyasekharan, <email xlink:href="mailto:csiadj@nus.edu.sg">csiadj@nus.edu.sg</email>
</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>29</day>
<month>01</month>
<year>2024</year>
</pub-date>
<pub-date pub-type="collection">
<year>2024</year>
</pub-date>
<volume>14</volume>
<elocation-id>1307839</elocation-id>
<history>
<date date-type="received">
<day>05</day>
<month>10</month>
<year>2023</year>
</date>
<date date-type="accepted">
<day>03</day>
<month>01</month>
<year>2024</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2024 De Mel, Lee, Tan, Tan, Poon, Chan, Lee, Chee, Lakshminarasappa, Jaynes and Jeyasekharan</copyright-statement>
<copyright-year>2024</copyright-year>
<copyright-holder>De Mel, Lee, Tan, Tan, Poon, Chan, Lee, Chee, Lakshminarasappa, Jaynes and Jeyasekharan</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<abstract>
<p>Deregulation of the DNA damage response (DDR) plays a critical role in the pathogenesis and progression of many cancers. The dependency of certain cancers on DDR pathways has enabled exploitation of such through synthetically lethal relationships e.g., Poly ADP-Ribose Polymerase (PARP) inhibitors for BRCA deficient ovarian cancers. Though lagging behind that of solid cancers, DDR inhibitors (DDRi) are being clinically developed for haematological cancers. Furthermore, a high proliferative index characterize many such cancers, suggesting a rationale for combinatorial strategies targeting DDR and replicative stress. In this review, we summarize pre-clinical and clinical data on DDR inhibition in haematological malignancies and highlight distinct haematological cancer subtypes with activity of DDR agents as single agents or in combination with chemotherapeutics and targeted agents. We aim to provide a framework to guide the design of future clinical trials involving haematological cancers for this important class of drugs.</p>
</abstract>
<kwd-group>
<kwd>DNA damage</kwd>
<kwd>inhibitors</kwd>
<kwd>combination therapy</kwd>
<kwd>haematologic malignancies</kwd>
<kwd>clinical trials</kwd>
</kwd-group>
<counts>
<fig-count count="1"/>
<table-count count="5"/>
<equation-count count="0"/>
<ref-count count="177"/>
<page-count count="16"/>
<word-count count="9265"/>
</counts>
<custom-meta-wrap>
<custom-meta>
<meta-name>section-in-acceptance</meta-name>
<meta-value>Hematologic Malignancies</meta-value>
</custom-meta>
</custom-meta-wrap>
</article-meta>
</front>
<body>
<sec id="s1" sec-type="intro">
<title>Introduction</title>
<p>DNA damage occurs due to a variety of endogenous or exogenous insults, contributing to genomic instability, a hallmark of cancer (<xref ref-type="bibr" rid="B1">1</xref>, <xref ref-type="bibr" rid="B2">2</xref>). DNA damage response (DDR) pathways have therefore evolved to maintain genomic stability, which is essential for safe and stable transfer of genetic information during cell division (<xref ref-type="bibr" rid="B1">1</xref>). Cells have distinct, though partially overlapping, pathways dedicated for the repair of distinct forms of DNA damage. These include homologous recombination repair (HR) or non-homologous end joining (NHEJ) (for double strand breaks(DSB)); base excision repair (BER) (for Single strand breaks (SSB), modified bases and abasic sites); nucleotide excision repair (NER) (for UV-induced lesions, and helix distorting adducts), the Fanconi anemia complex (for repairing inter-strand cross links (ICL)) and mismatch repair (MMR) (for mis-incorporated bases, insertions and deletions) (<xref ref-type="bibr" rid="B1">1</xref>). For each pathway, a network of DNA damage sensors, transducers and effectors coordinate the identification and repair of DNA in concert with cell cycle progression (<xref ref-type="bibr" rid="B3">3</xref>, <xref ref-type="bibr" rid="B4">4</xref>).</p>
<p>Defects in DDR pathways foster the accumulation of other mutations and are thus an &#x201c;enabling hallmark&#x201d; of almost all cancers (<xref ref-type="bibr" rid="B2">2</xref>). However, tumors deficient in specific DDR pathways are often over-reliant on other intact DDR pathways for survival, which presents a potential Achilles heel for pharmacologic inhibition via the principle of synthetic lethality (<xref ref-type="bibr" rid="B5">5</xref>). A prominent example of this synthetic lethality is the efficacy of Poly (ADP ribose) polymerase 1(PARP1) inhibition in HR-deficient tumors (which are over-reliant on the PARP enzyme for repair of replication associated damage) (<xref ref-type="bibr" rid="B6">6</xref>). PARP inhibitors are currently the most advanced DDR inhibitor in terms of clinical development. Although the majority of the clinical data are in the space of epithelial cancer, PARP inhibitors and other DDR inhibitors targeting ATM, ATR, CHK1/2, WEE1 and DNA-PK are being studied in a variety of hematologic neoplasms (<xref ref-type="bibr" rid="B7">7</xref>, <xref ref-type="bibr" rid="B8">8</xref>). In this review, we highlight key data supporting DDR inhibition in hematologic malignancies and discuss the opportunities and challenges for the clinical application of these agents. We focus primarily on inhibitors of kinases involved in DSB repair (which constitute the largest group of agents), beginning with the apical kinases and then progress to downstream kinases. For each kinase &#x201c;node&#x201d;, we will discuss each malignancy in the following order: myeloid neoplasms, precursor lymphoid neoplasms, multiple myeloma, and mature lymphoproliferative disorders. An overview of the development of DDR inhibitors in haematologic malignancies is shown in <xref ref-type="fig" rid="f1"><bold>Figure 1</bold></xref>.</p>
<fig id="f1" position="float">
<label>Figure&#xa0;1</label>
<caption>
<p>Schematic summarizing the DDR is tested pre-clinically across all haematological malignancies. Created with <uri xlink:href="https://BioRender.com">BioRender.com</uri>.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fonc-14-1307839-g001.tif"/>
</fig>
</sec>
<sec id="s2">
<title>Pre-clinical data for DDR inhibitors in hematological cancers</title>
<sec id="s2_1">
<title>Targeting ATM</title>
<p>ATM is a kinase involved in the early signaling of DSBs and is one of the apical sensors of the DSB DDR cascade (<xref ref-type="bibr" rid="B9">9</xref>). Its activation results in cell cycle arrest, and impacts multiple downstream pathways including homologous recombination (HR) repair (<xref ref-type="bibr" rid="B10">10</xref>). ATM inactivation is a common event in hematological cancers, often coinciding with the loss of a section of the 11q chromosomal arm (<xref ref-type="bibr" rid="B11">11</xref>&#x2013;<xref ref-type="bibr" rid="B15">15</xref>). Aberrations at the ATM locus have been observed in Chronic Lymphocytic Leukemia (CLL) (<xref ref-type="bibr" rid="B11">11</xref>, <xref ref-type="bibr" rid="B12">12</xref>), T-cell prolymphocytic leukemia (T-PLL) (<xref ref-type="bibr" rid="B14">14</xref>, <xref ref-type="bibr" rid="B15">15</xref>) diffuse large B-cell lymphoma (DLBCL) (<xref ref-type="bibr" rid="B16">16</xref>), mantle cell lymphoma (MCL) (<xref ref-type="bibr" rid="B13">13</xref>, <xref ref-type="bibr" rid="B17">17</xref>) and cutaneous T cell lymphoma (CTCL) (<xref ref-type="bibr" rid="B18">18</xref>). In CLL, inactivating mutations in the remaining ATM allele, after 11q deletion, result in a worse prognosis than those with loss of one allele alone through 11q deletion (<xref ref-type="bibr" rid="B12">12</xref>). Downregulation of ATM expression has also been reported in <italic>IDH1</italic>-mutant AML patients (<xref ref-type="bibr" rid="B19">19</xref>). The high incidence of lymphoid malignancies in those with Ataxia Telangiectasia (<xref ref-type="bibr" rid="B20">20</xref>), in conjunction with the frequency of somatic ATM aberrations described previously, is supportive of the notion that ATM acts a tumor suppressor in hematological cancers.</p>
<p>While defects in ATM function are now recognized across these cancers, less is known about scenarios that depend on ATM activity- with potential for synthetic lethal targeting. In addition to its role in repairing DNA damage, ATM also has pro-apoptotic functions (<xref ref-type="bibr" rid="B21">21</xref>, <xref ref-type="bibr" rid="B22">22</xref>). This suggests that ATM has multidimensional roles in maintaining genomic stability and targeting this kinase could be a double-edged sword. This may be a reason why ATM inhibitors have not been as successful as many other DDR targeting cancer therapeutics. As such, there are hitherto no registered clinical trials for ATM inhibitors in hematological malignancies. Nevertheless, we summarize below, proof-of-principle data generated in preclinical systems which highlight potential clinical scenarios where ATM targeting can be explored.</p>
<sec id="s2_1_1">
<title>ATM inhibition in myeloid malignancies</title>
<p>ATM signaling ostensibly activates anti-apoptotic NF-kB signaling in an acute myeloid leukemia (AML) cell line, and treatment with the ATM inhibitor KU-55933 increased apoptosis (<xref ref-type="bibr" rid="B23">23</xref>). In support of this, CD34+ bone marrow mononuclear cells of high-risk AML patients also undergo apoptosis in response to ATM inhibition, with a concomitant decrease in NF-kB signaling (<xref ref-type="bibr" rid="B23">23</xref>). Along a similar vein, the ATM inhibitor, AZD0156 (AstraZeneca), synergized with an inhibitor of anti-apoptotic protein, BFL-1, to induce apoptosis of AML cells (<xref ref-type="bibr" rid="B24">24</xref>). AZD0156 treatment resulted in prolonged survival in a murine model of MLL-rearranged AML, a form of AML that is resistant to genotoxic therapy due to an ineffectual p53 response (<xref ref-type="bibr" rid="B25">25</xref>). The MLL-AF9 fusion gene leads to leukemogenesis through differentiation arrest (<xref ref-type="bibr" rid="B26">26</xref>). Interestingly, perturbation of ATM resulted in terminal differentiation of murine myeloid blasts expressing MLL-AF9 (<xref ref-type="bibr" rid="B26">26</xref>), providing rationale for the use of ATM inhibitors for treatment of MLL-rearranged AML. ATM signaling can also influence survival through interaction with other signaling pathways, for example, maintaining antioxidant capacity of the AML blasts via G6PD, resulting in FLT3 inhibitor resistance (<xref ref-type="bibr" rid="B27">27</xref>). Indeed, in FLT-3 ITD mutant AML, which possess FLT-3 activating mutations, the FLT-3 inhibitor, Quizartinib, was synthetically lethal with ATM loss (<xref ref-type="bibr" rid="B27">27</xref>). These data collectively highlight the potential for targeting ATM in AML, with the MLL rearranged subset being the most likely to benefit. The question of whether efficacy may be enhanced by combining ATM inhibitors with other targeted agents remains to be answered.</p>
</sec>
<sec id="s2_1_2">
<title>ATM inhibition in acute lymphoblastic leukemia</title>
<p>As with AML, ATM signaling to the NF-kB pathway promotes tumor survival in acute lymphoblastic leukemia (ALL). In ALL cell line models, chemotherapy upregulated chemoprotective cytokines in an ATM and NF-kB dependent manner (<xref ref-type="bibr" rid="B28">28</xref>). Congruent with this, inhibition of either ATM using KU-60019 or the NF-kB pathway using pyrrolidinedithiocarbamate ammonium (PDTC) enhanced chemo sensitivity in an ALL xenograft model (<xref ref-type="bibr" rid="B28">28</xref>). Similarly, inhibition of ATM using KU-55933 increased etoposide-induced apoptosis in Jurkat (T-lymphoblastic leukemia) cell lines, while sparing resting T-cells (<xref ref-type="bibr" rid="B29">29</xref>). Further studies are required to evaluate ATM inhibitors in MLL rearranged ALL, as with AML, the selection of optimal combinatorial partners is an important area for future investigation.</p>
</sec>
<sec id="s2_1_3">
<title>ATM inhibition in multiple myeloma and mature lymphoproliferative neoplasms</title>
<p>ATM inhibition through KU-55933 has been shown to have limited efficacy against multiple myeloma (MM) cells lines either alone (<xref ref-type="bibr" rid="B30">30</xref>, <xref ref-type="bibr" rid="B31">31</xref>) or in combination with doxorubicin (<xref ref-type="bibr" rid="B31">31</xref>). However, MEDI2228, a B-cell maturation antigen (BCMA) specific antibody conjugated with the DNA cross-linking agent tesirine, synergized with AZD0156 in MM cells lines (<xref ref-type="bibr" rid="B32">32</xref>). MEDI2228 also synergized with Bortezomib, a proteasome inhibitor that perturbs the NFkB pathway and is used as a standard of care for the treatment of MM (<xref ref-type="bibr" rid="B32">32</xref>). Synergy with both AZD0156 and Bortezomib is consistent with the observation in AML/ALL cells that ATM signals to the NFkB pathway (see above for AML/ALL). Further studies exploring the interplay between ATM, NF-kB and proteasome function in MM are required. With BCMA targeting immunotherapies becoming a vital part of MM treatment (<xref ref-type="bibr" rid="B33">33</xref>), their synergy with ATM inhibition would be of great interest and should be evaluated in future studies.</p>
<p>In Mantle Cell Lymphoma (MCL) cell lines, the combination of the ATM inhibitor KU-60019 with the histone deacetylase (HDAC) inhibitor Romidepsin (<xref ref-type="bibr" rid="B34">34</xref>) was found to be synergistic via downregulation of the CDK inhibitor p21 (<xref ref-type="bibr" rid="B35">35</xref>). Future studies should evaluate the combination of ATM inhibitors with Bruton Tyrosine Kinase (BTK) and BH3 mimetics in MCL as these combinations are more likely to be taken forward into clinical trials.</p>
</sec>
</sec>
<sec id="s2_2">
<title>Targeting ATR</title>
<p>ATR is an apical DDR kinase that is critical for initiating cell cycle arrest specifically in the context of replication stress (<xref ref-type="bibr" rid="B9">9</xref>). ATR is also postulated to have a direct role in HR repair (<xref ref-type="bibr" rid="B36">36</xref>). Unlike with ATM, ATR-initiated signaling is not commonly disrupted in hematologic malignancies (<xref ref-type="bibr" rid="B37">37</xref>). In fact, it is often observed to be augmented, for example, in murine BCR-Abl+ myeloid cells and primary chronic myeloid leukemia (CML) cells (<xref ref-type="bibr" rid="B37">37</xref>). A subset of MM characterized by chromosomal instability also has an enrichment of genes in the ATR signaling axis (<xref ref-type="bibr" rid="B38">38</xref>). In this malignancy, ATR signaling has also been implicated in resistance to the alkylating agent, melphalan, as observed in a resistant MM cell line (<xref ref-type="bibr" rid="B39">39</xref>). In contrast to ATM inhibitors, ATR inhibitors are at a more advanced phase of clinical development. The pre-clinical rationale for their use is described below.</p>
<sec id="s2_2_1">
<title>ATR inhibition  in myeloid malignancies</title>
<p>The ATR inhibitor AZ20 has antitumor activity against AML with MLL rearrangements in both <italic>in vitro</italic> models (mouse), and <italic>in vivo</italic> allograft and human xenograft mouse models (<xref ref-type="bibr" rid="B25">25</xref>). In MLL-AF9 expressing murine myeloid blasts, perturbation of ATR resulted in terminal differentiation in a similar manner to ATM inhibition (described above) (<xref ref-type="bibr" rid="B26">26</xref>), suggesting that like with ATM inhibitors, ATR inhibitors will be effective against this subgroup of AML.</p>
<p>ATR inhibitors synergize with a wide variety of agents in AML. The ATR inhibitors AZ20 and AZD6738 (AstraZeneca) combined with the replication stress-inducing agent, cytarabine, were both shown to be synergistic against AML cell lines and primary patient samples (<xref ref-type="bibr" rid="B40">40</xref>). This combination resulted in abrogation of the G2/M checkpoint and increased replication stress (represented by increased &#x3b3;H2AX and increased RPA32-bound chromatin), leading to increased apoptosis (<xref ref-type="bibr" rid="B40">40</xref>). In a similar manner, the activity of the ATR inhibitor VE-821 was potentiated by other replication stress inducers, hydroxyurea and gemcitabine, in AML cell lines and primary samples coinciding with abrogation of ribonucleotide reductase (RNR) expression and inhibition of replication fork progression (<xref ref-type="bibr" rid="B41">41</xref>). The efficacy of this combination was demonstrated in AML xenografts where VX-970 (an orally bioavailable derivative of VE-821 [Merck]) in combination with gemcitabine induced a significant reduction in graft growth and higher survival rates (<xref ref-type="bibr" rid="B41">41</xref>). The combination of VX-970 with hydroxyurea would be an attractive all-oral low-intensity therapeutic option for clinical trials in elderly patients with AML.</p>
<p>RNA polymerase I (Pol I) has been shown to have greater transcriptional activity in AML cells as compared to normal myeloid precursors (<xref ref-type="bibr" rid="B42">42</xref>). Inhibition of Pol I promotes G2/M arrest by activating the ATR checkpoint, implying that ATR inhibitors would be appropriate combinatorial candidates (<xref ref-type="bibr" rid="B42">42</xref>). Indeed, AZD6738 was shown to be synergistic with Pol I inhibitor, CX5461, in AML cell lines and primary AML samples (<xref ref-type="bibr" rid="B42">42</xref>). Finally, the combination of WEE1 inhibition (using AZD1775 (AstraZeneca)) with ATR inhibition (using VE-822) in AML cell lines led to apoptosis via disruption of the G2/M checkpoint and increased replication stress (<xref ref-type="bibr" rid="B43">43</xref>). The above data suggest that combining ATR inhibition with replication stress inducers may be an effective strategy for treating AML.</p>
</sec>
<sec id="s2_2_2">
<title>ATR inhibition in acute lymphoblastic leukemia</title>
<p>In acute leukemias, VE-822 treatment resulted in reduced output from both RNR and deoxycytidine kinase (dCK) pathways of deoxynucleotide synthesis in ALL cells, with the combination of VE-822 with RNR and dCK inhibition (with 3-AP and DI-82, respectively) being lethal (<xref ref-type="bibr" rid="B44">44</xref>). The combination of ATR inhibition and interference with deoxynucleotide triphosphate synthesis is thus a promising strategy for evaluation. In B-ALL cells, as with AML, the pol 1 inhibitor CX5461 activates the ATR pathway and mediates G2 checkpoint arrest, and thus induced apoptosis synergistically in combination with VE-822 (<xref ref-type="bibr" rid="B45">45</xref>), providing another alternative combination strategy through exacerbation of replication stress. Treatment of ALL cell lines and primary ALL cells with VE-821 in combination with doxorubicin also proved effective (<xref ref-type="bibr" rid="B46">46</xref>).</p>
<p>In an <italic>in vitro</italic> and <italic>in vivo</italic> murine model of infant B-ALL with concomitant activated Ras, AZ20 was synergistic with MEK inhibition (using trametinib), which was corroborated in PDX mouse models (<xref ref-type="bibr" rid="B47">47</xref>). The recent discovery that T-ALL with BRCA2 mutations were vulnerable to VE-821 and AZ6738 (<xref ref-type="bibr" rid="B48">48</xref>) confirms that reliable biomarkers of sensitivity to ATR inhibition would augment the clinical application of these agents in acute leukemias.</p>
</sec>
<sec id="s2_2_3">
<title>ATR inhibition in multiple myeloma</title>
<p>Increased replicative stress leading to dependency on ATR signaling is well described in MM (<xref ref-type="bibr" rid="B31">31</xref>, <xref ref-type="bibr" rid="B38">38</xref>), with efficacy of VE-821 and VX-970 demonstrated against MM cell lines and patient samples (<xref ref-type="bibr" rid="B31">31</xref>, <xref ref-type="bibr" rid="B38">38</xref>). The alkylator, melphalan, which is frequently used for MM treatment, has shown good synergy with VX-970 <italic>in vitro</italic> and in an <italic>in vivo</italic> orthotopic MM mouse model (<xref ref-type="bibr" rid="B31">31</xref>). Combinatorial treatment of VX-970 or VE-821 and ATM inhibitor, KU-55933, demonstrated increased cell death in some MM cell lines (<xref ref-type="bibr" rid="B30">30</xref>, <xref ref-type="bibr" rid="B31">31</xref>). However, the greater single agent efficacy seen with ATR inhibitors, compared to ATM inhibitors (see above), suggests that MM is more vulnerable to perturbations in pathways required for managing replication stress. AZD6738 was synergistic with antibody drug conjugate, MEDI2228, in MM cells similar to ATM inhibitor-MEDI2228 combinations (<xref ref-type="bibr" rid="B32">32</xref>), suggesting focused exposure to DNA damaging payloads may increase the dependence of MM on both DNA damaging pathways.</p>
</sec>
<sec id="s2_2_4">
<title>ATR inhibition in mature lymphoid neoplasms</title>
<p>AZD6738 treatment induced mitotic catastrophe in ATM and p53 defective CLL cells and was synergistic with chemotherapy, these findings being corroborated in xenograft models (<xref ref-type="bibr" rid="B49">49</xref>). Synergy between ATR inhibition and defective ATM was also observed in ATM-deficient MCL xenografts treated with AZD6738 (<xref ref-type="bibr" rid="B50">50</xref>). AZD6738 was also shown to synergize with CHK1 (AZD7762 [Astra Zeneca]) or WEE1 (AZD1775[Astra Zeneca]) inhibitors against MCL and diffuse large B cell lymphoma (DLBCL) <italic>in vitro</italic> and <italic>in vivo (</italic>
<xref ref-type="bibr" rid="B51">51</xref>). In this context, the efficacy of ATR inhibition and synergy of the combinations was independent of ATM, TP53 and MYC mutational/expression status (<xref ref-type="bibr" rid="B51">51</xref>). AZD6738 demonstrates efficacy in non-GCB DLBCL cell lines that harbor CDKN2A deletion and high MYC expression (<xref ref-type="bibr" rid="B52">52</xref>). A xenograft model using these cell lines also demonstrated efficacy with AZD6738 and that synergy was possible in combination with AZD1775 or Rituximab and Bendamustine (R-Benda) (<xref ref-type="bibr" rid="B52">52</xref>).</p>
<p>The ATR inhibitor BAY 1895344 (Bayer) showed efficacy activity against certain lymphoma cell lines and in MCL xenograft models (<xref ref-type="bibr" rid="B53">53</xref>). Importantly, the <italic>in vivo</italic> efficacy of this agent appeared greater than that of AZD6738 and the ATR inhibitor, VX-970, suggesting promise for further development (<xref ref-type="bibr" rid="B53">53</xref>). In cutaneous T-cell lymphoma cell lines, VE-821 or VE-822 was synergistic with phototherapy, suggesting an potential combination for evaluation in trials (<xref ref-type="bibr" rid="B54">54</xref>). Given their high level of replication stress, ATR inhibition is more likely to be successful in aggressive lymphomas with a high proliferative index, and these should be prioritized for future clinical trials.</p>
</sec>
</sec>
<sec id="s2_3">
<title>Targeting DNA PK</title>
<p>DNA-PK, another apical kinase in the DDR pathway, is a sensor of DSB more prominently in G1 when non-homologous end joining (NHEJ) is in operation (<xref ref-type="bibr" rid="B55">55</xref>). DNA-PK is also an important component of the cellular response to replication stress, and is known to be required for activation of CHK1 and CHK2 (<xref ref-type="bibr" rid="B56">56</xref>). As with ATR, the activity of this kinase appears to be largely intact across the hematological malignancies. Overexpression of DNA-PK (both at the mRNA and protein level) has been shown to confer an inferior prognosis in CLL patients (<xref ref-type="bibr" rid="B57">57</xref>, <xref ref-type="bibr" rid="B58">58</xref>), suggesting this kinase as a potential target for some hematological malignancies. However, there are currently no clinical trials for DNA-PK inhibitors in this context. The pre-clinical evidence underlying the rationale for DNA-PK inhibitors in hematological malignancies is outlined below.</p>
<sec id="s2_3_1">
<title>DNA-PK inhibition in acute leukemias</title>
<p>The DNA PK inhibitor NU7026 augmented the activity of topoisomerase II poisons against myeloid leukemia cells lines (<xref ref-type="bibr" rid="B59">59</xref>). Similarly M3814, a selective DNA-PK inhibitor, potentiated the activity of ionizing radiation as well as the anthracycline topoisomerase II inhibitor, daunorubicin, alone or in combination with cytarabine, in AML cell lines and an AML PDX mouse model; this potentiation was only observed in p53 wild type AML cells (<xref ref-type="bibr" rid="B60">60</xref>). M3814 also enhanced the activity of DNA damaging agent, calicheamicin, in AML cells as well as the activity of antibody drug conjugate gemtuzumab ozogomycin in AML xenograft mouse models (<xref ref-type="bibr" rid="B61">61</xref>). This combination would be promising for evaluation in clinical trials of relapsed or refractory AML and elderly patients who are not eligible for intensive chemotherapy. DNA PK is also overexpressed in B-ALL and in this context the DNA-PK inhibitor NU7441 potentiated apoptosis in combination with doxorubicin (<xref ref-type="bibr" rid="B62">62</xref>), suggesting the potential for a combination trial.</p>
</sec>
<sec id="s2_3_2">
<title>DNA-PK inhibition in multiple myeloma</title>
<p>NU7026 showed modest activity against MM cells as a single agent but potentiated the effect of doxorubicin, suggesting that MM cells rely on DNA-PK to repair anthracycline induced DSB (<xref ref-type="bibr" rid="B63">63</xref>). NU7026 also potentiated the activity of ionizing radiation on MM cells both as a single agent and in combination with PARP inhibitor, AG14361(Pfizer) (<xref ref-type="bibr" rid="B64">64</xref>). Conversely, a separate study suggested that NU7026 improved the survival of MM cell lines treated with radiation (<xref ref-type="bibr" rid="B65">65</xref>). These heterogenous results seen with DNA-PK inhibition in MM highlight the need for analysis of DNA-PK inhibitors in a larger breadth of MM models before clinical evaluation.</p>
</sec>
<sec id="s2_3_3">
<title>DNA-PK inhibition in mature lymphoid neoplasms</title>
<p>Deletions of the short arms of chromosomes 11 and 17 are makers of treatment refractoriness in CLL (<xref ref-type="bibr" rid="B57">57</xref>), contributing to the loss of function of ATM (<xref ref-type="bibr" rid="B11">11</xref>, <xref ref-type="bibr" rid="B12">12</xref>) and p53 (<xref ref-type="bibr" rid="B66">66</xref>, <xref ref-type="bibr" rid="B67">67</xref>), respectively. Overexpression of DNA-PK was consistently associated with del(11p) and del(17p) and this overexpression (both at the mRNA and protein level) conferred an inferior prognosis in CLL patients (<xref ref-type="bibr" rid="B57">57</xref>, <xref ref-type="bibr" rid="B58">58</xref>). NU7441 could sensitize patient cells to fludarabine, chlorambucil (<xref ref-type="bibr" rid="B57">57</xref>) and mitoxantrone (<xref ref-type="bibr" rid="B58">58</xref>), proffering a strategy to overcome this refractoriness. CC-115 is a dual mammalian target of rapamycin (mTOR) kinase and DNA-PK inhibitor that demonstrated efficacy in CLL patient cells, inducing apoptosis and suppressing cellular proliferation, irrespective of ATM or TP53 mutations (<xref ref-type="bibr" rid="B68">68</xref>).</p>
<p>With respect to T-cell lymphomas, the prevalence of DSBs and overreliance on NHEJ in Adult T-cell leukemia lymphoma (ATLL) makes it an attractive target for DNA PK inhibition (<xref ref-type="bibr" rid="B69">69</xref>, <xref ref-type="bibr" rid="B70">70</xref>). The dual DNA-PK and topoisomerase II inhibitor, NK314 was active against ATLL <italic>in vitro</italic> and <italic>in vivo (</italic>
<xref ref-type="bibr" rid="B71">71</xref>). These data provide the basis for clinical trials of DNA-PK inhibition for ATLL, a malignancy that has limited therapeutic options.</p>
</sec>
</sec>
<sec id="s2_4">
<title>Targeting CHK1/CHK2</title>
<p>CHK1 and CHK2 are effector proteins downstream of the apical kinases ATR and ATM, transmitting the DNA damage signals that lead to cell cycle arrest, facilitating DNA repair and promoting cell survival (<xref ref-type="bibr" rid="B9">9</xref>). CHK1 is a vital kinase in the replication stress response, mediating S phase check point activation, replication fork stabilization and DNA repair in response to ATM signaling (<xref ref-type="bibr" rid="B1">1</xref>).Mutations in the CHK kinases are not apparent in hematological malignancies and as with other nodes of the DDR signaling appears largely intact. In fact, increased CHK1 activity is observed in AML patient samples with complex karyotypes (<xref ref-type="bibr" rid="B72">72</xref>). Prolonged or increased CHK1 signaling is also seen in CML patient samples and murine myeloid BCR-Abl+ cell lines upon DNA damage, compared to non-transformed samples (<xref ref-type="bibr" rid="B37">37</xref>). In T/B ALL patient samples and cells lines, the CHK1 protein itself is overexpressed and constitutively active (<xref ref-type="bibr" rid="B73">73</xref>, <xref ref-type="bibr" rid="B74">74</xref>). Importantly, overexpression CHK1 has been associated with poor prognosis in AML and resistance to cytotoxic agents in AML patient samples (<xref ref-type="bibr" rid="B75">75</xref>).</p>
<p>The development of CHK1 inhibitors spans more than two decades, however, invariably CHK1 inhibition as a monotherapy has resulted in modest effects and combination with traditional genotoxic agents results in unacceptable toxicities (<xref ref-type="bibr" rid="B76">76</xref>). Nevertheless, as described below, numerous biomarker-based or combinatorial strategies have been evaluated preclinically to exploit the anti-cancer activity of CHK inhibitors.</p>
<sec id="s2_4_1">
<title>CHK1/CHK2 inhibition in myeloid malignancies</title>
<p>AZD7762(AstraZeneca) is an ATP-competitive inhibitor of both CHK1 and CHK2 (<xref ref-type="bibr" rid="B77">77</xref>) which induced apoptosis in AML cell lines as well as primary samples. The effect was particularly pronounced in cases with complex cytogenetics as well as FLT-3 ITD mutated cell lines (<xref ref-type="bibr" rid="B78">78</xref>, <xref ref-type="bibr" rid="B79">79</xref>). As seen with ATR inhibitors, cytarabine synergized with CHK1 inhibitor MK-8776 (Merck). Incorporation of cytarabine into DNA led to replication associated damage and activation of the ATR/CHK1 pathway, leveraging on the role of CHK1 in the replication stress response (<xref ref-type="bibr" rid="B80">80</xref>). In keeping with these data, MK-8776 in combination with cytarabine, led to reduced proliferation and impaired replication fork progression in AML blasts (<xref ref-type="bibr" rid="B75">75</xref>). It is noteworthy that MK-8776 also potentiated the effects of HDAC inhibitors in AML cell lines (<xref ref-type="bibr" rid="B81">81</xref>). The observation that granulocyte colony stimulating factor (GCSF) could force quiescent leukemic cells into the cell cycle and sensitize them to a CHK1 inhibitor (GDC-0575; Genentech)/cytarabine combination adds another interesting possibility for clinical evaluation (<xref ref-type="bibr" rid="B82">82</xref>).</p>
</sec>
<sec id="s2_4_2">
<title>CHK1/CHK2 inhibition in acute lymphoblastic leukemia</title>
<p>While CHK1 inhibitors have a wide cytotoxicity profile, leukemia cell lines were shown to be more sensitive to selective CHK1 inhibition (V158411 [Vernalis]) than lung and colon cancer cell lines (<xref ref-type="bibr" rid="B83">83</xref>). CHK1 is overexpressed and constitutively active in ALL cell lines and patient samples (<xref ref-type="bibr" rid="B73">73</xref>, <xref ref-type="bibr" rid="B74">74</xref>). Inhibition of CHK1 with PF-0477736 (Pfizer) in this context resulted in reduced viability in cancer cell lines, but not in normal cells (<xref ref-type="bibr" rid="B73">73</xref>, <xref ref-type="bibr" rid="B74">74</xref>). These results were corroborated in a xenograft mouse model (<xref ref-type="bibr" rid="B73">73</xref>) and an allograft mouse model (<xref ref-type="bibr" rid="B74">74</xref>) suggesting potential for clinical translation if a dosing schedule with minimal toxicity can be established. The CHK1 inhibitor prexasertib (Eli Lilly) exhibited single agent activity against both ALL cell lines and primary leukemic blasts, but not in healthy patient mononuclear cells (<xref ref-type="bibr" rid="B84">84</xref>). In cell lines prexasertib was synergistic with the tyrosine kinase inhibitor, imatinib, and purine nucleoside antimetabolite, clofarabine, with the prexasertib/imatinib combination also showing activity against primary leukemic blasts (<xref ref-type="bibr" rid="B84">84</xref>). Prexasertib, also acted as chemosensitizer in combination with doxorubicin in ALL cell lines and primary ALL cells (<xref ref-type="bibr" rid="B46">46</xref>). The combination of CHK1 inhibition with other targeted agents as well as immunotherapies against ALL are likely to be more promising than their combination with cytotoxic agents given the hematologic toxicity and the chemo resistant nature of the relapsed ALL.</p>
</sec>
<sec id="s2_4_3">
<title>CHK1/CHK2 inhibition in multiple myeloma</title>
<p>Targeting of CHK1 and CHK2 is also being actively studied in MM. AZD7762 was investigated in MM cell lines (including those with <italic>TP53</italic> loss) in combination with melphalan, bendamustine and doxorubicin (<xref ref-type="bibr" rid="B85">85</xref>). Combination with the CHK1 inhibitor potentiated the efficacy of all three cytotoxic agents confirming the hypothesis that MM cells rely on CHK1 to overcome DNA damage. It is noteworthy that AZD7762 did not synergize with bortezomib in this study. Given that PARP inhibitors <italic>do</italic> synergize with proteasome inhibitors in MM, this contrast highlights the need for clinical trials of DDR inhibitor combinations in MM to be guided by pre-clinical studies (<xref ref-type="bibr" rid="B85">85</xref>). Dai et&#xa0;al. proposed that inhibition of src could potentiate the activity of CHK1 inhibitors in MM, based on the observation that Chk1 inhibition activates the Ras/MEK/ERK pathway in this disease (<xref ref-type="bibr" rid="B86">86</xref>). Supporting this hypothesis, treatment with the src inhibitor dasatinib augmented sensitivity to CHK1 inhibition (with UCN-01) in MM cell lines, primary CD138+ cells from MM patients, and mouse xenograft mouse models (<xref ref-type="bibr" rid="B86">86</xref>).</p>
</sec>
<sec id="s2_4_4">
<title>CHK1/CHK2 inhibition in mature lymphoid neoplasms</title>
<p>Lymphoma cell lines, like leukemia cell lines, were shown to be more sensitive to selective CHK1 inhibition (with V158411) than lung and colon cell lines (<xref ref-type="bibr" rid="B83">83</xref>). MK-8776 enhanced the cytotoxicity of a variety of nucleoside analogs (fludarabine, cytarabine, gemcitabine) against CLL cell lines, including those with <italic>TP53</italic> mutations (<xref ref-type="bibr" rid="B87">87</xref>). More recently, MU380, an analogue of MK-8776, had potent single agent activity against <italic>TP53</italic> deficient CLL cells (<xref ref-type="bibr" rid="B88">88</xref>). These studies indicate the significant potential of CHK1 inhibition against high risk CLL, which remains an unmet clinical need.</p>
<p>AZD7762 treatment induces rapid DNA damage accumulation and apoptosis in DLBCL cell lines as well as primary samples (<xref ref-type="bibr" rid="B89">89</xref>). AZD7762 treatment also leads to apoptosis in MYC-deregulated mouse B-cell lymphoma cells <italic>in vitro</italic> and mitigates disease progression of p53 knockout, MYC deregulated B cell lymphoma transplant mouse models <italic>in vivo (</italic>
<xref ref-type="bibr" rid="B90">90</xref>). There was also a striking synergy with the PARP inhibitor, veliparib (AbbVie), in this setting (<xref ref-type="bibr" rid="B90">90</xref>).The role of CHK1 in the induction of HR following DSB (<xref ref-type="bibr" rid="B91">91</xref>) may be a plausible mechanism for the synergy of AZD7762 and veliparib but further studies would be required to verify this.</p>
<p>The dual CHK1/CHK2 inhibitor, PF-0477736 (Pfizer), is active in DLBCL cell lines and primary patient samples and also sensitizes <italic>TP53</italic> mutant DLBCL cell lines to doxorubicin (<xref ref-type="bibr" rid="B89">89</xref>). Notably, transfection of <italic>TP53</italic> wild-type cell lines with dominant-negative p53 did not result in increased sensitivity to PF-0477736 alone or with doxorubicin suggesting that this sensitivity is dependent on p53 loss, rather than p53 inactivation alone (<xref ref-type="bibr" rid="B89">89</xref>). CHK2 has also been noted to demonstrate cross-talk with ERK1/2 in DLBCL, with synergistic cytotoxicity of combined ERK and CHK2 inhibition in DLBCL cell lines, primary samples and <italic>in vivo</italic> models suggesting strong potential for clinical translation (<xref ref-type="bibr" rid="B92">92</xref>). In the E&#xb5;MYC murine lymphoma model, disruption to the in the NF-&#x3ba;B pathway was correlated with resistance to CHK1 inhibition (<xref ref-type="bibr" rid="B93">93</xref>, <xref ref-type="bibr" rid="B94">94</xref>). While these findings warrant validation in primary DLBCL specimens, they provide promise of generating robust biomarkers for use in clinical trials.</p>
<p>In MCL, PF-0477736 showed synergy with ibrutinib in sensitive cell lines, but only achieved cytostatic responses in ibrutinib resistant cell lines (<xref ref-type="bibr" rid="B95">95</xref>). A CHK1i-resistant MCL cell line (JEKO-1R), developed to be resistant to both PF-0477736 and AZD7762 (<xref ref-type="bibr" rid="B96">96</xref>), had an increased expression of genes involving pro-survival pathways and reduced cyclin D1 expression. Partial restoration of sensitivity to CHK1 inhibition by dasatinib treatment suggests that simultaneous targeting of other oncogenic signaling is worthy of exploration in combination with CHK1 inhibitors (<xref ref-type="bibr" rid="B96">96</xref>). Given the overlapping toxicity of CHK1 inhibitors and chemotherapy, combination strategies with other targeted agents could represent a promising opportunity.</p>
</sec>
</sec>
<sec id="s2_5">
<title>Targeting WEE1</title>
<p>WEE1 is a substrate in the DDR response cascade downstream of CHK1 (<xref ref-type="bibr" rid="B97">97</xref>). Its primary role is to prevent mitotic entry upon DDR by phosphorylating CDK1 to inhibit its function, and ultimately causing cell cycle arrest in G2 (<xref ref-type="bibr" rid="B97">97</xref>). WEE1 also plays an important role in the replication stress response, functioning similarly to CHK1 in maintaining genomic stability (<xref ref-type="bibr" rid="B1">1</xref>). Elevated expression of WEE1 has been observed in primary ALL patient samples and cell lines compared to normal mononuclear cells and bone marrow cells (<xref ref-type="bibr" rid="B98">98</xref>, <xref ref-type="bibr" rid="B99">99</xref>), but otherwise this signaling axis is ostensibly functional across hematological malignancies. WEE1 inhibitors have reached clinical trials, though at least one has been terminated due to safety concerns (see <xref ref-type="table" rid="T1">
<bold>Table&#xa0;1</bold>
</xref>). Several WEE1 inhibitors have been tested preclinically in hematological malignancies, and the results are discussed below.</p>
<table-wrap id="T1" position="float">
<label>Table&#xa0;1</label>
<caption>
<p>List of ongoing or completed clinical trials of WEE1 inhibitors in advanced hematological malignancies.</p>
</caption>
<table frame="hsides">
<thead>
<tr>
<th valign="top" align="left">Pathway</th>
<th valign="top" align="left">Compounds</th>
<th valign="top" align="left">Latest Stage of Development and Trial Details</th>
<th valign="top" align="left">Clinical Trial Identifier(s)</th>
<th valign="top" align="left">Current Status (Ongoing or Published include reference if published)</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="top" rowspan="2" align="left">Targeting WEE 1</td>
<td valign="top" align="left">AZD1775</td>
<td valign="top" align="left">Phase II as monotherapy or in combination with cytarabine in patients with AML and MDS</td>
<td valign="top" align="left">NCT02666950</td>
<td valign="top" align="left">Completed(not published)</td>
</tr>
<tr>
<td valign="top" align="left">AZD1775</td>
<td valign="top" align="left">Phase II as monotherapy or in combination with Ara-C (cytarabine) in advanced AML, MDS and myelofibrosis</td>
<td valign="top" align="left">NCT03718143</td>
<td valign="top" align="left">Terminated (Safety concerns) Not published</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>The compounds targeting the checkpoint inhibitor pathway and its latest stage of development along with the trial details are indicated. AML, Acute Myeloid Leukemia; MDS, Myelodysplastic syndrome.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<sec id="s2_5_1">
<title>WEE1 inhibition in myeloid malignancies</title>
<p>While WEE1 inhibition as monotherapy appears to only have modest effects in AML cell lines, the WEE1 inhibitor AZD1775 (AstraZeneca) shows evidence of synergy with the PARP inhibitor olaparib (AstraZeneca) in primary AML samples as well as murine models (<xref ref-type="bibr" rid="B100">100</xref>), suggesting possibilities for DDRi combination trials in AML. Along these lines, siRNA knockdown of CHK1 and ATR enhanced the activity of AZD1775 against AML cells <italic>in vitro (</italic>
<xref ref-type="bibr" rid="B101">101</xref>). Similarly, combined treatment with inhibitors of CHK1 (MK-8776) and WEE1 (AZD1775) was synergistic against AML cells, likely through abrogation of the replication stress response. This data provides a potential rationale for evaluation of this combination in clinical trials, although overlapping toxicity will be a concern. AZD1775 has been shown to synergize with HDAC inhibitors (panobinostat, vorinostat and SBHA) against AML cells, independent of p53 status (<xref ref-type="bibr" rid="B102">102</xref>, <xref ref-type="bibr" rid="B103">103</xref>). Importantly, this combination was shown to have no effect on normal CD34+ progenitors (<xref ref-type="bibr" rid="B102">102</xref>), and may thus have a favorable toxicity profile compared to the WEE1-CHK1 inhibitor combination.</p>
</sec>
<sec id="s2_5_2">
<title>WEE1 inhibition in acute lymphoblastic leukemia</title>
<p>WEE1 inhibition through AZD1775 induces apoptosis as a single agent in primary samples of B and T- ALL (<xref ref-type="bibr" rid="B98">98</xref>). As with AML, described above, combinations of WEE1 inhibitors with other DDR inhibitors appear active in ALL. A combination of olaparib and AZD1775 was synergistic against ALL cells <italic>in vitro</italic> (<xref ref-type="bibr" rid="B100">100</xref>) and a combination of the CHK1 inhibitor PF-0477736 with AZD1775 showed synergy against primary ALL samples (<xref ref-type="bibr" rid="B104">104</xref>). WEE1 inhibition also induced changes in the metabolism of T-ALL cells resulting in increased dependence on glutaminolysis. Dual inhibition of WEE1(with AZD1775) and glutaminase (with BPTES) showed synergy in T-ALL cell lines, and in patient-derived xenograft mouse models, supporting this hypothesis (<xref ref-type="bibr" rid="B99">99</xref>). Further studies exploring alterations in cellular metabolism during DDR inhibition are warranted.</p>
<p>For immediate clinical development, combinations of WEE1 inhibition with chemotherapeutics are promising. AZD1775 synergized with cytarabine, among other cytotoxic agents, against T-ALL cell lines and cell line xenograft models (<xref ref-type="bibr" rid="B105">105</xref>). In ALL cell lines, AZD1775 synergized with doxorubicin to induce apoptosis associated with increased mitotic entry and deregulation of the NOTCH pathway, with minimal effects on normal progenitors (<xref ref-type="bibr" rid="B106">106</xref>).These data support the combination of WEE1 inhibitors with conventional chemotherapeutics for evaluation in clinical trials of relapsed or refractory ALL.</p>
</sec>
<sec id="s2_5_3">
<title>WEE1 inhibition in multiple myeloma</title>
<p>AZD1775 has single agent activity against bortezomib/lenalidomide resistant MM cell lines and patient samples, inducing apoptosis regardless of p53 status (<xref ref-type="bibr" rid="B107">107</xref>). AZD1775 also sensitized MM cells to bortezomib and synergized with the HDAC inhibitor, vorinostat, indicating potential strategies for combination trials (<xref ref-type="bibr" rid="B108">108</xref>). Separately, WEE1 inhibition may also be a combination partner for antibody-drug conjugates. MEDI2228 (described previously in the ATM section) induces significant levels of DNA damage with DDR pathway activation and reduces the viability of both cell lines and patient samples (<xref ref-type="bibr" rid="B32">32</xref>). Inhibition of WEE1 was shown to synergize with MEDI2228, suggesting potential for clinical combination therapy (<xref ref-type="bibr" rid="B32">32</xref>). Given its role in the response to replication stress, WEE1 inhibitors may have greater efficacy in those subsets of MM with greater replication stress. Further pre-clinical studies would be required before these agents can progress to clinical trials in MM.</p>
</sec>
<sec id="s2_5_4">
<title>WEE1 inhibition in mature lymphoid neoplasms</title>
<p>In the setting of MCL, the combination of AZD1775 and the CHK1 inhibitor PF-0477736 was synergistic <italic>in vitro</italic> and in PDX models (<xref ref-type="bibr" rid="B109">109</xref>). In DLBCL, the same combination was not only shown to induce apoptosis but also to destabilize MYC protein (<xref ref-type="bibr" rid="B110">110</xref>). Interestingly the sensitivity to the combination did not correlate with the degree of MYC expression or molecular subtype suggesting that factors other than MYC-induced replicative stress may be involved. AZD1775 increased the dependency of DLBCL cells on BCL-2 and MCL-1, with enhanced apoptosis when AZD1775 was combined with BCL2(venetoclax/navitoclax) or MCL-1 (S63845) inhibitors (<xref ref-type="bibr" rid="B111">111</xref>). AZD1775 also synergized with CHOP (doxorubicin in particular), radiotherapy or rituximab in DLBCL cell lines (<xref ref-type="bibr" rid="B112">112</xref>). These data provide a framework for the design of combination clinical trials with WEE1 inhibitors in lymphoma, although further pre-clinical studies are needed to identify the appropriate molecular subtypes of DLBCL for a particular WEE1-based combination.</p>
</sec>
</sec>
<sec id="s2_6">
<title>Targeting Poly-ADP-ribose polymerase (PARP)</title>
<p>PARP is a DDR effector protein that interacts directly with damaged DNA and catalyses the formation of poly(ADP-ribose) chains on itself and other proximal proteins; this post-translation modification functions to recruit other DDR-related proteins (<xref ref-type="bibr" rid="B6">6</xref>). Inhibition of PARP has gained prominence in the field of solid tumors through its effectiveness, particularly against BRCA-deficient cancers (<xref ref-type="bibr" rid="B6">6</xref>). Though BRCA deficiency is not a common feature in hematological malignancies (<xref ref-type="bibr" rid="B113">113</xref>), the expression of PARP is found to be aberrant in blood cancers. It is overexpressed in AML cell lines and patient samples (<xref ref-type="bibr" rid="B114">114</xref>, <xref ref-type="bibr" rid="B115">115</xref>), and this expression can be augmented by oncogenic KRAS (<xref ref-type="bibr" rid="B116">116</xref>). Increased PARP expression has also been observed in CML cell lines (<xref ref-type="bibr" rid="B117">117</xref>). Importantly, high PARP levels have been associated with poor clinical outcome in AML (<xref ref-type="bibr" rid="B114">114</xref>) and a poor early response to treatment in pediatric ALL (<xref ref-type="bibr" rid="B118">118</xref>). Considering these observations, it is not surprising that PARP inhibitors have been evaluated extensively in several hematological malignancies, as described below.</p>
<sec id="s2_6_1">
<title>PARP inhibitors and myeloid malignancies</title>
<p>The PARP inhibitor olaparib demonstrated efficacy against AML cell lines as well as primary samples with high phospho- gamma H2AX levels (<xref ref-type="bibr" rid="B115">115</xref>). Mutational and gene expression profiling has identified a BRCA-deficient subset of AML which may be more sensitive to PARP inhibition (<xref ref-type="bibr" rid="B119">119</xref>). Consistent with this, BCAT1 overexpression resulted in a BRCA deficient phenotype and was associated with increased sensitivity of AML cell lines to talazoparib (Pfizer) as a single agent as well as in combination with daunorubicin (<xref ref-type="bibr" rid="B120">120</xref>). Similarly, another PARP inhibitor, KU-0058948, had efficacy against both AML cell lines and primary samples due to defects in the HR pathway, with synergism noted along with the HDAC inhibitor, MS275 (<xref ref-type="bibr" rid="B121">121</xref>).</p>
<p>Interestingly, in the context of transformed primary mouse hematopoietic cells, specific translocations appear to affect dependency on PARP activity. The presence of either AML1-ETO and PML-RAR&#x3b1; fusion genes were associated with sensitivity to PARP inhibitors (olaparib and veliparib) whereas AML driven by MLL fusions were resistant to PARP inhibition (<xref ref-type="bibr" rid="B122">122</xref>). The KM2A-AF9 fusion protein resulting from the MLL rearrangement was shown to upregulate HOXA9, a transcription factor known to upregulate the HR recombinase, RAD51, and thus possibly confer resistance to PARP inhibition (<xref ref-type="bibr" rid="B122">122</xref>, <xref ref-type="bibr" rid="B123">123</xref>). These studies highlight the variability of response to PARP inhibitors <italic>in vitro</italic> and suggest that biomarker driven clinical trials may be a valid strategy for clinical translation of PARP inhibition for AML.</p>
<p>Overall, the pre-clinical efficacy of PARP inhibitors is lower in myeloproliferative neoplasms (MPN) when compared to AML. BCR-ABL driven leukemias (e.g. CML) are known to have upregulation of alt-NHEJ related proteins including DNA Ligase III&#x3b1; and PARP (<xref ref-type="bibr" rid="B117">117</xref>). CML primary samples and cell lines required simultaneous inhibition of PARP (with NU1025) and DNA ligase III&#x3b1; (with L67) to reduce survival (<xref ref-type="bibr" rid="B117">117</xref>). The efficacy of these inhibitors was correlated with the expression of these proteins. Talazoparib, and olaparib also had modest activity against cell lines and primary samples of Philadelphia negative MPN (<xref ref-type="bibr" rid="B124">124</xref>). One study demonstrated that almost 50% of MPN cases had impaired formation of RAD51 foci in response to ionizing radiation, which was associated with sensitivity to olaparib and veliparib (<xref ref-type="bibr" rid="B125">125</xref>). Clinical trials evaluating the efficacy of PARP inhibitors in CML should therefore be stratified by such biomarkers and could potentially be conducted in combination with BCR ABL inhibitors.</p>
</sec>
<sec id="s2_6_2">
<title>PARP inhibition in acute lymphoblastic leukemias</title>
<p>The translocation t (17,19) (q22;p13) results in the formation of the TCF3-HLF fusion protein and characterizes a rare subtype of pediatric ALL (&lt; 1%) (<xref ref-type="bibr" rid="B126">126</xref>). TCF3-HLF expression impairs HR repair (<xref ref-type="bibr" rid="B127">127</xref>). Congruent with this, olaparib and veliparib showed significant activity against TCF3-HLF B-ALL <italic>in vitro</italic> (<xref ref-type="bibr" rid="B127">127</xref>), and in combination with temozolomide in TCF3-HLF xenograft models (<xref ref-type="bibr" rid="B127">127</xref>). The combination of the PARP inhibitor, rucaparib (Clovis), with 5-fluorouracil showed significant activity against T-ALL cell lines and primary allograft and xenograft animal models, with preferential effects on leukemic blasts in comparison to normal mononuclear cells (<xref ref-type="bibr" rid="B128">128</xref>). 5 Fluorouracil is however not a standard treatment for T-ALL; hence the clinical applicability of this regimen is doubtful. Evaluation of PARP inhibitors with agents in clinical use for relapsed T-ALL is hence required.</p>
<p>LIM domain only 2 (LMO2) is a cysteine rich protein implicated in the maintenance of hematopoietic stem cells (<xref ref-type="bibr" rid="B129">129</xref>, <xref ref-type="bibr" rid="B130">130</xref>). LMO2 is deregulated in T-ALL associated with translocations involving chromosome 11p and in B-ALL with t (17,19) (<xref ref-type="bibr" rid="B131">131</xref>, <xref ref-type="bibr" rid="B132">132</xref>). LMO2 inhibits recruitment of BRCA1 to sites of DSB via an interaction with 53BP1 (<xref ref-type="bibr" rid="B130">130</xref>). The HR deficiency occurring as a result of LMO2 expression rendered T-ALL cells more sensitive to PARP inhibition (using olaparib), both as a single agent as well as in combination with doxorubicin (<xref ref-type="bibr" rid="B130">130</xref>). However in another study, PARP inhibition (with PJ-34) did not induce apoptosis in unselected B and T- ALL cell lines as single agents or in combination with a NOTCH inhibitor (DAPT) (<xref ref-type="bibr" rid="B133">133</xref>). These data suggest that PARP inhibition may represent an option for clinical trials focusing on ALL with LMO2 overexpression.</p>
</sec>
<sec id="s2_6_3">
<title>PARP inhibition in multiple myeloma</title>
<p>Single-agent olaparib induced DSBs and apoptosis at low micromolar concentrations in both MM cell lines and primary samples, particularly in the setting of MYC overexpression (<xref ref-type="bibr" rid="B134">134</xref>). Genome wide loss of heterozygosity (LOH) is associated with dysfunctional HR and sensitivity to PARP inhibitors; LOH occurs in MM and is indeed associated with dysfunctional HR in a subset of patients (<xref ref-type="bibr" rid="B135">135</xref>). This lends credence to the rationale for clinical evaluation of PARP inhibitors in this disease. However, the incorporation of PARP inhibitors into treatment protocols will likely need to be done in combination with currently used agents for MM, and there is pre-clinical evidence for the efficacy of PARP inhibitor combinations.</p>
<p>The combination of bortezomib with veliparib or olaparib was associated with increased cytotoxicity (compared to either drug alone) in both MM cell lines and cell line xenografts (<xref ref-type="bibr" rid="B136">136</xref>&#x2013;<xref ref-type="bibr" rid="B138">138</xref>). The underlying mechanism is postulated to be that proteosome inhibition induces impairment of HR in MM cells through abrogation of &#x3b3;-H2AX polyubiquitylation (<xref ref-type="bibr" rid="B136">136</xref>, <xref ref-type="bibr" rid="B139">139</xref>). PARP inhibitors (PJ-34, bufalin) have also been combined with melphalan and other cytotoxic agents showing synergy in multi-drug resistant MM cell lines (<xref ref-type="bibr" rid="B140">140</xref>&#x2013;<xref ref-type="bibr" rid="B142">142</xref>). Additional targeting of NHEJ using a DNA&#x2013;PK inhibitor, NU7026, augmented the cytotoxicity of the melphalan/veliparib combination in drug resistant MM cell lines and cell line xenografts (<xref ref-type="bibr" rid="B143">143</xref>), suggesting that dual DDR inhibitor combinations may also be attractive options for evaluation in clinical trials. Separately, the CDK inhibitor, dinaciclib, was shown to impair the expression of HR related genes and sensitize MM cells to veliparib <italic>in vitro</italic> and <italic>in vivo</italic> (<xref ref-type="bibr" rid="B144">144</xref>). As CDK inhibitors such as dinaciclib have single agent efficacy in MM (<xref ref-type="bibr" rid="B144">144</xref>, <xref ref-type="bibr" rid="B145">145</xref>) and are being studied actively as a therapeutic option, further mechanistic and pre-clinical studies of PARP inhibitors combined with other CDK inhibitors are warranted.</p>
</sec>
<sec id="s2_6_4">
<title>PARP inhibition in mature lymphoproliferative neoplasms</title>
<p>ATM deficient tumors are also hypothesized to be susceptible to PARP inhibition (<xref ref-type="bibr" rid="B1">1</xref>, <xref ref-type="bibr" rid="B146">146</xref>). ATM deficient CLL cells showed increased <italic>in vitro</italic> sensitivity to olaparib compared to those with intact ATM (<xref ref-type="bibr" rid="B147">147</xref>). These findings have also been confirmed in murine models of ATM deficient CLL (<xref ref-type="bibr" rid="B148">148</xref>). Interestingly, although CLL cells were also sensitive to talazoparib, the correlation of cytotoxicity with ATM loss was less clear in this setting (<xref ref-type="bibr" rid="B149">149</xref>). These data suggest that synthetic lethality profiles may differ between PARP inhibitors, and that clinical responses to such in lymphoid malignancies will be heterogeneous. Careful patient selection based on robust biomarkers will be required for the optimal design of clinical trials.</p>
<p>In keeping with the CLL, ATM loss in MCL was shown to be associated with <italic>in vitro</italic> sensitivity to PARP inhibitors (PJ-34, olaparib) (<xref ref-type="bibr" rid="B150">150</xref>). Interestingly, PARP inhibition with olaparib was shown to be even more effective in MCL cell lines with combined loss of ATM and <italic>TP53</italic> than those with ATM loss alone (<xref ref-type="bibr" rid="B151">151</xref>). As loss of <italic>TP53</italic> is known to herald a poor prognosis in MCL (<xref ref-type="bibr" rid="B152">152</xref>), and since olaparib synergized with the BTK inhibitor, ibrutinib, in MCL cell lines (<xref ref-type="bibr" rid="B153">153</xref>), these data provide promising grounds for the design of a PARP inhibitor-BTK combination in this high risk subset of MCL.</p>
<p>In the setting of unselected DLBCL cell lines, olaparib showed limited single agent activity but potential for cell kill when combined with rituximab (<xref ref-type="bibr" rid="B154">154</xref>). As with T-ALL (described above), LMO2 expression impaired HR in DLBCL and conferred sensitivity to PARP inhibition (with olaparib) as a single agent as well as in combination with genotoxic agents (doxorubicin alone or the R-CHOP regimen) (<xref ref-type="bibr" rid="B130">130</xref>). As LMO2 expression is an independent poor prognostic factor in DLBCL treated with the R-CHOP regimen (<xref ref-type="bibr" rid="B155">155</xref>), there is a rationale for the evaluation of PARP inhibition in combination with chemo-immunotherapy in LMO2-expressing DLBCL. Gemcitabine, melphalan and busulphan (Gem/Mel/Bu) is a potent conditioning regimen for relapsed lymphomas (<xref ref-type="bibr" rid="B156">156</xref>), and addition of olaparib to Gem/Mel/Bu resulted in a three-fold reduction in lymphoma cell line proliferation <italic>in vitro (</italic>
<xref ref-type="bibr" rid="B157">157</xref>). Although these data are promising, the potential hematologic toxicity of this regimen would be a concern when considering clinical evaluation.</p>
</sec>
</sec>
<sec id="s2_7">
<title>Clinical trials investigating DDR inhibitors in hematologic malignancies</title>
<p>Numerous clinical trials are currently in progress evaluating DDR inhibitors in hematologic malignancies. Trials involving PARP inhibitors either as single agents or in combination comprise the majority, with ATR inhibitors also being actively investigated. These clinical trials are summarized in <xref ref-type="table" rid="T1">
<bold>Tables&#xa0;1</bold>
</xref>&#x2013;<xref ref-type="table" rid="T5">
<bold>5</bold>
</xref>, and key findings from the reported trial results as well as major points of interest regarding the ongoing trials are discussed below.</p>
<table-wrap id="T2" position="float">
<label>Table&#xa0;2</label>
<caption>
<p>List of ongoing or completed clinical trials of ATR inhibitors in advanced hematological malignancies.</p>
</caption>
<table frame="hsides">
<thead>
<tr>
<th valign="top" align="left">Pathway</th>
<th valign="top" align="left">Compounds</th>
<th valign="top" align="left">Latest Stage of Development and Trial Details</th>
<th valign="top" align="left">Clinical Trial Identifier(s)</th>
<th valign="top" align="left">Current Status (Ongoing or Published include reference if published)</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="top" rowspan="5" align="left">HRR (Targeting ATR)</td>
<td valign="top" align="left">BAY1895344</td>
<td valign="top" align="left">Phase I as monotherapy in patients with advanced solid tumors and lymphomas</td>
<td valign="top" align="left">NCT03188965</td>
<td valign="top" align="left">Recruiting</td>
</tr>
<tr>
<td valign="top" align="left">AZD6738</td>
<td valign="top" align="left">Phase I as monotherapy in patients with R/R CLL, Prolymphocytic leukemia (PLL) or B cell lymphomas</td>
<td valign="top" align="left">NCT01955668</td>
<td valign="top" align="left">Completed(not published).</td>
</tr>
<tr>
<td valign="top" align="left">AZD6738</td>
<td valign="top" align="left">Phase I/II as monotherapy or in combination with Acalabrutinib in R/R high-risk CLL</td>
<td valign="top" align="left">NCT03328273</td>
<td valign="top" align="left">Active, not recruiting&#x2003;</td>
</tr>
<tr>
<td valign="top" align="left">AZD6738</td>
<td valign="top" align="left">Phase I as monotherapy in the treatment of MDS or Chronic Myelomonocytic Leukemia (CMML)</td>
<td valign="top" align="left">NCT03770429</td>
<td valign="top" align="left">Recruiting</td>
</tr>
<tr>
<td valign="top" align="left">AZD6738</td>
<td valign="top" align="left">Phase I as combination therapy with Paclitaxel in refractory cancer</td>
<td valign="top" align="left">NCT02630199</td>
<td valign="top" align="left">Recruiting</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>The compounds targeting the HRR pathway and its latest stage of development along with the trial details are indicated. ATR, Ataxia Telangiectasia and Rad3-related; CLL, Chronic Lymphocytic Leukemia; MDS, Myelodysplastic syndrome; R/R, Relapsed or Refractory.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="T3" position="float">
<label>Table&#xa0;3</label>
<caption>
<p>List of ongoing or completed clinical trials of DNA-PK inhibitors in advanced hematological malignancies.</p>
</caption>
<table frame="hsides">
<thead>
<tr>
<th valign="top" align="left">Pathway</th>
<th valign="top" align="left">Compounds</th>
<th valign="top" align="left">Latest Stage of Development and Trial Details</th>
<th valign="top" align="left">Clinical Trial Identifier(s)</th>
<th valign="top" align="left">Current Status (Ongoing or Published include reference if published)</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="top" align="left">NHEJ (Targeting DNA-PK)</td>
<td valign="top" align="left">MSC2490484A</td>
<td valign="top" align="left">Phase I as monotherapy in advanced solid tumors or CLL</td>
<td valign="top" align="left">NCT02316197</td>
<td valign="top" align="left">Completed (<xref ref-type="bibr" rid="B158">158</xref>)</td>
</tr>
<tr>
<td valign="top" align="left">NHEJ (Targeting DNA-PK and mTOR kinase)</td>
<td valign="top" align="left">CC-115</td>
<td valign="top" align="left">Phase I as monotherapy in advanced solid tumors or CLL</td>
<td valign="top" align="left">NCT01353625</td>
<td valign="top" align="left">Completed</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>The compounds targeting the various pathways and its latest stage of development along with the trial details are indicated. CLL, Chronic Lymphocytic Leukemia; DNA-PK, DNA-dependent protein kinase; NHEJ, Non-homologous end joining; mTOR, mammalian target of rapamycin.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="T4" position="float">
<label>Table&#xa0;4</label>
<caption>
<p>List of completed clinical trials of CHK1 inhibitors in advanced hematological malignancies.</p>
</caption>
<table frame="hsides">
<thead>
<tr>
<th valign="top" align="left">Pathway</th>
<th valign="top" align="left">Compounds</th>
<th valign="top" align="left">Latest Stage of Development and Trial Details</th>
<th valign="top" align="left">Clinical Trial Identifier(s)</th>
<th valign="top" align="left">Current Status (Ongoing or <break/>Published&#xa0;include reference if published)</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="top" rowspan="2" align="left">Targeting CHK1</td>
<td valign="top" align="left">MK-8776</td>
<td valign="top" align="left">Phase II as cytarabine monotherapy or in combination with MK-8776 in adult patients with relapsed AML</td>
<td valign="top" align="left">NCT01870596</td>
<td valign="top" align="left">Completed (<xref ref-type="bibr" rid="B159">159</xref>)</td>
</tr>
<tr>
<td valign="top" align="left">SRA737</td>
<td valign="top" align="left">Phase II for Advanced Solid Tumors or NHL</td>
<td valign="top" align="left">NCT02797964</td>
<td valign="top" align="left">Completed(not published)</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>The compounds targeting the checkpoint inhibitor pathway and its latest stage of development along with the trial details are indicated. CHK1, Checkpoint kinase 1; AML, Acute Myeloid Leukemia; NHL, Non-Hodgkin Lymphoma.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="T5" position="float">
<label>Table&#xa0;5</label>
<caption>
<p>List of ongoing or completed clinical trials of PARP inhibitors in advanced hematological malignancies.</p>
</caption>
<table frame="hsides">
<thead>
<tr>
<th valign="top" align="left">Pathway</th>
<th valign="top" align="left">Compounds</th>
<th valign="top" align="left">Latest Stage of Development and Trial Details</th>
<th valign="top" align="left">Clinical Trial Identifier(s)</th>
<th valign="top" align="left">Current Status (Ongoing or Published include reference if published)</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="top" rowspan="18" align="left">BER (Targeting PARP).</td>
<td valign="top" align="left">talazoparib</td>
<td valign="top" align="left">Phase I in patients with advanced hematological malignancies (AML, MDS, CLL, MCL)</td>
<td valign="top" align="left">NCT01399840</td>
<td valign="top" align="left">Completed (<xref ref-type="bibr" rid="B160">160</xref>)</td>
</tr>
<tr>
<td valign="top" align="left">talazoparib</td>
<td valign="top" align="left">Phase I in patients with AML or MDS that have a mutation in the cohesin complex</td>
<td valign="top" align="left">NCT03974217</td>
<td valign="top" align="left">Ongoing</td>
</tr>
<tr>
<td valign="top" align="left">talazoparib</td>
<td valign="top" align="left">Phase I/II in combination with Decitabine in patients with untreated and refractory/relapsed (R/R) AML</td>
<td valign="top" align="left">NCT02878785</td>
<td valign="top" align="left">Ongoing</td>
</tr>
<tr>
<td valign="top" align="left">talazoparib</td>
<td valign="top" align="left">Phase I/Ib in combination with gemtuzumab ozogamicin in patients with R/R CD33 positive AML</td>
<td valign="top" align="left">NCT04207190</td>
<td valign="top" align="left">Active, recruiting</td>
</tr>
<tr>
<td valign="top" align="left">veliparib</td>
<td valign="top" align="left">Phase I in combination with Temozolomide in patients with acute leukemia</td>
<td valign="top" align="left">NCT01139970</td>
<td valign="top" align="left">Active, not recruiting</td>
</tr>
<tr>
<td valign="top" align="left">veliparib</td>
<td valign="top" align="left">Phase I in combination with Bortezomib (proteasome inhibitor) in multiple myeloma</td>
<td valign="top" align="left">NCT01495351</td>
<td valign="top" align="left">Completed (<xref ref-type="bibr" rid="B161">161</xref>)</td>
</tr>
<tr>
<td valign="top" align="left">veliparib</td>
<td valign="top" align="left">Phase I as monotherapy in refractory solid tumors or hematologic cancers</td>
<td valign="top" align="left">NCT00387608</td>
<td valign="top" align="left">Completed (<xref ref-type="bibr" rid="B162">162</xref>)</td>
</tr>
<tr>
<td valign="top" align="left">veliparib</td>
<td valign="top" align="left">Phase I in combination with Cyclophosphamide in refractory solid tumors and lymphoid cancers (lymphoma and CLL)</td>
<td valign="top" align="left">NCT01445522</td>
<td valign="top" align="left">Completed (not yet published)</td>
</tr>
<tr>
<td valign="top" align="left">veliparib</td>
<td valign="top" align="left">Phase I in combination with Topotecan in refractory solid tumors, lymphomas and CLL</td>
<td valign="top" align="left">NCT00553189</td>
<td valign="top" align="left">Completed (<xref ref-type="bibr" rid="B163">163</xref>)</td>
</tr>
<tr>
<td valign="top" align="left">veliparib</td>
<td valign="top" align="left">Phase I in combination with Topotecan +/- Carboplatin in R/R acute leukemia, high-risk myelodysplasia, or aggressive myeloproliferative disorders</td>
<td valign="top" align="left">NCT00588991</td>
<td valign="top" align="left">Active, not recruiting</td>
</tr>
<tr>
<td valign="top" align="left">veliparib</td>
<td valign="top" align="left">Phase I/II in combination with Bendamustine Hydrochloride +/- Rituximab in lymphoma, multiple myeloma or R/R solid tumors</td>
<td valign="top" align="left">NCT01326702</td>
<td valign="top" align="left">Completed (<xref ref-type="bibr" rid="B164">164</xref>)</td>
</tr>
<tr>
<td valign="top" align="left">veliparib</td>
<td valign="top" align="left">Phase I in combination with Cyclophosphamide and Doxorubicin in metastatic/unresectable solid tumors or NHL</td>
<td valign="top" align="left">NCT00740805</td>
<td valign="top" align="left">Active, not recruiting.</td>
</tr>
<tr>
<td valign="top" align="left">veliparib</td>
<td valign="top" align="left">Phase II in combination with Topotecan, Carboplatin +/- Veliparib in advanced myeloproliferative disorders, AML or chronic myelomonocytic leukemia</td>
<td valign="top" align="left">NCT03289910</td>
<td valign="top" align="left">Active, not recruiting</td>
</tr>
<tr>
<td valign="top" align="left">veliparib</td>
<td valign="top" align="left">Phase I/Ib in combination with Nivolumab in patients with advanced refractory solid cancers and lymphoma</td>
<td valign="top" align="left">NCT03061188</td>
<td valign="top" align="left">Active, not recruiting</td>
</tr>
<tr>
<td valign="top" align="left">CEP-9722</td>
<td valign="top" align="left">Phase I in combination with Gemcitabine and Cisplatin in advanced solid tumors or MCL</td>
<td valign="top" align="left">NCT01345357</td>
<td valign="top" align="left">Completed(not published)</td>
</tr>
<tr>
<td valign="top" align="left">olaparib</td>
<td valign="top" align="left">Phase II as monotherapy in Isocitrate Dehydrogenase (IDH) mutant relapsed or refractory AML and MDS</td>
<td valign="top" align="left">NCT03953898</td>
<td valign="top" align="left">Recruiting</td>
</tr>
<tr>
<td valign="top" align="left">olaparib</td>
<td valign="top" align="left">Phase II as monotherapy in solid tumors, NHL or histiocytic disorders with defects in DDR genes</td>
<td valign="top" align="left">NCT03233204</td>
<td valign="top" align="left">Recruiting</td>
</tr>
<tr>
<td valign="top" align="left">olaparib</td>
<td valign="top" align="left">Phase I in combination with high dose chemotherapy (Olaparib, Vorinostat, Gemcitabine, Busulfan and Melphalan) in R/R lymphomas undergoing stem cell transplant</td>
<td valign="top" align="left">NCT03259503</td>
<td valign="top" align="left">Ongoing</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>The compounds targeting the BER pathway and its latest stage of development along with the trial details are indicated. ALL, Acute Lymphoblastic Leukemia; AML, Acute Myeloid Leukemia; BER, Base excision repair; CLL, Chronic Lymphocytic Leukemia; DDR, DNA Damage Repair; MCL, Mantle Cell Lymphoma; MDS, Myelodysplastic syndrome; NHL, Non-Hodgkin Lymphoma; PARP, poly ADP ribose polymerase; R/R, Relapsed or Refractory.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>PARP inhibitors are the most advanced among DDR inhibitors in terms of clinical development in hematological cancers (<xref ref-type="bibr" rid="B165">165</xref>). Following a successful phase 0 trial demonstrating PARP inhibition histologically in tumor biopsies (<xref ref-type="bibr" rid="B162">162</xref>), a number of phase 1 studies have sought to evaluate the safety and tolerability of veliparib in advanced cancer. Myelosuppression has been the key dose limiting toxicity (DLT) identified in these studies with some efficacy signals also seen (<xref ref-type="bibr" rid="B163">163</xref>). Among two patients with lymphoid malignancies included in a phase 1 trial of veliparib with oral cyclophosphamide, one patient with CLL/SLL achieved prolonged stable disease (<xref ref-type="bibr" rid="B166">166</xref>).</p>
<p>Veliparib (V) was also combined with bendamustine (B) +/- rituximab (R) in relapsed/refractory patients with solid malignancies, lymphoma or MM (<xref ref-type="bibr" rid="B164">164</xref>). There were 14 lymphoma patients and 1 MM patient among the 34 recruited, 5 out of 7 patients on the VB arm achieved an objective response while 6 out of 7 patients on the VBR arm achieved an objective response. The single MM patient achieved a partial response (PR). The combination was well tolerated with grade &gt;3 neutropenia and thrombocytopenia occurring in 12.2% and 9.8% of patients respectively. Given that BR is an established treatment regimen in indolent B-cell lymphomas, this combination would be a promising option to be taken forward into phase II trials.</p>
<p>Based on pre-clinical data showing synergy between bortezomib and PARP inhibitors, Neri et&#xa0;al. conducted a phase 1 trial evaluating veliparib in combination with bortezomib/dexamethasone in relapsed or refractory MM (<xref ref-type="bibr" rid="B161">161</xref>). The combination was well tolerated and the overall response rate of 39% was encouraging given that close to 80% of the patients had prior bortezomib treatment. Importantly, patients with mutations in HR related genes were found to have a higher response rate, supporting the biological rationale for the study (<xref ref-type="bibr" rid="B161">161</xref>). Future phase II studies using this combination should ideally employ similar biomarkers to better select patients.</p>
<p>Veliparib is also being studied in combination with topotecan/carboplatin in MPN, AML and chronic myelomonocytic leukaemia in two phase II trials (NCT03289910 and NCT03289910). These ongoing trials will provide valuable data on the potential synergy between veliparib and DNA damaging chemotherapy. Haematologic toxicity may however be a concern with these combinations.</p>
<p>Olaparib was evaluated in a phase 1 trial in patients with relapsed CLL (n=9), T-PLL (n=2) or MCL (n=4) (<xref ref-type="bibr" rid="B167">167</xref>). The treatment was well tolerated with grade 3 hematologic toxicities occurring in ten patients. In patients with the ATM or SF3B1 mutations, a longer median survival time of 192 days was seen compared to 89 days in the unmutated group. These data suggest ATM and SF3B1 mutations may be a potential biomarker for patient selection in future studies of PARP inhibitors in lymphoma. It is noteworthy that Olaparib is being studied in an ongoing phase I trial (NCT03259503) in combination with vorinostat, busulphan, melphalan and gemcitabine in patients with relapsed lymphoma undergoing stem cell transplant. While the synergy between Olaparib and the histone deacetylase (HDAC) inhibitor would be of interest, haematologic toxicity is certainly a concern. Olaparib is also under investigation as monotherapy in an ongoing phase II trial (NCT03953898) for patients with relapsed AML with isocitrate dehydrogenase mutations. If this trial shows promising results, the combination of Olaparib with IDH inhibitors maybe a consideration for future studies. Talozaparib monotherapy was studied in a phase 1 trial involving patients with AML, MDS, CLL and MCL (<xref ref-type="bibr" rid="B160">160</xref>). Hematologic toxicities were again the key DLTs, and stable disease was seen in patients with AML, MDS and MCL while transfusion independence was reported in patients with AML and MDS. Taken together, these data suggest that PARP inhibitors have limited clinical efficacy as monotherapy or in combination with cytotoxic agents in hematologic malignancies.</p>
<p>Combining PARP inhibitors with other targeted agents in acute leukemias is therefore a strategy being pursued. Talozaparib is being studied in a phase I/II trial in combination with decitabine (NCT02878785) in relapsed AML as well as with gemtuzumab ozogomycin (NCT04207190), in relapsed CD33 positive AML. These trials are currently ongoing, and their results will demonstrate the potential synergy between PARP inhibitors and other targeted therapies for AML. The combination with gemtuzumab in particular would be of interest for the core binding factor acute leukaemias given their success in the frontline setting (<xref ref-type="bibr" rid="B168">168</xref>).Combinations of PARP inhibitors with immunotherapy are particularly worthy of exploration given that hematologic toxicities with the latter are not as prominent as with cytotoxic chemotherapy.</p>
<p>Beyond PARP inhibitors, the majority of the reported clinical data are for the CHK1 and DNA-PK inhibitors. Based on the pre-clinical data previously discussed (<xref ref-type="bibr" rid="B80">80</xref>), the combination of the CHK1 inhibitor MK-8776 with cytarabine was evaluated in a phase 1 trial in relapsed or refractory AML. Promising safety and preliminary efficacy results were seen in this study, prompting the advancement of this combination to the phase II setting (<xref ref-type="bibr" rid="B169">169</xref>). In a randomized phase II comparison of cytarabine as a single agent with cytarabine + MK-8776, Webster et&#xa0;al. demonstrated a significant increase in DNA damage in the combination arm based on &#x3b3;H2AX expression (<xref ref-type="bibr" rid="B159">159</xref>). Interestingly, no significant difference in complete response rates were seen between the arms: (36% and 44% for the cytarabine and combination arms respectively). Definitive conclusions on therapeutic benefit may be difficult to draw based on the small number of patients enrolled in the study (n=32), hence larger randomized studies are called for to further evaluate this promising combination.</p>
<p>Several trials are evaluating ATR inhibitors as monotherapy and in combination with cytotoxic or targeted agents. The combination with acalabrutinib in relapsed high risk CLL (NCT03328273) is of particular interest as these agents are less likely to have overlapping toxicities and may have potential synergy, especially in the more aggressive subsets with high levels of replication stress.</p>
<p>Based on promising preclinical data, the DNA-PK/MTORK inhibitor CC-115 was studied in a phase 1 trial which included eight patients with ATM mutant CLL (<xref ref-type="bibr" rid="B68">68</xref>, <xref ref-type="bibr" rid="B170">170</xref>). Two patients achieved a partial remission (PR) while three achieved a PR with lymphocytosis. Although preliminary, these results in a heavily pretreated population of high risk CLL suggest this agent is worthy of further evaluation in phase II studies.</p>
</sec>
<sec id="s2_8">
<title>Conclusions &amp; future directions</title>
<p>In conclusion, we present an overview of promising pre-clinical and early phase clinical trial data supporting the use of DDR inhibitors as a viable treatment modality in haematological malignancies. We consider the following as priorities for evaluation in future clinical trials. Targeting replication stress via ATR,CHK1 or WEE1 inhibition would be of value in MM, given the importance of replication stress in this malignancy. CHK1/WEE1 inhibitors also show promise in B-cell lymphomas and would be of particular interest in MYC driven subsets given their high replication stress. The combination of these agents with immunotherapy in the B-cell malignancies would also be worthy of exploration. Combining ATR inhibitors with inducers of replication stress would be of interest in AML, given the <italic>in-vitro</italic> synergy that has been reported, especially in elderly patients who are not suitable for intensive chemotherapy. Targeting ATM maybe synthetically lethal with MLL rearrangements in acute leukaemias, and this strategy should be studied further in this subgroup of patients.</p>
<p>Identifying the right patient population, disease subsets, and combinatorial drug partners are key questions that need to be answered before these agents can move into mainstream clinical practice. The validation of robust biomarkers for sensitivity to DDR inhibitors will be a key step forward and should be used in the design of future clinical trials (<xref ref-type="bibr" rid="B171">171</xref>).</p>
<p>A better understanding of the cross talk between DDR pathways in specific tumors as well as how this manifests in terms of mutational, gene expression or proteomic profiling will also be critical for this purpose (<xref ref-type="bibr" rid="B172">172</xref>). Ex vivo drug sensitivity testing in association with artificial intelligence based predictive models provides an exciting opportunity for personalized cancer therapeutics (<xref ref-type="bibr" rid="B173">173</xref>&#x2013;<xref ref-type="bibr" rid="B175">175</xref>). Such platforms create a vast drug combination search space and can discover efficacious combinations agnostic of underlying mechanisms. Evaluation of DDR inhibitors using such platforms is therefore a promising arena for future research and has the potential to identify new DDRi-DDRi, DDRi&#x2014;chemotherapy drug combinations. In addition to personalized recommendations, recurring combinations identified can also be used to uncover novel biomarkers of sensitivity that may be applicable to the wider population of cancer patients.</p>
<p>Challenges to be overcome with such ex vivo approaches include recreating the immune microenvironment, which plays a crucial role in drug sensitivity in hematologic malignancies (<xref ref-type="bibr" rid="B176">176</xref>) hence the development of such platform enhancements are a pressing need. In support of this, there is growing interest in the interaction between the DDR and immune dysregulation, providing opportunities for simultaneous targeting of immune checkpoints with DDR inhibition (<xref ref-type="bibr" rid="B177">177</xref>). A better understanding of how deregulation of DDR pathways affects immune checkpoints in specific malignancies will be central to taking this field forward.</p>
</sec>
</sec>
<sec id="s3" sec-type="author-contributions">
<title>Author contributions</title>
<p>SD: Conceptualization, Writing &#x2013; original draft. AL: Writing &#x2013; original draft. JT: Writing &#x2013; original draft. RT: Writing &#x2013; original draft. LP: Writing &#x2013; review &amp; editing. EC: Writing &#x2013; review &amp; editing. JL: Writing &#x2013; review &amp; editing. YC: Writing &#x2013; review &amp; editing. SL:&#xa0;Writing &#x2013; review &amp; editing. PJ: Writing &#x2013; original draft. AJ: Conceptualization, Writing &#x2013; original draft, Writing &#x2013; review &amp; editing.</p>
</sec>
</body>
<back>
<sec id="s4" sec-type="funding-information">
<title>Funding</title>
<p>The author(s) declare financial support was received for the research, authorship, and/or publication of this article. Work in AJ&#x2019;s laboratory is funded by a core grant from the Cancer Science Institute of Singapore, National University of Singapore through the National Research Foundation Singapore and the Singapore Ministry of Education under its Research Centres of Excellence initiative.</p>
</sec>
<sec id="s5" sec-type="COI-statement">
<title>Conflict of interest</title>
<p>AJ has received consultancy fees from Roche, Gilead, Turbine Ltd, AstraZeneca, Antegene, Janssen, MSD and IQVIA; and research funding from Janssen and AstraZeneca. SD has been on advisory boards for Amgen and Pfizer.</p>
<p>The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec id="s6" sec-type="disclaimer">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="B1">
<label>1</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>O'Connor</surname> <given-names>MJ</given-names>
</name>
</person-group>. <article-title>Targeting the DNA damage response in cancer</article-title>. <source>Mol Cell</source> (<year>2015</year>) <volume>60</volume>(<issue>4</issue>):<page-range>547&#x2013;60</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.molcel.2015.10.040</pub-id>
</citation>
</ref>
<ref id="B2">
<label>2</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hanahan</surname> <given-names>D</given-names>
</name>
<name>
<surname>Weinberg</surname> <given-names>RA</given-names>
</name>
</person-group>. <article-title>Hallmarks of cancer: the next generation</article-title>. <source>Cell</source> (<year>2011</year>) <volume>144</volume>(<issue>5</issue>):<page-range>646&#x2013;74</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.cell.2011.02.013</pub-id>
</citation>
</ref>
<ref id="B3">
<label>3</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Harper</surname> <given-names>JW</given-names>
</name>
<name>
<surname>Elledge</surname> <given-names>SJ</given-names>
</name>
</person-group>. <article-title>The DNA damage response: ten years after</article-title>. <source>Mol Cell</source> (<year>2007</year>) <volume>28</volume>(<issue>5</issue>):<page-range>739&#x2013;45</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.molcel.2007.11.015</pub-id>
</citation>
</ref>
<ref id="B4">
<label>4</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pearl</surname> <given-names>LH</given-names>
</name>
<name>
<surname>Schierz</surname> <given-names>AC</given-names>
</name>
<name>
<surname>Ward</surname> <given-names>SE</given-names>
</name>
<name>
<surname>Al-Lazikani</surname> <given-names>B</given-names>
</name>
<name>
<surname>Pearl</surname> <given-names>FMG</given-names>
</name>
</person-group>. <article-title>Therapeutic opportunities within the DNA damage response</article-title>. <source>Nat Rev Cancer</source> (<year>2015</year>) <volume>15</volume>(<issue>3</issue>):<page-range>166&#x2013;80</page-range>. doi: <pub-id pub-id-type="doi">10.1038/nrc3891</pub-id>
</citation>
</ref>
<ref id="B5">
<label>5</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pili&#xe9;</surname> <given-names>PG</given-names>
</name>
<name>
<surname>Tang</surname> <given-names>C</given-names>
</name>
<name>
<surname>Mills</surname> <given-names>GB</given-names>
</name>
<name>
<surname>Yap</surname> <given-names>TA</given-names>
</name>
</person-group>. <article-title>State-of-the-art strategies for targeting the DNA damage response in cancer</article-title>. <source>Nat Rev Clin Oncol</source> (<year>2019</year>) <volume>16</volume>(<issue>2</issue>):<fpage>81</fpage>&#x2013;<lpage>104</lpage>. doi: <pub-id pub-id-type="doi">10.1038/s41571-018-0114-z</pub-id>
</citation>
</ref>
<ref id="B6">
<label>6</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rouleau</surname> <given-names>M</given-names>
</name>
<name>
<surname>Patel</surname> <given-names>A</given-names>
</name>
<name>
<surname>Hendzel</surname> <given-names>MJ</given-names>
</name>
<name>
<surname>Kaufmann</surname> <given-names>SH</given-names>
</name>
<name>
<surname>Poirier</surname> <given-names>GG</given-names>
</name>
</person-group>. <article-title>PARP inhibition: PARP1 and beyond</article-title>. <source>Nat Rev Cancer</source> (<year>2010</year>) <volume>10</volume>(<issue>4</issue>):<fpage>293</fpage>&#x2013;<lpage>301</lpage>. doi: <pub-id pub-id-type="doi">10.1038/nrc2812</pub-id>
</citation>
</ref>
<ref id="B7">
<label>7</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Alhmoud</surname> <given-names>JF</given-names>
</name>
<name>
<surname>Mustafa</surname> <given-names>AG</given-names>
</name>
<name>
<surname>Malki</surname> <given-names>MI</given-names>
</name>
</person-group>. <article-title>Targeting DNA repair pathways in hematological Malignancies</article-title>. <source>Int J Mol Sci</source> (<year>2020</year>) <volume>21</volume>(<issue>19</issue>). doi: <pub-id pub-id-type="doi">10.3390/ijms21197365</pub-id>
</citation>
</ref>
<ref id="B8">
<label>8</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Takagi</surname> <given-names>M</given-names>
</name>
</person-group>. <article-title>DNA damage response and hematological Malignancy</article-title>. <source>Int J Hematol</source> (<year>2017</year>) <volume>106</volume>(<issue>3</issue>):<page-range>345&#x2013;56</page-range>. doi: <pub-id pub-id-type="doi">10.1007/s12185-017-2226-0</pub-id>
</citation>
</ref>
<ref id="B9">
<label>9</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ashwell</surname> <given-names>S</given-names>
</name>
<name>
<surname>Zabludoff</surname> <given-names>S</given-names>
</name>
</person-group>. <article-title>DNA damage detection and repair pathways&#x2014;Recent advances with inhibitors of checkpoint kinases in cancer therapy</article-title>. <source>Clin Cancer Res</source> (<year>2008</year>) <volume>14</volume>(<issue>13</issue>):<page-range>4032&#x2013;7</page-range>. doi: <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-07-5138</pub-id>
</citation>
</ref>
<ref id="B10">
<label>10</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bakr</surname> <given-names>A</given-names>
</name>
<name>
<surname>Oing</surname> <given-names>C</given-names>
</name>
<name>
<surname>K&#xf6;cher</surname> <given-names>S</given-names>
</name>
<name>
<surname>Borgmann</surname> <given-names>K</given-names>
</name>
<name>
<surname>Dornreiter</surname> <given-names>I</given-names>
</name>
<name>
<surname>Petersen</surname> <given-names>C</given-names>
</name>
<etal/>
</person-group>. <article-title>Involvement of ATM in homologous recombination after end resection and RAD51 nucleofilament formation</article-title>. <source>Nucleic Acids Res</source> (<year>2015</year>) <volume>43</volume>(<issue>6</issue>):<page-range>3154&#x2013;66</page-range>. doi: <pub-id pub-id-type="doi">10.1093/nar/gkv160</pub-id>
</citation>
</ref>
<ref id="B11">
<label>11</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Austen</surname> <given-names>B</given-names>
</name>
<name>
<surname>Powell</surname> <given-names>JE</given-names>
</name>
<name>
<surname>Alvi</surname> <given-names>A</given-names>
</name>
<name>
<surname>Edwards</surname> <given-names>I</given-names>
</name>
<name>
<surname>Hooper</surname> <given-names>L</given-names>
</name>
<name>
<surname>Starczynski</surname> <given-names>J</given-names>
</name>
<etal/>
</person-group>. <article-title>Mutations in the ATM gene lead to impaired overall and treatment-free survival that is independent of IGVH mutation status in patients with B-CLL</article-title>. <source>Blood</source> (<year>2005</year>) <volume>106</volume>(<issue>9</issue>):<page-range>3175&#x2013;82</page-range>. doi: <pub-id pub-id-type="doi">10.1182/blood-2004-11-4516</pub-id>
</citation>
</ref>
<ref id="B12">
<label>12</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Austen</surname> <given-names>B</given-names>
</name>
<name>
<surname>Skowronska</surname> <given-names>A</given-names>
</name>
<name>
<surname>Baker</surname> <given-names>C</given-names>
</name>
<name>
<surname>Powell</surname> <given-names>JE</given-names>
</name>
<name>
<surname>Gardiner</surname> <given-names>A</given-names>
</name>
<name>
<surname>Oscier</surname> <given-names>D</given-names>
</name>
<etal/>
</person-group>. <article-title>Mutation status of the residual ATM allele is an important determinant of the cellular response to chemotherapy and survival in patients with chronic lymphocytic leukemia containing an 11q deletion</article-title>. <source>J Clin Oncol</source> (<year>2007</year>) <volume>25</volume>(<issue>34</issue>):<page-range>5448&#x2013;57</page-range>. doi: <pub-id pub-id-type="doi">10.1200/JCO.2007.11.2649</pub-id>
</citation>
</ref>
<ref id="B13">
<label>13</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stilgenbauer</surname> <given-names>S</given-names>
</name>
<name>
<surname>Winkler</surname> <given-names>D</given-names>
</name>
<name>
<surname>Ott</surname> <given-names>G</given-names>
</name>
<name>
<surname>Schaffner</surname> <given-names>C</given-names>
</name>
<name>
<surname>Leupolt</surname> <given-names>E</given-names>
</name>
<name>
<surname>Bentz</surname> <given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>Molecular characterization of 11q deletions points to a pathogenic role of the ATM gene in mantle cell lymphoma</article-title>. <source>Blood</source> (<year>1999</year>) <volume>94</volume>(<issue>9</issue>):<page-range>3262&#x2013;4</page-range>. doi: <pub-id pub-id-type="doi">10.1182/blood.V94.9.3262</pub-id>
</citation>
</ref>
<ref id="B14">
<label>14</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yuille</surname> <given-names>MA</given-names>
</name>
<name>
<surname>Coignet</surname> <given-names>LJ</given-names>
</name>
<name>
<surname>Abraham</surname> <given-names>SM</given-names>
</name>
<name>
<surname>Yaqub</surname> <given-names>F</given-names>
</name>
<name>
<surname>Luo</surname> <given-names>L</given-names>
</name>
<name>
<surname>Matutes</surname> <given-names>E</given-names>
</name>
<etal/>
</person-group>. <article-title>ATM is usually rearranged in T-cell prolymphocytic leukaemia</article-title>. <source>Oncogene</source> (<year>1998</year>) <volume>16</volume>(<issue>6</issue>):<page-range>789&#x2013;96</page-range>. doi: <pub-id pub-id-type="doi">10.1038/sj.onc.1201603</pub-id>
</citation>
</ref>
<ref id="B15">
<label>15</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kiel</surname> <given-names>MJ</given-names>
</name>
<name>
<surname>Velusamy</surname> <given-names>T</given-names>
</name>
<name>
<surname>Rolland</surname> <given-names>D</given-names>
</name>
<name>
<surname>Sahasrabuddhe</surname> <given-names>AA</given-names>
</name>
<name>
<surname>Chung</surname> <given-names>F</given-names>
</name>
<name>
<surname>Bailey</surname> <given-names>NG</given-names>
</name>
<etal/>
</person-group>. <article-title>Integrated genomic sequencing reveals mutational landscape of T-cell prolymphocytic leukemia</article-title>. <source>Blood</source> (<year>2014</year>) <volume>124</volume>(<issue>9</issue>):<page-range>1460&#x2013;72</page-range>. doi: <pub-id pub-id-type="doi">10.1182/blood-2014-03-559542</pub-id>
</citation>
</ref>
<ref id="B16">
<label>16</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>de Miranda</surname> <given-names>NF</given-names>
</name>
<name>
<surname>Peng</surname> <given-names>R</given-names>
</name>
<name>
<surname>Georgiou</surname> <given-names>K</given-names>
</name>
<name>
<surname>Wu</surname> <given-names>C</given-names>
</name>
<name>
<surname>Falk Sorqvist</surname> <given-names>E</given-names>
</name>
<name>
<surname>Berglund</surname> <given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>DNA repair genes are selectively mutated in diffuse large B cell lymphomas</article-title>. <source>J Exp Med</source> (<year>2013</year>) <volume>210</volume>(<issue>9</issue>):<page-range>1729&#x2013;42</page-range>. doi: <pub-id pub-id-type="doi">10.1084/jem.20122842</pub-id>
</citation>
</ref>
<ref id="B17">
<label>17</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schaffner</surname> <given-names>C</given-names>
</name>
<name>
<surname>Idler</surname> <given-names>I</given-names>
</name>
<name>
<surname>Stilgenbauer</surname> <given-names>S</given-names>
</name>
<name>
<surname>Dohner</surname> <given-names>H</given-names>
</name>
<name>
<surname>Lichter</surname> <given-names>P</given-names>
</name>
</person-group>. <article-title>Mantle cell lymphoma is characterized by inactivation of the ATM gene</article-title>. <source>Proc Natl Acad Sci USA</source> (<year>2000</year>) <volume>97</volume>(<issue>6</issue>):<page-range>2773&#x2013;8</page-range>. doi: <pub-id pub-id-type="doi">10.1073/pnas.050400997</pub-id>
</citation>
</ref>
<ref id="B18">
<label>18</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Choi</surname> <given-names>J</given-names>
</name>
<name>
<surname>Goh</surname> <given-names>G</given-names>
</name>
<name>
<surname>Walradt</surname> <given-names>T</given-names>
</name>
<name>
<surname>Hong</surname> <given-names>BS</given-names>
</name>
<name>
<surname>Bunick</surname> <given-names>CG</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>K</given-names>
</name>
<etal/>
</person-group>. <article-title>Genomic landscape of cutaneous T cell lymphoma</article-title>. <source>Nat Genet</source> (<year>2015</year>) <volume>47</volume>(<issue>9</issue>):<page-range>1011&#x2013;9</page-range>. doi: <pub-id pub-id-type="doi">10.1038/ng.3356</pub-id>
</citation>
</ref>
<ref id="B19">
<label>19</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Inoue</surname> <given-names>S</given-names>
</name>
<name>
<surname>Li</surname> <given-names>WY</given-names>
</name>
<name>
<surname>Tseng</surname> <given-names>A</given-names>
</name>
<name>
<surname>Beerman</surname> <given-names>I</given-names>
</name>
<name>
<surname>Elia</surname> <given-names>AJ</given-names>
</name>
<name>
<surname>Bendall</surname> <given-names>SC</given-names>
</name>
<etal/>
</person-group>. <article-title>Mutant IDH1 downregulates ATM and alters DNA repair and sensitivity to DNA damage independent of TET2</article-title>. <source>Cancer Cell</source> (<year>2016</year>) <volume>30</volume>(<issue>2</issue>):<page-range>337&#x2013;48</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.ccell.2016.05.018</pub-id>
</citation>
</ref>
<ref id="B20">
<label>20</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Taylor</surname> <given-names>A</given-names>
</name>
<name>
<surname>Metcalfe</surname> <given-names>J</given-names>
</name>
<name>
<surname>Thick</surname> <given-names>J</given-names>
</name>
<name>
<surname>Mak</surname> <given-names>Y</given-names>
</name>
</person-group>. <article-title>Leukemia and lymphoma in ataxia telangiectasia</article-title>. <source>Blood</source> (<year>1996</year>) <volume>87</volume>(<issue>2</issue>):<page-range>423&#x2013;38</page-range>. doi: <pub-id pub-id-type="doi">10.1182/blood.V87.2.423.bloodjournal872423</pub-id>
</citation>
</ref>
<ref id="B21">
<label>21</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kamer</surname> <given-names>I</given-names>
</name>
<name>
<surname>Sarig</surname> <given-names>R</given-names>
</name>
<name>
<surname>Zaltsman</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Niv</surname> <given-names>H</given-names>
</name>
<name>
<surname>Oberkovitz</surname> <given-names>G</given-names>
</name>
<name>
<surname>Regev</surname> <given-names>L</given-names>
</name>
<etal/>
</person-group>. <article-title>Proapoptotic BID is an ATM effector in the DNA-damage response</article-title>. <source>Cell</source> (<year>2005</year>) <volume>122</volume>(<issue>4</issue>):<fpage>593</fpage>&#x2013;<lpage>603</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.cell.2005.06.014</pub-id>
</citation>
</ref>
<ref id="B22">
<label>22</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Aki</surname> <given-names>T</given-names>
</name>
<name>
<surname>Uemura</surname> <given-names>K</given-names>
</name>
</person-group>. <article-title>Cell death and survival pathways involving ATM protein kinase</article-title>. <source>Genes (Basel)</source> (<year>2021</year>) <volume>12</volume>(<issue>10</issue>). doi: <pub-id pub-id-type="doi">10.3390/genes12101581</pub-id>
</citation>
</ref>
<ref id="B23">
<label>23</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Grosjean-Raillard</surname> <given-names>J</given-names>
</name>
<name>
<surname>Tailler</surname> <given-names>M</given-names>
</name>
<name>
<surname>Ades</surname> <given-names>L</given-names>
</name>
<name>
<surname>Perfettini</surname> <given-names>JL</given-names>
</name>
<name>
<surname>Fabre</surname> <given-names>C</given-names>
</name>
<name>
<surname>Braun</surname> <given-names>T</given-names>
</name>
<etal/>
</person-group>. <article-title>ATM mediates constitutive NF-kappaB activation in high-risk myelodysplastic syndrome and acute myeloid leukemia</article-title>. <source>Oncogene</source> (<year>2009</year>) <volume>28</volume>(<issue>8</issue>):<page-range>1099&#x2013;109</page-range>. doi: <pub-id pub-id-type="doi">10.1038/onc.2008.457</pub-id>
</citation>
</ref>
<ref id="B24">
<label>24</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guerra</surname> <given-names>RM</given-names>
</name>
<name>
<surname>Bird</surname> <given-names>GH</given-names>
</name>
<name>
<surname>Harvey</surname> <given-names>EP</given-names>
</name>
<name>
<surname>Dharia</surname> <given-names>NV</given-names>
</name>
<name>
<surname>Korshavn</surname> <given-names>KJ</given-names>
</name>
<name>
<surname>Prew</surname> <given-names>MS</given-names>
</name>
<etal/>
</person-group>. <article-title>Precision targeting of BFL-1/A1 and an ATM co-dependency in human cancer</article-title>. <source>Cell Rep</source> (<year>2018</year>) <volume>24</volume>(<issue>13</issue>):<fpage>3393</fpage>&#x2013;<lpage>403.e5</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.celrep.2018.08.089</pub-id>
</citation>
</ref>
<ref id="B25">
<label>25</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Morgado-Palacin</surname> <given-names>I</given-names>
</name>
<name>
<surname>Day</surname> <given-names>A</given-names>
</name>
<name>
<surname>Murga</surname> <given-names>M</given-names>
</name>
<name>
<surname>Lafarga</surname> <given-names>V</given-names>
</name>
<name>
<surname>Anton</surname> <given-names>ME</given-names>
</name>
<name>
<surname>Tubbs</surname> <given-names>A</given-names>
</name>
<etal/>
</person-group>. <article-title>Targeting the kinase activities of ATR and ATM exhibits antitumoral activity in mouse models of MLL-rearranged AML</article-title>. <source>Sci Signal</source> (<year>2016</year>) <volume>9</volume>(<issue>445</issue>):<fpage>ra91</fpage>. doi: <pub-id pub-id-type="doi">10.1126/scisignal.aad8243</pub-id>
</citation>
</ref>
<ref id="B26">
<label>26</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Santos</surname> <given-names>MA</given-names>
</name>
<name>
<surname>Faryabi</surname> <given-names>RB</given-names>
</name>
<name>
<surname>Ergen</surname> <given-names>AV</given-names>
</name>
<name>
<surname>Day</surname> <given-names>AM</given-names>
</name>
<name>
<surname>Malhowski</surname> <given-names>A</given-names>
</name>
<name>
<surname>Canela</surname> <given-names>A</given-names>
</name>
<etal/>
</person-group>. <article-title>DNA-damage-induced differentiation of leukaemic cells as an anti-cancer barrier</article-title>. <source>Nature</source> (<year>2014</year>) <volume>514</volume>(<issue>7520</issue>):<page-range>107&#x2013;11</page-range>. doi: <pub-id pub-id-type="doi">10.1038/nature13483</pub-id>
</citation>
</ref>
<ref id="B27">
<label>27</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gregory</surname> <given-names>MA</given-names>
</name>
<name>
<surname>D&#x2019;Alessandro</surname> <given-names>A</given-names>
</name>
<name>
<surname>Alvarez-Calderon</surname> <given-names>F</given-names>
</name>
<name>
<surname>Kim</surname> <given-names>J</given-names>
</name>
<name>
<surname>Nemkov</surname> <given-names>T</given-names>
</name>
<name>
<surname>Adane</surname> <given-names>B</given-names>
</name>
<etal/>
</person-group>. <article-title>ATM/G6PD-driven redox metabolism promotes FLT3 inhibitor resistance in acute myeloid leukemia</article-title>. <source>Proc Natl Acad Sci</source> (<year>2016</year>) <volume>113</volume>(<issue>43</issue>):<page-range>E6669&#x2013;E78</page-range>. doi: <pub-id pub-id-type="doi">10.1073/pnas.1603876113</pub-id>
</citation>
</ref>
<ref id="B28">
<label>28</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname> <given-names>Y-L</given-names>
</name>
<name>
<surname>Tang</surname> <given-names>C</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>M-Y</given-names>
</name>
<name>
<surname>Huang</surname> <given-names>W-L</given-names>
</name>
<name>
<surname>Xu</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Sun</surname> <given-names>H-Y</given-names>
</name>
<etal/>
</person-group>. <article-title>Blocking ATM-dependent NF-&#x3ba;B pathway overcomes niche protection and improves chemotherapy response in acute lymphoblastic leukemia</article-title>. <source>Leukemia</source> (<year>2019</year>) <volume>33</volume>(<issue>10</issue>):<page-range>2365&#x2013;78</page-range>. doi: <pub-id pub-id-type="doi">10.1038/s41375-019-0458-0</pub-id>
</citation>
</ref>
<ref id="B29">
<label>29</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Korwek</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Sewastianik</surname> <given-names>T</given-names>
</name>
<name>
<surname>Bielak-Zmijewska</surname> <given-names>A</given-names>
</name>
<name>
<surname>Mosieniak</surname> <given-names>G</given-names>
</name>
<name>
<surname>Alster</surname> <given-names>O</given-names>
</name>
<name>
<surname>Moreno-Villanueva</surname> <given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>Inhibition of ATM blocks the etoposide-induced DNA damage response and apoptosis of resting human T cells</article-title>. <source>DNA Repair (Amst)</source> (<year>2012</year>) <volume>11</volume>(<issue>11</issue>):<page-range>864&#x2013;73</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.dnarep.2012.08.006</pub-id>
</citation>
</ref>
<ref id="B30">
<label>30</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Herrero</surname> <given-names>AB</given-names>
</name>
<name>
<surname>Guti&#xe9;rrez</surname> <given-names>NC</given-names>
</name>
</person-group>. <article-title>Targeting ongoing DNA damage in multiple myeloma: effects of DNA damage response inhibitors on plasma cell survival</article-title>. <source>Front Oncol</source> (<year>2017</year>) <volume>7</volume>. doi: <pub-id pub-id-type="doi">10.3389/fonc.2017.00098</pub-id>
</citation>
</ref>
<ref id="B31">
<label>31</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Botrugno</surname> <given-names>OA</given-names>
</name>
<name>
<surname>Bianchessi</surname> <given-names>S</given-names>
</name>
<name>
<surname>Zambroni</surname> <given-names>D</given-names>
</name>
<name>
<surname>Frenquelli</surname> <given-names>M</given-names>
</name>
<name>
<surname>Belloni</surname> <given-names>D</given-names>
</name>
<name>
<surname>Bongiovanni</surname> <given-names>L</given-names>
</name>
<etal/>
</person-group>. <article-title>ATR addiction in multiple myeloma: synthetic lethal approaches exploiting established therapies</article-title>. <source>Haematologica</source> (<year>2019</year>).</citation>
</ref>
<ref id="B32">
<label>32</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xing</surname> <given-names>L</given-names>
</name>
<name>
<surname>Lin</surname> <given-names>L</given-names>
</name>
<name>
<surname>Yu</surname> <given-names>T</given-names>
</name>
<name>
<surname>Li</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Cho</surname> <given-names>S-F</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>J</given-names>
</name>
<etal/>
</person-group>. <article-title>A novel BCMA PBD-ADC with ATM/ATR/WEE1 inhibitors or bortezomib induce synergistic lethality in multiple myeloma</article-title>. <source>Leukemia</source> (<year>2020</year>). doi: <pub-id pub-id-type="doi">10.1038/s41375-020-0745-9</pub-id>
</citation>
</ref>
<ref id="B33">
<label>33</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shah</surname> <given-names>N</given-names>
</name>
<name>
<surname>Chari</surname> <given-names>A</given-names>
</name>
<name>
<surname>Scott</surname> <given-names>E</given-names>
</name>
<name>
<surname>Mezzi</surname> <given-names>K</given-names>
</name>
<name>
<surname>Usmani</surname> <given-names>SZ</given-names>
</name>
</person-group>. <article-title>B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches</article-title>. <source>Leukemia</source> (<year>2020</year>) <volume>34</volume>(<issue>4</issue>):<fpage>985</fpage>&#x2013;<lpage>1005</lpage>. doi: <pub-id pub-id-type="doi">10.1038/s41375-020-0734-z</pub-id>
</citation>
</ref>
<ref id="B34">
<label>34</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Prince</surname> <given-names>HM</given-names>
</name>
<name>
<surname>Dickinson</surname> <given-names>M</given-names>
</name>
</person-group>. <article-title>Romidepsin for cutaneous T-cell lymphoma</article-title>. <source>Clin Cancer Res</source> (<year>2012</year>) <volume>18</volume>(<issue>13</issue>):<page-range>3509&#x2013;15</page-range>. doi: <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-11-3144</pub-id>
</citation>
</ref>
<ref id="B35">
<label>35</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Scotto</surname> <given-names>L</given-names>
</name>
<name>
<surname>Jirau-Serrano</surname> <given-names>X</given-names>
</name>
<name>
<surname>Zullo</surname> <given-names>K</given-names>
</name>
<name>
<surname>Mangone</surname> <given-names>M</given-names>
</name>
<name>
<surname>Amengual</surname> <given-names>JE</given-names>
</name>
<name>
<surname>Deng</surname> <given-names>C</given-names>
</name>
<etal/>
</person-group>. <article-title>The ATM inhibitor KU60019 synergizes the antineoplastic effect of romidepsin in mantle cell lymphoma (MCL)</article-title>. <source>Blood</source> (<year>2015</year>) <volume>126</volume>(<issue>23</issue>):<fpage>3703</fpage>. doi: <pub-id pub-id-type="doi">10.1182/blood.V126.23.3703.3703</pub-id>
</citation>
</ref>
<ref id="B36">
<label>36</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Buisson</surname> <given-names>R</given-names>
</name>
<name>
<surname>Niraj</surname> <given-names>J</given-names>
</name>
<name>
<surname>Rodrigue</surname> <given-names>A</given-names>
</name>
<name>
<surname>Ho</surname> <given-names>CK</given-names>
</name>
<name>
<surname>Kreuzer</surname> <given-names>J</given-names>
</name>
<name>
<surname>Foo</surname> <given-names>TK</given-names>
</name>
<etal/>
</person-group>. <article-title>Coupling of homologous recombination and the checkpoint by ATR</article-title>. <source>Mol Cell</source> (<year>2017</year>) <volume>65</volume>(<issue>2</issue>):<page-range>336&#x2013;46</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.molcel.2016.12.007</pub-id>
</citation>
</ref>
<ref id="B37">
<label>37</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nieborowska-Skorska</surname> <given-names>M</given-names>
</name>
<name>
<surname>Stoklosa</surname> <given-names>T</given-names>
</name>
<name>
<surname>Datta</surname> <given-names>M</given-names>
</name>
<name>
<surname>Czechowska</surname> <given-names>A</given-names>
</name>
<name>
<surname>Rink</surname> <given-names>L</given-names>
</name>
<name>
<surname>Slupianek</surname> <given-names>A</given-names>
</name>
<etal/>
</person-group>. <article-title>ATR-chk1 axis protects BCR/ABL leukemia cells from the lethal effect of DNA double-strand breaks</article-title>. <source>Cell Cycle</source> (<year>2006</year>) <volume>5</volume>(<issue>9</issue>):<fpage>994</fpage>&#x2013;<lpage>1000</lpage>. doi: <pub-id pub-id-type="doi">10.4161/cc.5.9.2722</pub-id>
</citation>
</ref>
<ref id="B38">
<label>38</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cottini</surname> <given-names>F</given-names>
</name>
<name>
<surname>Hideshima</surname> <given-names>T</given-names>
</name>
<name>
<surname>Suzuki</surname> <given-names>R</given-names>
</name>
<name>
<surname>Tai</surname> <given-names>YT</given-names>
</name>
<name>
<surname>Bianchini</surname> <given-names>G</given-names>
</name>
<name>
<surname>Richardson</surname> <given-names>PG</given-names>
</name>
<etal/>
</person-group>. <article-title>Synthetic lethal approaches exploiting DNA damage in aggressive myeloma</article-title>. <source>Cancer Discov</source> (<year>2015</year>) <volume>5</volume>(<issue>9</issue>):<page-range>972&#x2013;87</page-range>. doi: <pub-id pub-id-type="doi">10.1158/2159-8290.CD-14-0943</pub-id>
</citation>
</ref>
<ref id="B39">
<label>39</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sousa</surname> <given-names>MML</given-names>
</name>
<name>
<surname>Zub</surname> <given-names>KA</given-names>
</name>
<name>
<surname>Aas</surname> <given-names>PA</given-names>
</name>
<name>
<surname>Hanssen-Bauer</surname> <given-names>A</given-names>
</name>
<name>
<surname>Demirovic</surname> <given-names>A</given-names>
</name>
<name>
<surname>Sarno</surname> <given-names>A</given-names>
</name>
<etal/>
</person-group>. <article-title>An inverse switch in DNA base excision and strand break repair contributes to melphalan resistance in multiple myeloma cells</article-title>. <source>PloS One</source> (<year>2013</year>) <volume>8</volume>(<issue>2</issue>):<elocation-id>e55493</elocation-id>. doi: <pub-id pub-id-type="doi">10.1371/journal.pone.0055493</pub-id>
</citation>
</ref>
<ref id="B40">
<label>40</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ma</surname> <given-names>J</given-names>
</name>
<name>
<surname>Li</surname> <given-names>X</given-names>
</name>
<name>
<surname>Su</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Zhao</surname> <given-names>J</given-names>
</name>
<name>
<surname>Luedtke</surname> <given-names>DA</given-names>
</name>
<name>
<surname>Epshteyn</surname> <given-names>V</given-names>
</name>
<etal/>
</person-group>. <article-title>Mechanisms responsible for the synergistic antileukemic interactions between ATR inhibition and cytarabine in acute myeloid leukemia cells</article-title>. <source>Sci Rep</source> (<year>2017</year>) <volume>7</volume>:<fpage>41950</fpage>. doi: <pub-id pub-id-type="doi">10.1038/srep41950</pub-id>
</citation>
</ref>
<ref id="B41">
<label>41</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fordham</surname> <given-names>SE</given-names>
</name>
<name>
<surname>Blair</surname> <given-names>HJ</given-names>
</name>
<name>
<surname>Elstob</surname> <given-names>CJ</given-names>
</name>
<name>
<surname>Plummer</surname> <given-names>R</given-names>
</name>
<name>
<surname>Drew</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Curtin</surname> <given-names>NJ</given-names>
</name>
<etal/>
</person-group>. <article-title>Inhibition of ATR acutely sensitizes acute myeloid leukemia cells to nucleoside analogs that target ribonucleotide reductase</article-title>. <source>Blood Adv</source> (<year>2018</year>) <volume>2</volume>(<issue>10</issue>):<page-range>1157&#x2013;69</page-range>. doi: <pub-id pub-id-type="doi">10.1182/bloodadvances.2017015214</pub-id>
</citation>
</ref>
<ref id="B42">
<label>42</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname> <given-names>T</given-names>
</name>
<name>
<surname>Shatara</surname> <given-names>M</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>F</given-names>
</name>
<name>
<surname>Knight</surname> <given-names>T</given-names>
</name>
<name>
<surname>Edwards</surname> <given-names>H</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>G</given-names>
</name>
<etal/>
</person-group>. <article-title>Simultaneous cotargeting of ATR and RNA Polymerase I transcription demonstrates synergistic antileukemic effects on acute myeloid leukemia</article-title>. <source>Signal Transduct Target Ther</source> (<year>2019</year>) <volume>4</volume>(<issue>1</issue>):<fpage>44</fpage>. doi: <pub-id pub-id-type="doi">10.1038/s41392-019-0076-3</pub-id>
</citation>
</ref>
<ref id="B43">
<label>43</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Qi</surname> <given-names>W</given-names>
</name>
<name>
<surname>Xu</surname> <given-names>X</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>M</given-names>
</name>
<name>
<surname>Li</surname> <given-names>X</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>C</given-names>
</name>
<name>
<surname>Sun</surname> <given-names>L</given-names>
</name>
<etal/>
</person-group>. <article-title>Inhibition of Wee1 sensitizes AML cells to ATR inhibitor VE-822-induced DNA damage and apoptosis</article-title>. <source>Biochem Pharmacol</source> (<year>2019</year>) <volume>164</volume>:<page-range>273&#x2013;82</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.bcp.2019.04.022</pub-id>
</citation>
</ref>
<ref id="B44">
<label>44</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Le</surname> <given-names>TM</given-names>
</name>
<name>
<surname>Poddar</surname> <given-names>S</given-names>
</name>
<name>
<surname>Capri</surname> <given-names>JR</given-names>
</name>
<name>
<surname>Abt</surname> <given-names>ER</given-names>
</name>
<name>
<surname>Kim</surname> <given-names>W</given-names>
</name>
<name>
<surname>Wei</surname> <given-names>L</given-names>
</name>
<etal/>
</person-group>. <article-title>ATR inhibition facilitates targeting of leukemia dependence on convergent nucleotide biosynthetic pathways</article-title>. <source>Nat Commun</source> (<year>2017</year>) <volume>8</volume>(<issue>1</issue>):<fpage>241</fpage>. doi: <pub-id pub-id-type="doi">10.1038/s41467-017-00221-3</pub-id>
</citation>
</ref>
<ref id="B45">
<label>45</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Negi</surname> <given-names>SS</given-names>
</name>
<name>
<surname>Brown</surname> <given-names>P</given-names>
</name>
</person-group>. <article-title>rRNA synthesis inhibitor, CX-5461, activates ATM/ATR pathway in acute lymphoblastic leukemia, arrests cells in G2 phase and induces apoptosis</article-title>. <source>Oncotarget</source> (<year>2015</year>) <volume>6</volume>(<issue>20</issue>). doi: <pub-id pub-id-type="doi">10.18632/oncotarget.4093</pub-id>
</citation>
</ref>
<ref id="B46">
<label>46</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ghelli Luserna Di Ror&#xe0;</surname> <given-names>A</given-names>
</name>
<name>
<surname>Ghetti</surname> <given-names>M</given-names>
</name>
<name>
<surname>Ledda</surname> <given-names>L</given-names>
</name>
<name>
<surname>Ferrari</surname> <given-names>A</given-names>
</name>
<name>
<surname>Bocconcelli</surname> <given-names>M</given-names>
</name>
<name>
<surname>Padella</surname> <given-names>A</given-names>
</name>
<etal/>
</person-group>. <article-title>Exploring the ATR-CHK1 pathway in the response of doxorubicin-induced DNA damages in acute lymphoblastic leukemia cells</article-title>. <source>Cell Biol Toxicol</source> (<year>2021</year>). doi: <pub-id pub-id-type="doi">10.1007/s10565-021-09640-x</pub-id>
</citation>
</ref>
<ref id="B47">
<label>47</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chu</surname> <given-names>SH</given-names>
</name>
<name>
<surname>Song</surname> <given-names>EJ</given-names>
</name>
<name>
<surname>Chabon</surname> <given-names>JR</given-names>
</name>
<name>
<surname>Minehart</surname> <given-names>J</given-names>
</name>
<name>
<surname>Matovina</surname> <given-names>CN</given-names>
</name>
<name>
<surname>Makofske</surname> <given-names>JL</given-names>
</name>
<etal/>
</person-group>. <article-title>Inhibition of MEK and ATR is effective in a B-cell acute lymphoblastic leukemia model driven by Mll-Af4 and activated Ras</article-title>. <source>Blood Adv</source> (<year>2018</year>) <volume>2</volume>(<issue>19</issue>):<page-range>2478&#x2013;90</page-range>. doi: <pub-id pub-id-type="doi">10.1182/bloodadvances.2018021592</pub-id>
</citation>
</ref>
<ref id="B48">
<label>48</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pouliot</surname> <given-names>GP</given-names>
</name>
<name>
<surname>Degar</surname> <given-names>J</given-names>
</name>
<name>
<surname>Hinze</surname> <given-names>L</given-names>
</name>
<name>
<surname>Kochupurakkal</surname> <given-names>B</given-names>
</name>
<name>
<surname>Vo</surname> <given-names>CD</given-names>
</name>
<name>
<surname>Burns</surname> <given-names>MA</given-names>
</name>
<etal/>
</person-group>. <article-title>Fanconi-BRCA pathway mutations in childhood T-cell acute lymphoblastic leukemia</article-title>. <source>PloS One</source> (<year>2019</year>) <volume>14</volume>(<issue>11</issue>):<elocation-id>e0221288</elocation-id>. doi: <pub-id pub-id-type="doi">10.1371/journal.pone.0221288</pub-id>
</citation>
</ref>
<ref id="B49">
<label>49</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kwok</surname> <given-names>M</given-names>
</name>
<name>
<surname>Davies</surname> <given-names>N</given-names>
</name>
<name>
<surname>Agathanggelou</surname> <given-names>A</given-names>
</name>
<name>
<surname>Smith</surname> <given-names>E</given-names>
</name>
<name>
<surname>Oldreive</surname> <given-names>C</given-names>
</name>
<name>
<surname>Petermann</surname> <given-names>E</given-names>
</name>
<etal/>
</person-group>. <article-title>ATR inhibition induces synthetic lethality and overcomes chemoresistance in TP53- or ATM-defective chronic lymphocytic leukemia cells</article-title>. <source>Blood</source> (<year>2016</year>) <volume>127</volume>(<issue>5</issue>):<page-range>582&#x2013;95</page-range>. doi: <pub-id pub-id-type="doi">10.1182/blood-2015-05-644872</pub-id>
</citation>
</ref>
<ref id="B50">
<label>50</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Menezes</surname> <given-names>DL</given-names>
</name>
<name>
<surname>Holt</surname> <given-names>J</given-names>
</name>
<name>
<surname>Tang</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Feng</surname> <given-names>J</given-names>
</name>
<name>
<surname>Barsanti</surname> <given-names>P</given-names>
</name>
<name>
<surname>Pan</surname> <given-names>Y</given-names>
</name>
<etal/>
</person-group>. <article-title>A synthetic lethal screen reveals enhanced sensitivity to ATR inhibitor treatment in mantle cell lymphoma with ATM loss-of-function</article-title>. <source>Mol Cancer Res MCR</source> (<year>2015</year>) <volume>13</volume>(<issue>1</issue>):<page-range>120&#x2013;9</page-range>. doi: <pub-id pub-id-type="doi">10.1158/1541-7786.MCR-14-0240</pub-id>
</citation>
</ref>
<ref id="B51">
<label>51</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Restelli</surname> <given-names>V</given-names>
</name>
<name>
<surname>Chil&#xe0;</surname> <given-names>R</given-names>
</name>
<name>
<surname>Vagni</surname> <given-names>M</given-names>
</name>
<name>
<surname>Lupi</surname> <given-names>M</given-names>
</name>
<name>
<surname>Tarantelli</surname> <given-names>C</given-names>
</name>
<name>
<surname>Spriano</surname> <given-names>F</given-names>
</name>
<etal/>
</person-group>. <article-title>DNA damage response inhibitor combinations exert synergistic antitumor activity in aggressive B cell lymphomas</article-title>. <source>Mol Cancer Ther</source> (<year>2019</year>). doi: <pub-id pub-id-type="doi">10.1158/1535-7163.MCT-18-0919</pub-id>
</citation>
</ref>
<ref id="B52">
<label>52</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Young</surname> <given-names>LA</given-names>
</name>
<name>
<surname>O'Connor</surname> <given-names>LO</given-names>
</name>
<name>
<surname>de Renty</surname> <given-names>C</given-names>
</name>
<name>
<surname>Veldman-Jones</surname> <given-names>MH</given-names>
</name>
<name>
<surname>Dorval</surname> <given-names>T</given-names>
</name>
<name>
<surname>Wilson</surname> <given-names>Z</given-names>
</name>
<etal/>
</person-group>. <article-title>Differential activity of ATR and WEE1 inhibitors in a highly sensitive subpopulation of DLBCL linked to replication stress</article-title>. <source>Cancer Res</source> (<year>2019</year>) <volume>79</volume>(<issue>14</issue>):<page-range>3762&#x2013;75</page-range>. doi: <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-18-2480</pub-id>
</citation>
</ref>
<ref id="B53">
<label>53</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wengner</surname> <given-names>AM</given-names>
</name>
<name>
<surname>Siemeister</surname> <given-names>G</given-names>
</name>
<name>
<surname>L&#xfc;cking</surname> <given-names>U</given-names>
</name>
<name>
<surname>Lefranc</surname> <given-names>J</given-names>
</name>
<name>
<surname>Wortmann</surname> <given-names>L</given-names>
</name>
<name>
<surname>Lienau</surname> <given-names>P</given-names>
</name>
<etal/>
</person-group>. <article-title>The novel ATR inhibitor BAY 1895344 is efficacious as monotherapy and combined with DNA damage&#x2013;inducing or repair&#x2013;compromising therapies in preclinical cancer models</article-title>. <source>Mol Cancer Ther</source> (<year>2020</year>) <volume>19</volume>(<issue>1</issue>):<fpage>26</fpage>&#x2013;<lpage>38</lpage>. doi: <pub-id pub-id-type="doi">10.1158/1535-7163.MCT-19-0019</pub-id>
</citation>
</ref>
<ref id="B54">
<label>54</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Biskup</surname> <given-names>E</given-names>
</name>
<name>
<surname>Naym</surname> <given-names>DG</given-names>
</name>
<name>
<surname>Gniadecki</surname> <given-names>R</given-names>
</name>
</person-group>. <article-title>Small-molecule inhibitors of Ataxia Telangiectasia and Rad3 related kinase (ATR) sensitize lymphoma cells to UVA radiation</article-title>. <source>J Dermatol Sci</source> (<year>2016</year>) <volume>84</volume>(<issue>3</issue>):<page-range>239&#x2013;47</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.jdermsci.2016.09.010</pub-id>
</citation>
</ref>
<ref id="B55">
<label>55</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Burma</surname> <given-names>S</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>DJ</given-names>
</name>
</person-group>. <article-title>Role of DNA&#x2013;PK in the cellular response to DNA double-strand breaks</article-title>. <source>DNA Repair</source> (<year>2004</year>) <volume>3</volume>(<issue>8</issue>):<page-range>909&#x2013;18</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.dnarep.2004.03.021</pub-id>
</citation>
</ref>
<ref id="B56">
<label>56</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname> <given-names>CY</given-names>
</name>
<name>
<surname>Huang</surname> <given-names>EYH</given-names>
</name>
<name>
<surname>Huang</surname> <given-names>SC</given-names>
</name>
<name>
<surname>Chung</surname> <given-names>BC</given-names>
</name>
</person-group>. <article-title>DNA-PK/Chk2 induces centrosome amplification during prolonged replication stress</article-title>. <source>Oncogene</source> (<year>2015</year>) <volume>34</volume>(<issue>10</issue>):<page-range>1263&#x2013;9</page-range>. doi: <pub-id pub-id-type="doi">10.1038/onc.2014.74</pub-id>
</citation>
</ref>
<ref id="B57">
<label>57</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Willmore</surname> <given-names>E</given-names>
</name>
<name>
<surname>Elliott</surname> <given-names>SL</given-names>
</name>
<name>
<surname>Mainou-Fowler</surname> <given-names>T</given-names>
</name>
<name>
<surname>Summerfield</surname> <given-names>GP</given-names>
</name>
<name>
<surname>Jackson</surname> <given-names>GH</given-names>
</name>
<name>
<surname>O'Neill</surname> <given-names>F</given-names>
</name>
<etal/>
</person-group>. <article-title>DNA-dependent protein kinase is a therapeutic target and an indicator of poor prognosis in B-cell chronic lymphocytic leukemia</article-title>. <source>Clin Cancer Res</source> (<year>2008</year>) <volume>14</volume>(<issue>12</issue>):<page-range>3984&#x2013;92</page-range>. doi: <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-07-5158</pub-id>
</citation>
</ref>
<ref id="B58">
<label>58</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Elliott</surname> <given-names>SL</given-names>
</name>
<name>
<surname>Crawford</surname> <given-names>C</given-names>
</name>
<name>
<surname>Mulligan</surname> <given-names>E</given-names>
</name>
<name>
<surname>Summerfield</surname> <given-names>G</given-names>
</name>
<name>
<surname>Newton</surname> <given-names>P</given-names>
</name>
<name>
<surname>Wallis</surname> <given-names>J</given-names>
</name>
<etal/>
</person-group>. <article-title>Mitoxantrone in combination with an inhibitor of DNA-dependent protein kinase: a potential therapy for high risk B-cell chronic lymphocytic leukaemia</article-title>. <source>Br J Haematol</source> (<year>2011</year>) <volume>152</volume>(<issue>1</issue>):<fpage>61</fpage>&#x2013;<lpage>71</lpage>. doi: <pub-id pub-id-type="doi">10.1111/j.1365-2141.2010.08425.x</pub-id>
</citation>
</ref>
<ref id="B59">
<label>59</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Willmore</surname> <given-names>E</given-names>
</name>
<name>
<surname>de Caux</surname> <given-names>S</given-names>
</name>
<name>
<surname>Sunter</surname> <given-names>NJ</given-names>
</name>
<name>
<surname>Tilby</surname> <given-names>MJ</given-names>
</name>
<name>
<surname>Jackson</surname> <given-names>GH</given-names>
</name>
<name>
<surname>Austin</surname> <given-names>CA</given-names>
</name>
<etal/>
</person-group>. <article-title>A novel DNA-dependent protein kinase inhibitor, NU7026, potentiates the cytotoxicity of topoisomerase II poisons used in the treatment of leukemia</article-title>. <source>Blood</source> (<year>2004</year>) <volume>103</volume>(<issue>12</issue>):<page-range>4659&#x2013;65</page-range>. doi: <pub-id pub-id-type="doi">10.1182/blood-2003-07-2527</pub-id>
</citation>
</ref>
<ref id="B60">
<label>60</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Haines</surname> <given-names>E</given-names>
</name>
<name>
<surname>Nishida</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Carr</surname> <given-names>MI</given-names>
</name>
<name>
<surname>Montoya</surname> <given-names>RH</given-names>
</name>
<name>
<surname>Ostermann</surname> <given-names>LB</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>W</given-names>
</name>
<etal/>
</person-group>. <article-title>DNA-PK inhibitor peposertib enhances p53-dependent cytotoxicity of DNA double-strand break inducing therapy in acute leukemia</article-title>. <source>Sci Rep</source> (<year>2021</year>) <volume>11</volume>(<issue>1</issue>):<fpage>12148</fpage>. doi: <pub-id pub-id-type="doi">10.1038/s41598-021-90500-3</pub-id>
</citation>
</ref>
<ref id="B61">
<label>61</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Carr</surname> <given-names>MI</given-names>
</name>
<name>
<surname>Zimmermann</surname> <given-names>A</given-names>
</name>
<name>
<surname>Chiu</surname> <given-names>L-Y</given-names>
</name>
<name>
<surname>Zenke</surname> <given-names>FT</given-names>
</name>
<name>
<surname>Blaukat</surname> <given-names>A</given-names>
</name>
<name>
<surname>Vassilev</surname> <given-names>LT</given-names>
</name>
</person-group>. <article-title>DNA-PK inhibitor, M3814, as a new combination partner of mylotarg in the treatment of acute myeloid leukemia</article-title>. <source>Front Oncol</source> (<year>2020</year>) <volume>10</volume>(<issue>127</issue>). doi: <pub-id pub-id-type="doi">10.3389/fonc.2020.00127</pub-id>
</citation>
</ref>
<ref id="B62">
<label>62</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Alikarami</surname> <given-names>F</given-names>
</name>
<name>
<surname>Safa</surname> <given-names>M</given-names>
</name>
<name>
<surname>Faranoush</surname> <given-names>M</given-names>
</name>
<name>
<surname>Hayat</surname> <given-names>P</given-names>
</name>
<name>
<surname>Kazemi</surname> <given-names>A</given-names>
</name>
</person-group>. <article-title>Inhibition of DNA-PK enhances chemosensitivity of B-cell precursor acute lymphoblastic leukemia cells to doxorubicin</article-title>. <source>BioMed Pharmacother</source> (<year>2017</year>) <volume>94</volume>:<page-range>1077&#x2013;93</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.biopha.2017.08.022</pub-id>
</citation>
</ref>
<ref id="B63">
<label>63</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Demel</surname> <given-names>H-R</given-names>
</name>
<name>
<surname>Feuerecker</surname> <given-names>B</given-names>
</name>
<name>
<surname>Piontek</surname> <given-names>G</given-names>
</name>
<name>
<surname>Seidl</surname> <given-names>C</given-names>
</name>
<name>
<surname>Blechert</surname> <given-names>B</given-names>
</name>
<name>
<surname>Pickhard</surname> <given-names>A</given-names>
</name>
<etal/>
</person-group>. <article-title>Effects of topoisomerase inhibitors that induce DNA damage response on glucose metabolism and PI3K/Akt/mTOR signaling in multiple myeloma cells</article-title>. <source>Am J Cancer Res</source> (<year>2015</year>) <volume>5</volume>(<issue>5</issue>):<page-range>1649&#x2013;64</page-range>.</citation>
</ref>
<ref id="B64">
<label>64</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Veuger</surname> <given-names>SJ</given-names>
</name>
<name>
<surname>Curtin</surname> <given-names>NJ</given-names>
</name>
<name>
<surname>Richardson</surname> <given-names>CJ</given-names>
</name>
<name>
<surname>Smith</surname> <given-names>GC</given-names>
</name>
<name>
<surname>Durkacz</surname> <given-names>BW</given-names>
</name>
</person-group>. <article-title>Radiosensitization and DNA repair inhibition by the combined use of novel inhibitors of DNA-dependent protein kinase and poly(ADP-ribose) polymerase-1</article-title>. <source>Cancer Res</source> (<year>2003</year>) <volume>63</volume>(<issue>18</issue>):<page-range>6008&#x2013;15</page-range>.</citation>
</ref>
<ref id="B65">
<label>65</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname> <given-names>C</given-names>
</name>
<name>
<surname>Betti</surname> <given-names>C</given-names>
</name>
<name>
<surname>Singh</surname> <given-names>S</given-names>
</name>
<name>
<surname>Toor</surname> <given-names>A</given-names>
</name>
<name>
<surname>Vaughan</surname> <given-names>A</given-names>
</name>
</person-group>. <article-title>Impaired NHEJ function in multiple myeloma</article-title>. <source>Mutat Res</source> (<year>2009</year>) <volume>660</volume>(<issue>1-2</issue>):<fpage>66</fpage>&#x2013;<lpage>73</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.mrfmmm.2008.10.019</pub-id>
</citation>
</ref>
<ref id="B66">
<label>66</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>D&#xf6;hner</surname> <given-names>H</given-names>
</name>
<name>
<surname>Stilgenbauer</surname> <given-names>S</given-names>
</name>
<name>
<surname>Benner</surname> <given-names>A</given-names>
</name>
<name>
<surname>Leupolt</surname> <given-names>E</given-names>
</name>
<name>
<surname>Kr&#xf6;ber</surname> <given-names>A</given-names>
</name>
<name>
<surname>Bullinger</surname> <given-names>L</given-names>
</name>
<etal/>
</person-group>. <article-title>Genomic aberrations and survival in chronic lymphocytic leukemia</article-title>. <source>N Engl J Med</source> (<year>2000</year>) <volume>343</volume>(<issue>26</issue>):<page-range>1910&#x2013;6</page-range>. doi: <pub-id pub-id-type="doi">10.1056/NEJM200012283432602</pub-id>
</citation>
</ref>
<ref id="B67">
<label>67</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kay</surname> <given-names>NE</given-names>
</name>
<name>
<surname>O'Brien</surname> <given-names>SM</given-names>
</name>
<name>
<surname>Pettitt</surname> <given-names>AR</given-names>
</name>
<name>
<surname>Stilgenbauer</surname> <given-names>S</given-names>
</name>
</person-group>. <article-title>The role of prognostic factors in assessing &#x2018;high-risk&#x2019; subgroups of patients with chronic lymphocytic leukemia</article-title>. <source>Leukemia</source> (<year>2007</year>) <volume>21</volume>(<issue>9</issue>):<page-range>1885&#x2013;91</page-range>. doi: <pub-id pub-id-type="doi">10.1038/sj.leu.2404802</pub-id>
</citation>
</ref>
<ref id="B68">
<label>68</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Thijssen</surname> <given-names>R</given-names>
</name>
<name>
<surname>Ter Burg</surname> <given-names>J</given-names>
</name>
<name>
<surname>Garrick</surname> <given-names>B</given-names>
</name>
<name>
<surname>van Bochove</surname> <given-names>GG</given-names>
</name>
<name>
<surname>Brown</surname> <given-names>JR</given-names>
</name>
<name>
<surname>Fernandes</surname> <given-names>SM</given-names>
</name>
<etal/>
</person-group>. <article-title>Dual TORK/DNA-PK inhibition blocks critical signaling pathways in chronic lymphocytic leukemia</article-title>. <source>Blood</source> (<year>2016</year>) <volume>128</volume>(<issue>4</issue>):<page-range>574&#x2013;83</page-range>. doi: <pub-id pub-id-type="doi">10.1182/blood-2016-02-700328</pub-id>
</citation>
</ref>
<ref id="B69">
<label>69</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chaib-Mezrag</surname> <given-names>H</given-names>
</name>
<name>
<surname>Lemacon</surname> <given-names>D</given-names>
</name>
<name>
<surname>Fontaine</surname> <given-names>H</given-names>
</name>
<name>
<surname>Bellon</surname> <given-names>M</given-names>
</name>
<name>
<surname>Bai</surname> <given-names>XT</given-names>
</name>
<name>
<surname>Drac</surname> <given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>Tax impairs DNA replication forks and increases DNA breaks in specific oncogenic genome regions</article-title>. <source>Mol Cancer</source> (<year>2014</year>) <volume>13</volume>:<fpage>205</fpage>. doi: <pub-id pub-id-type="doi">10.1186/1476-4598-13-205</pub-id>
</citation>
</ref>
<ref id="B70">
<label>70</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Baydoun</surname> <given-names>HH</given-names>
</name>
<name>
<surname>Bai</surname> <given-names>XT</given-names>
</name>
<name>
<surname>Shelton</surname> <given-names>S</given-names>
</name>
<name>
<surname>Nicot</surname> <given-names>C</given-names>
</name>
</person-group>. <article-title>HTLV-I tax increases genetic instability by inducing DNA double strand breaks during DNA replication and switching repair to NHEJ</article-title>. <source>PloS One</source> (<year>2012</year>) <volume>7</volume>(<issue>8</issue>):<elocation-id>e42226</elocation-id>. doi: <pub-id pub-id-type="doi">10.1371/journal.pone.0042226</pub-id>
</citation>
</ref>
<ref id="B71">
<label>71</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hisatomi</surname> <given-names>T</given-names>
</name>
<name>
<surname>Sueoka-Aragane</surname> <given-names>N</given-names>
</name>
<name>
<surname>Sato</surname> <given-names>A</given-names>
</name>
<name>
<surname>Tomimasu</surname> <given-names>R</given-names>
</name>
<name>
<surname>Ide</surname> <given-names>M</given-names>
</name>
<name>
<surname>Kurimasa</surname> <given-names>A</given-names>
</name>
<etal/>
</person-group>. <article-title>NK314 potentiates antitumor activity with adult T-cell leukemia-lymphoma cells by inhibition of dual targets on topoisomerase II&#x3b1; and DNA-dependent protein kinase</article-title>. <source>Blood</source> (<year>2011</year>) <volume>117</volume>(<issue>13</issue>):<page-range>3575&#x2013;84</page-range>. doi: <pub-id pub-id-type="doi">10.1182/blood-2010-02-270439</pub-id>
</citation>
</ref>
<ref id="B72">
<label>72</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cavelier</surname> <given-names>C</given-names>
</name>
<name>
<surname>Didier</surname> <given-names>C</given-names>
</name>
<name>
<surname>Prade</surname> <given-names>N</given-names>
</name>
<name>
<surname>Mansat-De Mas</surname> <given-names>V</given-names>
</name>
<name>
<surname>Manenti</surname> <given-names>S</given-names>
</name>
<name>
<surname>Recher</surname> <given-names>C</given-names>
</name>
<etal/>
</person-group>. <article-title>Constitutive activation of the DNA damage signaling pathway in acute myeloid leukemia with complex karyotype: potential importance for checkpoint targeting therapy</article-title>. <source>Cancer Res</source> (<year>2009</year>) <volume>69</volume>(<issue>22</issue>):<page-range>8652&#x2013;61</page-range>. doi: <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-09-0939</pub-id>
</citation>
</ref>
<ref id="B73">
<label>73</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sarmento</surname> <given-names>LM</given-names>
</name>
<name>
<surname>P&#xf3;voa</surname> <given-names>V</given-names>
</name>
<name>
<surname>Nascimento</surname> <given-names>R</given-names>
</name>
<name>
<surname>Real</surname> <given-names>G</given-names>
</name>
<name>
<surname>Antunes</surname> <given-names>I</given-names>
</name>
<name>
<surname>Martins</surname> <given-names>LR</given-names>
</name>
<etal/>
</person-group>. <article-title>CHK1 overexpression in T-cell acute lymphoblastic leukemia is essential for proliferation and survival by preventing excessive replication stress</article-title>. <source>Oncogene</source> (<year>2015</year>) <volume>34</volume>(<issue>23</issue>):<page-range>2978&#x2013;90</page-range>. doi: <pub-id pub-id-type="doi">10.1038/onc.2014.248</pub-id>
</citation>
</ref>
<ref id="B74">
<label>74</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Iacobucci</surname> <given-names>I</given-names>
</name>
<name>
<surname>Di Ror&#xe0;</surname> <given-names>AGL</given-names>
</name>
<name>
<surname>Falzacappa</surname> <given-names>MVV</given-names>
</name>
<name>
<surname>Agostinelli</surname> <given-names>C</given-names>
</name>
<name>
<surname>Derenzini</surname> <given-names>E</given-names>
</name>
<name>
<surname>Ferrari</surname> <given-names>A</given-names>
</name>
<etal/>
</person-group>. <article-title>
<italic>In vitro</italic> and in <italic>vivo</italic> single-agent efficacy of checkpoint kinase inhibition in acute lymphoblastic leukemia</article-title>. <source>J Hematol Oncol</source> (<year>2015</year>) <volume>8</volume>(<issue>1</issue>):<fpage>125</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s13045-015-0206-5</pub-id>
</citation>
</ref>
<ref id="B75">
<label>75</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>David</surname> <given-names>L</given-names>
</name>
<name>
<surname>Fernandez-Vidal</surname> <given-names>A</given-names>
</name>
<name>
<surname>Bertoli</surname> <given-names>S</given-names>
</name>
<name>
<surname>Grgurevic</surname> <given-names>S</given-names>
</name>
<name>
<surname>Lepage</surname> <given-names>B</given-names>
</name>
<name>
<surname>Deshaies</surname> <given-names>D</given-names>
</name>
<etal/>
</person-group>. <article-title>CHK1 as a therapeutic target to bypass chemoresistance in AML</article-title>. <source>Sci Signaling</source> (<year>2016</year>) <volume>9</volume>(<issue>445</issue>):<page-range>ra90&#x2013;ra</page-range>. doi: <pub-id pub-id-type="doi">10.1126/scisignal.aac9704</pub-id>
</citation>
</ref>
<ref id="B76">
<label>76</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dent</surname> <given-names>P</given-names>
</name>
</person-group>. <article-title>Investigational CHK1 inhibitors in early phase clinical trials for the treatment of cancer</article-title>. <source>Expert Opin Investig Drugs</source> (<year>2019</year>) <volume>28</volume>(<issue>12</issue>):<page-range>1095&#x2013;100</page-range>. doi: <pub-id pub-id-type="doi">10.1080/13543784.2019.1694661</pub-id>
</citation>
</ref>
<ref id="B77">
<label>77</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zabludoff</surname> <given-names>SD</given-names>
</name>
<name>
<surname>Deng</surname> <given-names>C</given-names>
</name>
<name>
<surname>Grondine</surname> <given-names>MR</given-names>
</name>
<name>
<surname>Sheehy</surname> <given-names>AM</given-names>
</name>
<name>
<surname>Ashwell</surname> <given-names>S</given-names>
</name>
<name>
<surname>Caleb</surname> <given-names>BL</given-names>
</name>
<etal/>
</person-group>. <article-title>AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies</article-title>. <source>Mol Cancer Ther</source> (<year>2008</year>) <volume>7</volume>(<issue>9</issue>):<page-range>2955&#x2013;66</page-range>. doi: <pub-id pub-id-type="doi">10.1158/1535-7163.MCT-08-0492</pub-id>
</citation>
</ref>
<ref id="B78">
<label>78</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Didier</surname> <given-names>C</given-names>
</name>
<name>
<surname>Demur</surname> <given-names>C</given-names>
</name>
<name>
<surname>Grimal</surname> <given-names>F</given-names>
</name>
<name>
<surname>Jullien</surname> <given-names>D</given-names>
</name>
<name>
<surname>Manenti</surname> <given-names>S</given-names>
</name>
<name>
<surname>Ducommun</surname> <given-names>B</given-names>
</name>
</person-group>. <article-title>Evaluation of checkpoint kinase targeting therapy in acute myeloid leukemia with complex karyotype</article-title>. <source>Cancer Biol Ther</source> (<year>2012</year>) <volume>13</volume>(<issue>5</issue>):<page-range>307&#x2013;13</page-range>. doi: <pub-id pub-id-type="doi">10.4161/cbt.19074</pub-id>
</citation>
</ref>
<ref id="B79">
<label>79</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yuan</surname> <given-names>L</given-names>
</name>
<name>
<surname>Green</surname> <given-names>A</given-names>
</name>
<name>
<surname>David</surname> <given-names>L</given-names>
</name>
<name>
<surname>Dozier</surname> <given-names>C</given-names>
</name>
<name>
<surname>R&#xe9;cher</surname> <given-names>C</given-names>
</name>
<name>
<surname>Didier</surname> <given-names>C</given-names>
</name>
<etal/>
</person-group>. <article-title>Targeting CHK1 inhibits cell proliferation in FLT3-ITD positive acute myeloid leukemia</article-title>. <source>Leukemia Res</source> (<year>2014</year>) <volume>38</volume>. doi: <pub-id pub-id-type="doi">10.1016/j.leukres.2014.08.020</pub-id>
</citation>
</ref>
<ref id="B80">
<label>80</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schenk</surname> <given-names>EL</given-names>
</name>
<name>
<surname>Koh</surname> <given-names>BD</given-names>
</name>
<name>
<surname>Flatten</surname> <given-names>KS</given-names>
</name>
<name>
<surname>Peterson</surname> <given-names>KL</given-names>
</name>
<name>
<surname>Parry</surname> <given-names>D</given-names>
</name>
<name>
<surname>Hess</surname> <given-names>AD</given-names>
</name>
<etal/>
</person-group>. <article-title>Effects of selective checkpoint kinase 1 inhibition on cytarabine cytotoxicity in acute myelogenous leukemia cells <italic>in vitro</italic>
</article-title>. <source>Clin Cancer Res</source> (<year>2012</year>) <volume>18</volume>(<issue>19</issue>):<page-range>5364&#x2013;73</page-range>. doi: <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-12-0961</pub-id>
</citation>
</ref>
<ref id="B81">
<label>81</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dai</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>S</given-names>
</name>
<name>
<surname>Kmieciak</surname> <given-names>M</given-names>
</name>
<name>
<surname>Zhou</surname> <given-names>L</given-names>
</name>
<name>
<surname>Lin</surname> <given-names>H</given-names>
</name>
<name>
<surname>Pei</surname> <given-names>XY</given-names>
</name>
<etal/>
</person-group>. <article-title>The novel Chk1 inhibitor MK-8776 sensitizes human leukemia cells to HDAC inhibitors by targeting the intra-S checkpoint and DNA replication and repair</article-title>. <source>Mol Cancer Ther</source> (<year>2013</year>) <volume>12</volume>(<issue>6</issue>):<page-range>878&#x2013;89</page-range>. doi: <pub-id pub-id-type="doi">10.1158/1535-7163.MCT-12-0902</pub-id>
</citation>
</ref>
<ref id="B82">
<label>82</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Di Tullio</surname> <given-names>A</given-names>
</name>
<name>
<surname>Rouault-Pierre</surname> <given-names>K</given-names>
</name>
<name>
<surname>Abarrategi</surname> <given-names>A</given-names>
</name>
<name>
<surname>Mian</surname> <given-names>S</given-names>
</name>
<name>
<surname>Grey</surname> <given-names>W</given-names>
</name>
<name>
<surname>Gribben</surname> <given-names>J</given-names>
</name>
<etal/>
</person-group>. <article-title>The combination of CHK1 inhibitor with G-CSF overrides cytarabine resistance in human acute myeloid leukemia</article-title>. <source>Nat Commun</source> (<year>2017</year>) <volume>8</volume>(<issue>1</issue>):<fpage>1679</fpage>. doi: <pub-id pub-id-type="doi">10.1038/s41467-017-01834-4</pub-id>
</citation>
</ref>
<ref id="B83">
<label>83</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bryant</surname> <given-names>C</given-names>
</name>
<name>
<surname>Scriven</surname> <given-names>K</given-names>
</name>
<name>
<surname>Massey</surname> <given-names>AJ</given-names>
</name>
</person-group>. <article-title>Inhibition of the checkpoint kinase Chk1 induces DNA damage and cell death in human Leukemia and Lymphoma cells</article-title>. <source>Mol cancer</source> (<year>2014</year>) <volume>13</volume>:<page-range>147&#x2013;</page-range>. doi: <pub-id pub-id-type="doi">10.1186/1476-4598-13-147</pub-id>
</citation>
</ref>
<ref id="B84">
<label>84</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ghelli Luserna Di Ror&#xe0;</surname> <given-names>A</given-names>
</name>
<name>
<surname>Iacobucci</surname> <given-names>I</given-names>
</name>
<name>
<surname>Imbrogno</surname> <given-names>E</given-names>
</name>
<name>
<surname>Papayannidis</surname> <given-names>C</given-names>
</name>
<name>
<surname>Derenzini</surname> <given-names>E</given-names>
</name>
<name>
<surname>Ferrari</surname> <given-names>A</given-names>
</name>
<etal/>
</person-group>. <article-title>Prexasertib, a Chk1/Chk2 inhibitor, increases the effectiveness of conventional therapy in B-/T- cell progenitor acute lymphoblastic leukemia</article-title>. <source>Oncotarget</source> (<year>2016</year>) <volume>7</volume>(<issue>33</issue>). doi: <pub-id pub-id-type="doi">10.18632/oncotarget.10535</pub-id>
</citation>
</ref>
<ref id="B85">
<label>85</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Landau</surname> <given-names>HJ</given-names>
</name>
<name>
<surname>McNeely</surname> <given-names>SC</given-names>
</name>
<name>
<surname>Nair</surname> <given-names>JS</given-names>
</name>
<name>
<surname>Comenzo</surname> <given-names>RL</given-names>
</name>
<name>
<surname>Asai</surname> <given-names>T</given-names>
</name>
<name>
<surname>Friedman</surname> <given-names>H</given-names>
</name>
<etal/>
</person-group>. <article-title>The checkpoint kinase inhibitor AZD7762 potentiates chemotherapy-induced apoptosis of p53-mutated multiple myeloma cells</article-title>. <source>Mol Cancer Ther</source> (<year>2012</year>) <volume>11</volume>(<issue>8</issue>):<page-range>1781&#x2013;8</page-range>. doi: <pub-id pub-id-type="doi">10.1158/1535-7163.MCT-11-0949</pub-id>
</citation>
</ref>
<ref id="B86">
<label>86</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dai</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>S</given-names>
</name>
<name>
<surname>Shah</surname> <given-names>R</given-names>
</name>
<name>
<surname>Pei</surname> <given-names>X-Y</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>L</given-names>
</name>
<name>
<surname>Almenara</surname> <given-names>JA</given-names>
</name>
<etal/>
</person-group>. <article-title>Disruption of Src function potentiates Chk1-inhibitor-induced apoptosis in human multiple myeloma cells <italic>in vitro</italic> and <italic>in vivo</italic>
</article-title>. <source>Blood</source> (<year>2011</year>) <volume>117</volume>(<issue>6</issue>):<page-range>1947&#x2013;57</page-range>. doi: <pub-id pub-id-type="doi">10.1182/blood-2010-06-291146</pub-id>
</citation>
</ref>
<ref id="B87">
<label>87</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zemanova</surname> <given-names>J</given-names>
</name>
<name>
<surname>Hylse</surname> <given-names>O</given-names>
</name>
<name>
<surname>Collakova</surname> <given-names>J</given-names>
</name>
<name>
<surname>Vesely</surname> <given-names>P</given-names>
</name>
<name>
<surname>Oltova</surname> <given-names>A</given-names>
</name>
<name>
<surname>Borsky</surname> <given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>Chk1 inhibition significantly potentiates activity of nucleoside analogs in TP53-mutated B-lymphoid cells</article-title>. <source>Oncotarget</source> (<year>2016</year>) <volume>7</volume>(<issue>38</issue>):<page-range>62091&#x2013;106</page-range>. doi: <pub-id pub-id-type="doi">10.18632/oncotarget.11388</pub-id>
</citation>
</ref>
<ref id="B88">
<label>88</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Boudny</surname> <given-names>M</given-names>
</name>
<name>
<surname>Zemanova</surname> <given-names>J</given-names>
</name>
<name>
<surname>Khirsariya</surname> <given-names>P</given-names>
</name>
<name>
<surname>Borsky</surname> <given-names>M</given-names>
</name>
<name>
<surname>Verner</surname> <given-names>J</given-names>
</name>
<name>
<surname>Cerna</surname> <given-names>J</given-names>
</name>
<etal/>
</person-group>. <article-title>Novel CHK1 inhibitor MU380 exhibits significant single-agent activity in TP53-mutated chronic lymphocytic leukemia cells</article-title>. <source>Haematologica</source> (<year>2019</year>). doi: <pub-id pub-id-type="doi">10.3324/haematol.2018.203430</pub-id>
</citation>
</ref>
<ref id="B89">
<label>89</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Derenzini</surname> <given-names>E</given-names>
</name>
<name>
<surname>Agostinelli</surname> <given-names>C</given-names>
</name>
<name>
<surname>Imbrogno</surname> <given-names>E</given-names>
</name>
<name>
<surname>Iacobucci</surname> <given-names>I</given-names>
</name>
<name>
<surname>Casadei</surname> <given-names>B</given-names>
</name>
<name>
<surname>Brighenti</surname> <given-names>E</given-names>
</name>
<etal/>
</person-group>. <article-title>Constitutive activation of the DNA damage response pathway as a novel therapeutic target in diffuse large B-cell lymphoma</article-title>. <source>Oncotarget</source> (<year>2015</year>) <volume>6</volume>(<issue>9</issue>):<page-range>6553&#x2013;69</page-range>. doi: <pub-id pub-id-type="doi">10.18632/oncotarget.2720</pub-id>
</citation>
</ref>
<ref id="B90">
<label>90</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>H&#xf6;glund</surname> <given-names>A</given-names>
</name>
<name>
<surname>Str&#xf6;mvall</surname> <given-names>K</given-names>
</name>
<name>
<surname>Li</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Forshell</surname> <given-names>LP</given-names>
</name>
<name>
<surname>Nilsson</surname> <given-names>JA</given-names>
</name>
</person-group>. <article-title>Chk2 deficiency in Myc overexpressing lymphoma cells elicits a synergistic lethal response in combination with PARP inhibition</article-title>. <source>Cell Cycle (Georgetown Tex)</source> (<year>2011</year>) <volume>10</volume>(<issue>20</issue>):<page-range>3598&#x2013;607</page-range>. doi: <pub-id pub-id-type="doi">10.4161/cc.10.20.17887</pub-id>
</citation>
</ref>
<ref id="B91">
<label>91</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sorensen</surname> <given-names>CS</given-names>
</name>
<name>
<surname>Hansen</surname> <given-names>LT</given-names>
</name>
<name>
<surname>Dziegielewski</surname> <given-names>J</given-names>
</name>
<name>
<surname>Syljuasen</surname> <given-names>RG</given-names>
</name>
<name>
<surname>Lundin</surname> <given-names>C</given-names>
</name>
<name>
<surname>Bartek</surname> <given-names>J</given-names>
</name>
<etal/>
</person-group>. <article-title>The cell-cycle checkpoint kinase Chk1 is required for mammalian homologous recombination repair</article-title>. <source>Nat Cell Biol</source> (<year>2005</year>) <volume>7</volume>(<issue>2</issue>):<fpage>195</fpage>&#x2013;<lpage>201</lpage>. doi: <pub-id pub-id-type="doi">10.1038/ncb1212</pub-id>
</citation>
</ref>
<ref id="B92">
<label>92</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dai</surname> <given-names>B</given-names>
</name>
<name>
<surname>Zhao</surname> <given-names>XF</given-names>
</name>
<name>
<surname>Mazan-Mamczarz</surname> <given-names>K</given-names>
</name>
<name>
<surname>Hagner</surname> <given-names>P</given-names>
</name>
<name>
<surname>Corl</surname> <given-names>S</given-names>
</name>
<name>
<surname>Bahassi</surname> <given-names>EM</given-names>
</name>
<etal/>
</person-group>. <article-title>Functional and molecular interactions between ERK and CHK2 in diffuse large B-cell lymphoma</article-title>. <source>Nat Commun</source> (<year>2011</year>) <volume>2</volume>(<issue>1</issue>):<fpage>402</fpage>. doi: <pub-id pub-id-type="doi">10.1038/ncomms1404</pub-id>
</citation>
</ref>
<ref id="B93">
<label>93</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hunter</surname> <given-names>JE</given-names>
</name>
<name>
<surname>Campbell</surname> <given-names>AE</given-names>
</name>
<name>
<surname>Butterworth</surname> <given-names>JA</given-names>
</name>
<name>
<surname>Sellier</surname> <given-names>H</given-names>
</name>
<name>
<surname>Hannaway</surname> <given-names>NL</given-names>
</name>
<name>
<surname>Luli</surname> <given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>Mutation of the RelA(p65) Thr505 phosphosite disrupts the DNA replication stress response leading to CHK1 inhibitor resistance</article-title>. <source>Biochem J</source> (<year>2022</year>) <volume>479</volume>(<issue>19</issue>):<page-range>2087&#x2013;113</page-range>. doi: <pub-id pub-id-type="doi">10.1042/BCJ20220089</pub-id>
</citation>
</ref>
<ref id="B94">
<label>94</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hunter</surname> <given-names>JE</given-names>
</name>
<name>
<surname>Campbell</surname> <given-names>AE</given-names>
</name>
<name>
<surname>Hannaway</surname> <given-names>NL</given-names>
</name>
<name>
<surname>Kerridge</surname> <given-names>S</given-names>
</name>
<name>
<surname>Luli</surname> <given-names>S</given-names>
</name>
<name>
<surname>Butterworth</surname> <given-names>JA</given-names>
</name>
<etal/>
</person-group>. <article-title>Regulation of CHK1 inhibitor resistance by a c-Rel and USP1 dependent pathway</article-title>. <source>Biochem J</source> (<year>2022</year>) <volume>479</volume>(<issue>19</issue>):<page-range>2063&#x2013;86</page-range>. doi: <pub-id pub-id-type="doi">10.1042/BCJ20220102</pub-id>
</citation>
</ref>
<ref id="B95">
<label>95</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Restelli</surname> <given-names>V</given-names>
</name>
<name>
<surname>Lupi</surname> <given-names>M</given-names>
</name>
<name>
<surname>Vagni</surname> <given-names>M</given-names>
</name>
<name>
<surname>Chil&#xe0;</surname> <given-names>R</given-names>
</name>
<name>
<surname>Bertoni</surname> <given-names>F</given-names>
</name>
<name>
<surname>Damia</surname> <given-names>G</given-names>
</name>
<etal/>
</person-group>. <article-title>Combining ibrutinib with chk1 inhibitors synergistically targets mantle cell lymphoma cell lines</article-title>. <source>Targeted Oncol</source> (<year>2018</year>) <volume>13</volume>(<issue>2</issue>):<page-range>235&#x2013;45</page-range>. doi: <pub-id pub-id-type="doi">10.1007/s11523-018-0553-6</pub-id>
</citation>
</ref>
<ref id="B96">
<label>96</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Restelli</surname> <given-names>V</given-names>
</name>
<name>
<surname>Chil&#xe0;</surname> <given-names>R</given-names>
</name>
<name>
<surname>Lupi</surname> <given-names>M</given-names>
</name>
<name>
<surname>Rinaldi</surname> <given-names>A</given-names>
</name>
<name>
<surname>Kwee</surname> <given-names>I</given-names>
</name>
<name>
<surname>Bertoni</surname> <given-names>F</given-names>
</name>
<etal/>
</person-group>. <article-title>Characterization of a mantle cell lymphoma cell line resistant to the Chk1 inhibitor PF-00477736</article-title>. <source>Oncotarget</source> (<year>2015</year>) <volume>6</volume>(<issue>35</issue>). doi: <pub-id pub-id-type="doi">10.18632/oncotarget.5954</pub-id>
</citation>
</ref>
<ref id="B97">
<label>97</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Otto</surname> <given-names>T</given-names>
</name>
<name>
<surname>Sicinski</surname> <given-names>P</given-names>
</name>
</person-group>. <article-title>Cell cycle proteins as promising targets in cancer therapy</article-title>. <source>Nat Rev Cancer</source> (<year>2017</year>) <volume>17</volume>(<issue>2</issue>):<fpage>93</fpage>&#x2013;<lpage>115</lpage>. doi: <pub-id pub-id-type="doi">10.1038/nrc.2016.138</pub-id>
</citation>
</ref>
<ref id="B98">
<label>98</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ghelli</surname> <given-names>A</given-names>
</name>
<name>
<surname>Beeharry</surname> <given-names>N</given-names>
</name>
<name>
<surname>Imbrogno</surname> <given-names>E</given-names>
</name>
<name>
<surname>Ferrari</surname> <given-names>A</given-names>
</name>
<name>
<surname>Robustelli</surname> <given-names>V</given-names>
</name>
<name>
<surname>Righi</surname> <given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>Targeting WEE1 to enhance conventional therapies for acute lymphoblastic leukemia</article-title>. <source>J Hematol Oncol</source> (<year>2018</year>) <volume>11</volume>.</citation>
</ref>
<ref id="B99">
<label>99</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hu</surname> <given-names>J</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>T</given-names>
</name>
<name>
<surname>Xu</surname> <given-names>J</given-names>
</name>
<name>
<surname>Wu</surname> <given-names>S</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>L</given-names>
</name>
<name>
<surname>Su</surname> <given-names>H</given-names>
</name>
<etal/>
</person-group>. <article-title>WEE1 inhibition induces glutamine addiction in T-cell acute lymphoblastic leukemia</article-title>. <source>Haematologica</source> (<year>2020</year>), <elocation-id>haematol.2019.231126</elocation-id>.</citation>
</ref>
<ref id="B100">
<label>100</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Garcia</surname> <given-names>TB</given-names>
</name>
<name>
<surname>Snedeker</surname> <given-names>JC</given-names>
</name>
<name>
<surname>Baturin</surname> <given-names>D</given-names>
</name>
<name>
<surname>Gardner</surname> <given-names>L</given-names>
</name>
<name>
<surname>Fosmire</surname> <given-names>SP</given-names>
</name>
<name>
<surname>Zhou</surname> <given-names>C</given-names>
</name>
<etal/>
</person-group>. <article-title>A small-molecule inhibitor of WEE1, AZD1775, synergizes with olaparib by impairing homologous recombination and enhancing DNA damage and apoptosis in acute leukemia</article-title>. <source>Mol Cancer Ther</source> (<year>2017</year>) <volume>16</volume>(<issue>10</issue>):<page-range>2058&#x2013;68</page-range>. doi: <pub-id pub-id-type="doi">10.1158/1535-7163.MCT-16-0660</pub-id>
</citation>
</ref>
<ref id="B101">
<label>101</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chaudhuri</surname> <given-names>L</given-names>
</name>
<name>
<surname>Vincelette</surname> <given-names>N</given-names>
</name>
<name>
<surname>Koh</surname> <given-names>B</given-names>
</name>
<name>
<surname>Naylor</surname> <given-names>R</given-names>
</name>
<name>
<surname>Flatten</surname> <given-names>K</given-names>
</name>
<name>
<surname>Peterson</surname> <given-names>K</given-names>
</name>
<etal/>
</person-group>. <article-title>CHK1 and WEE1 inhibition combine synergistically to enhance therapeutic efficacy in acute myeloid leukemia ex vivo</article-title>. <source>Haematologica</source> (<year>2013</year>) <volume>99</volume>.</citation>
</ref>
<ref id="B102">
<label>102</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhou</surname> <given-names>L</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>S</given-names>
</name>
<name>
<surname>Kmieciak</surname> <given-names>M</given-names>
</name>
<name>
<surname>Leng</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Lin</surname> <given-names>H</given-names>
</name>
<etal/>
</person-group>. <article-title>A regimen combining the Wee1 inhibitor AZD1775 with HDAC inhibitors targets human acute myeloid leukemia cells harboring various genetic mutations</article-title>. <source>Leukemia</source> (<year>2015</year>) <volume>29</volume>(<issue>4</issue>):<page-range>807&#x2013;18</page-range>. doi: <pub-id pub-id-type="doi">10.1038/leu.2014.296</pub-id>
</citation>
</ref>
<ref id="B103">
<label>103</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Qi</surname> <given-names>W</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>W</given-names>
</name>
<name>
<surname>Edwards</surname> <given-names>H</given-names>
</name>
<name>
<surname>Chu</surname> <given-names>R</given-names>
</name>
<name>
<surname>Madlambayan</surname> <given-names>GJ</given-names>
</name>
<name>
<surname>Taub</surname> <given-names>JW</given-names>
</name>
<etal/>
</person-group>. <article-title>Synergistic anti-leukemic interactions between panobinostat and MK-1775 in acute myeloid leukemia ex vivo</article-title>. <source>Cancer Biol Ther</source> (<year>2015</year>) <volume>16</volume>(<issue>12</issue>):<page-range>1784&#x2013;93</page-range>. doi: <pub-id pub-id-type="doi">10.1080/15384047.2015.1095406</pub-id>
</citation>
</ref>
<ref id="B104">
<label>104</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ghelli Luserna Di Ror&#xe0;</surname> <given-names>A</given-names>
</name>
<name>
<surname>Bocconcelli</surname> <given-names>M</given-names>
</name>
<name>
<surname>Ferrari</surname> <given-names>A</given-names>
</name>
<name>
<surname>Terragna</surname> <given-names>C</given-names>
</name>
<name>
<surname>Bruno</surname> <given-names>S</given-names>
</name>
<name>
<surname>Imbrogno</surname> <given-names>E</given-names>
</name>
<etal/>
</person-group>. <article-title>Synergism through WEE1 and CHK1 inhibition in acute lymphoblastic leukemia</article-title>. <source>Cancers</source> (<year>2019</year>) <volume>11</volume>(<issue>11</issue>):<fpage>1654</fpage>.</citation>
</ref>
<ref id="B105">
<label>105</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ford</surname> <given-names>JB</given-names>
</name>
<name>
<surname>Baturin</surname> <given-names>D</given-names>
</name>
<name>
<surname>Burleson</surname> <given-names>TM</given-names>
</name>
<name>
<surname>Van Linden</surname> <given-names>AA</given-names>
</name>
<name>
<surname>Kim</surname> <given-names>YM</given-names>
</name>
<name>
<surname>Porter</surname> <given-names>CC</given-names>
</name>
</person-group>. <article-title>AZD1775 sensitizes T cell acute lymphoblastic leukemia cells to cytarabine by promoting apoptosis over DNA repair</article-title>. <source>Oncotarget</source> (<year>2015</year>) <volume>6</volume>(<issue>29</issue>):<page-range>28001&#x2013;10</page-range>. doi: <pub-id pub-id-type="doi">10.18632/oncotarget.4830</pub-id>
</citation>
</ref>
<ref id="B106">
<label>106</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Duan</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Dong</surname> <given-names>X</given-names>
</name>
<name>
<surname>Nie</surname> <given-names>J</given-names>
</name>
<name>
<surname>Li</surname> <given-names>P</given-names>
</name>
<name>
<surname>Lu</surname> <given-names>F</given-names>
</name>
<name>
<surname>Ma</surname> <given-names>D</given-names>
</name>
<etal/>
</person-group>. <article-title>Wee1 kinase inhibitor MK-1775 induces apoptosis of acute lymphoblastic leukemia cells and enhances the efficacy of doxorubicin involving downregulation of Notch pathway</article-title>. <source>Oncol Lett</source> (<year>2018</year>) <volume>16</volume>(<issue>4</issue>):<page-range>5473&#x2013;81</page-range>. doi: <pub-id pub-id-type="doi">10.3892/ol.2018.9291</pub-id>
</citation>
</ref>
<ref id="B107">
<label>107</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Barbosa</surname> <given-names>RSS</given-names>
</name>
<name>
<surname>Dantonio</surname> <given-names>PM</given-names>
</name>
<name>
<surname>Guimar&#xe3;es</surname> <given-names>T</given-names>
</name>
<name>
<surname>de Oliveira</surname> <given-names>MB</given-names>
</name>
<name>
<surname>Fook Alves</surname> <given-names>VL</given-names>
</name>
<name>
<surname>Sandes</surname> <given-names>AF</given-names>
</name>
<etal/>
</person-group>. <article-title>Sequential combination of bortezomib and WEE1 inhibitor, MK-1775, induced apoptosis in multiple myeloma cell lines</article-title>. <source>Biochem Biophys Res Commun</source> (<year>2019</year>) <volume>519</volume>(<issue>3</issue>):<fpage>597</fpage>&#x2013;<lpage>604</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.bbrc.2019.08.163</pub-id>
</citation>
</ref>
<ref id="B108">
<label>108</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tabayashi</surname> <given-names>T</given-names>
</name>
<name>
<surname>Tanaka</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Takahashi</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Kimura</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Tomikawa</surname> <given-names>T</given-names>
</name>
<name>
<surname>Anan</surname> <given-names>T</given-names>
</name>
<etal/>
</person-group>. <article-title>Abstract 1884: Dual targeting of cell cycle checkpoint and histone deacetylase overcomes bortezomib resistance in multiple myeloma</article-title>. <source>Cancer Res</source> (<year>2018</year>) <volume>78</volume>(<supplement>13 Supplement</supplement>):<page-range>1884&#x2013;</page-range>. doi: <pub-id pub-id-type="doi">10.1158/1538-7445.AM2018-1884</pub-id>
</citation>
</ref>
<ref id="B109">
<label>109</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chila</surname> <given-names>R</given-names>
</name>
<name>
<surname>Basana</surname> <given-names>A</given-names>
</name>
<name>
<surname>Lupi</surname> <given-names>M</given-names>
</name>
<name>
<surname>Guffanti</surname> <given-names>F</given-names>
</name>
<name>
<surname>Gaudio</surname> <given-names>E</given-names>
</name>
<name>
<surname>Rinaldi</surname> <given-names>A</given-names>
</name>
<etal/>
</person-group>. <article-title>Combined inhibition of Chk1 and Wee1 as a new therapeutic strategy for mantle cell lymphoma</article-title>. <source>Oncotarget</source> (<year>2015</year>) <volume>6</volume>(<issue>5</issue>):<page-range>3394&#x2013;408</page-range>. doi: <pub-id pub-id-type="doi">10.18632/oncotarget.2583</pub-id>
</citation>
</ref>
<ref id="B110">
<label>110</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Restelli</surname> <given-names>V</given-names>
</name>
<name>
<surname>Vagni</surname> <given-names>M</given-names>
</name>
<name>
<surname>Arribas</surname> <given-names>AJ</given-names>
</name>
<name>
<surname>Bertoni</surname> <given-names>F</given-names>
</name>
<name>
<surname>Damia</surname> <given-names>G</given-names>
</name>
<name>
<surname>Carrassa</surname> <given-names>L</given-names>
</name>
</person-group>. <article-title>Inhibition of CHK1 and WEE1 as a new therapeutic approach in diffuse large B cell lymphomas with MYC deregulation</article-title>. <source>Br J Haematol</source> (<year>2016</year>). doi: <pub-id pub-id-type="doi">10.1111/bjh.14506</pub-id>
</citation>
</ref>
<ref id="B111">
<label>111</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>de Jong</surname> <given-names>MRW</given-names>
</name>
<name>
<surname>Langendonk</surname> <given-names>M</given-names>
</name>
<name>
<surname>Reitsma</surname> <given-names>B</given-names>
</name>
<name>
<surname>Herbers</surname> <given-names>P</given-names>
</name>
<name>
<surname>Nijland</surname> <given-names>M</given-names>
</name>
<name>
<surname>Huls</surname> <given-names>G</given-names>
</name>
<etal/>
</person-group>. <article-title>WEE1 inhibition enhances anti-apoptotic dependency as a result of premature mitotic entry and DNA damage</article-title>. <source>Cancers (Basel)</source> (<year>2019</year>) <volume>11</volume>(<issue>11</issue>). doi: <pub-id pub-id-type="doi">10.3390/cancers11111743</pub-id>
</citation>
</ref>
<ref id="B112">
<label>112</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>de Jong</surname> <given-names>MRW</given-names>
</name>
<name>
<surname>Langendonk</surname> <given-names>M</given-names>
</name>
<name>
<surname>Reitsma</surname> <given-names>B</given-names>
</name>
<name>
<surname>Herbers</surname> <given-names>P</given-names>
</name>
<name>
<surname>Lodewijk</surname> <given-names>M</given-names>
</name>
<name>
<surname>Nijland</surname> <given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>WEE1 inhibition synergizes with CHOP chemotherapy and radiation therapy through induction of premature mitotic entry and DNA damage in diffuse large B-cell lymphoma</article-title>. <source>Ther Adv hematol</source> (<year>2020</year>) <volume>11</volume>:<page-range>2040620719898373&#x2013;</page-range>. doi: <pub-id pub-id-type="doi">10.1177/2040620719898373</pub-id>
</citation>
</ref>
<ref id="B113">
<label>113</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Skelding</surname> <given-names>KA</given-names>
</name>
<name>
<surname>Lincz</surname> <given-names>LF</given-names>
</name>
</person-group>. <article-title>PARP inhibitors and haematological Malignancies&#x2014;Friend or foe</article-title>? <source>Cancers</source> (<year>2021</year>) <volume>13</volume>(<issue>21</issue>):<fpage>5328</fpage>. doi: <pub-id pub-id-type="doi">10.3390/cancers13215328</pub-id>
</citation>
</ref>
<ref id="B114">
<label>114</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname> <given-names>X</given-names>
</name>
<name>
<surname>Li</surname> <given-names>C</given-names>
</name>
<name>
<surname>Jin</surname> <given-names>J</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>J</given-names>
</name>
<name>
<surname>Huang</surname> <given-names>J</given-names>
</name>
<name>
<surname>Ma</surname> <given-names>Z</given-names>
</name>
<etal/>
</person-group>. <article-title>High PARP-1 expression predicts poor survival in acute myeloid leukemia and PARP-1 inhibitor and SAHA-bendamustine hybrid inhibitor combination treatment synergistically enhances anti-tumor effects</article-title>. <source>EBioMedicine</source> (<year>2018</year>) <volume>38</volume>:<fpage>47</fpage>&#x2013;<lpage>56</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.ebiom.2018.11.025</pub-id>
</citation>
</ref>
<ref id="B115">
<label>115</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Faraoni</surname> <given-names>I</given-names>
</name>
<name>
<surname>Compagnone</surname> <given-names>M</given-names>
</name>
<name>
<surname>Lavorgna</surname> <given-names>S</given-names>
</name>
<name>
<surname>Angelini</surname> <given-names>DF</given-names>
</name>
<name>
<surname>Cencioni</surname> <given-names>MT</given-names>
</name>
<name>
<surname>Piras</surname> <given-names>E</given-names>
</name>
<etal/>
</person-group>. <article-title>BRCA1, PARP1 and gammaH2AX in acute myeloid leukemia: Role as biomarkers of response to the PARP inhibitor olaparib</article-title>. <source>Biochim Biophys Acta</source> (<year>2015</year>) <volume>1852</volume>(<issue>3</issue>):<page-range>462&#x2013;72</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.bbadis.2014.12.001</pub-id>
</citation>
</ref>
<ref id="B116">
<label>116</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hahnel</surname> <given-names>PS</given-names>
</name>
<name>
<surname>Enders</surname> <given-names>B</given-names>
</name>
<name>
<surname>Sasca</surname> <given-names>D</given-names>
</name>
<name>
<surname>Roos</surname> <given-names>WP</given-names>
</name>
<name>
<surname>Kaina</surname> <given-names>B</given-names>
</name>
<name>
<surname>Bullinger</surname> <given-names>L</given-names>
</name>
<etal/>
</person-group>. <article-title>Targeting components of the alternative NHEJ pathway sensitizes KRAS mutant leukemic cells to chemotherapy</article-title>. <source>Blood</source> (<year>2014</year>) <volume>123</volume>(<issue>15</issue>):<page-range>2355&#x2013;66</page-range>. doi: <pub-id pub-id-type="doi">10.1182/blood-2013-01-477620</pub-id>
</citation>
</ref>
<ref id="B117">
<label>117</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tobin</surname> <given-names>LA</given-names>
</name>
<name>
<surname>Robert</surname> <given-names>C</given-names>
</name>
<name>
<surname>Rapoport</surname> <given-names>AP</given-names>
</name>
<name>
<surname>Gojo</surname> <given-names>I</given-names>
</name>
<name>
<surname>Baer</surname> <given-names>MR</given-names>
</name>
<name>
<surname>Tomkinson</surname> <given-names>AE</given-names>
</name>
<etal/>
</person-group>. <article-title>Targeting abnormal DNA double-strand break repair in tyrosine kinase inhibitor-resistant chronic myeloid leukemias</article-title>. <source>Oncogene</source> (<year>2013</year>) <volume>32</volume>(<issue>14</issue>):<page-range>1784&#x2013;93</page-range>. doi: <pub-id pub-id-type="doi">10.1038/onc.2012.203</pub-id>
</citation>
</ref>
<ref id="B118">
<label>118</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kruk</surname> <given-names>A</given-names>
</name>
<name>
<surname>Ociepa</surname> <given-names>T</given-names>
</name>
<name>
<surname>Urasi&#x144;ski</surname> <given-names>T</given-names>
</name>
<name>
<surname>Grabarek</surname> <given-names>J</given-names>
</name>
<name>
<surname>Urasi&#x144;ska</surname> <given-names>E</given-names>
</name>
</person-group>. <article-title>PARP-1 expression in CD34+ leukemic cells in childhood acute lymphoblastic leukemia: relation to response to initial therapy and other prognostic factors</article-title>. <source>Polish J Pathol</source> (<year>2015</year>) <volume>66</volume>(<issue>3</issue>):<page-range>239&#x2013;45</page-range>. doi: <pub-id pub-id-type="doi">10.5114/pjp.2015.54957</pub-id>
</citation>
</ref>
<ref id="B119">
<label>119</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cramer-Morales</surname> <given-names>K</given-names>
</name>
<name>
<surname>Nieborowska-Skorska</surname> <given-names>M</given-names>
</name>
<name>
<surname>Scheibner</surname> <given-names>K</given-names>
</name>
<name>
<surname>Padget</surname> <given-names>M</given-names>
</name>
<name>
<surname>Irvine</surname> <given-names>DA</given-names>
</name>
<name>
<surname>Sliwinski</surname> <given-names>T</given-names>
</name>
<etal/>
</person-group>. <article-title>Personalized synthetic lethality induced by targeting RAD52 in leukemias identified by gene mutation and expression profile</article-title>. <source>Blood</source> (<year>2013</year>) <volume>122</volume>(<issue>7</issue>):<page-range>1293&#x2013;304</page-range>. doi: <pub-id pub-id-type="doi">10.1182/blood-2013-05-501072</pub-id>
</citation>
</ref>
<ref id="B120">
<label>120</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jin</surname> <given-names>J</given-names>
</name>
<name>
<surname>Jin</surname> <given-names>J</given-names>
</name>
<name>
<surname>Pan</surname> <given-names>J</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Huang</surname> <given-names>S</given-names>
</name>
<name>
<surname>Mao</surname> <given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>High expression of BCAT1 promotes acute myeloid leukemia progression and sensitize to PARP inhibitor</article-title>. <source>Blood</source> (<year>2019</year>) <volume>134</volume>(<supplement>Supplement_1</supplement>):<page-range>5041&#x2013;</page-range>. doi: <pub-id pub-id-type="doi">10.1182/blood-2019-125221</pub-id>
</citation>
</ref>
<ref id="B121">
<label>121</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gaymes</surname> <given-names>TJ</given-names>
</name>
<name>
<surname>Shall</surname> <given-names>S</given-names>
</name>
<name>
<surname>MacPherson</surname> <given-names>LJ</given-names>
</name>
<name>
<surname>Twine</surname> <given-names>NA</given-names>
</name>
<name>
<surname>Lea</surname> <given-names>NC</given-names>
</name>
<name>
<surname>Farzaneh</surname> <given-names>F</given-names>
</name>
<etal/>
</person-group>. <article-title>Inhibitors of poly ADP-ribose polymerase (PARP) induce apoptosis of myeloid leukemic cells: potential for therapy of myeloid leukemia and myelodysplastic syndromes</article-title>. <source>Haematologica</source> (<year>2009</year>) <volume>94</volume>(<issue>5</issue>):<page-range>638&#x2013;46</page-range>. doi: <pub-id pub-id-type="doi">10.3324/haematol.2008.001933</pub-id>
</citation>
</ref>
<ref id="B122">
<label>122</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Esposito</surname> <given-names>MT</given-names>
</name>
<name>
<surname>Zhao</surname> <given-names>L</given-names>
</name>
<name>
<surname>Fung</surname> <given-names>TK</given-names>
</name>
<name>
<surname>Rane</surname> <given-names>JK</given-names>
</name>
<name>
<surname>Wilson</surname> <given-names>A</given-names>
</name>
<name>
<surname>Martin</surname> <given-names>N</given-names>
</name>
<etal/>
</person-group>. <article-title>Synthetic lethal targeting of oncogenic transcription factors in acute leukemia by PARP inhibitors</article-title>. <source>Nat Med</source> (<year>2015</year>) <volume>21</volume>(<issue>12</issue>):<page-range>1481&#x2013;90</page-range>. doi: <pub-id pub-id-type="doi">10.1038/nm.3993</pub-id>
</citation>
</ref>
<ref id="B123">
<label>123</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dellomo</surname> <given-names>AJ</given-names>
</name>
<name>
<surname>Baer</surname> <given-names>MR</given-names>
</name>
<name>
<surname>Rassool</surname> <given-names>FV</given-names>
</name>
</person-group>. <article-title>Partnering with PARP inhibitors in acute myeloid leukemia with FLT3-ITD</article-title>. <source>Cancer Lett</source> (<year>2019</year>) <volume>454</volume>:<page-range>171&#x2013;8</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.canlet.2019.03.048</pub-id>
</citation>
</ref>
<ref id="B124">
<label>124</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nieborowska-Skorska</surname> <given-names>M</given-names>
</name>
<name>
<surname>Maifrede</surname> <given-names>S</given-names>
</name>
<name>
<surname>Dasgupta</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Sullivan</surname> <given-names>K</given-names>
</name>
<name>
<surname>Flis</surname> <given-names>S</given-names>
</name>
<name>
<surname>Le</surname> <given-names>BV</given-names>
</name>
<etal/>
</person-group>. <article-title>Ruxolitinib-induced defects in DNA repair cause sensitivity to PARP inhibitors in myeloproliferative neoplasms</article-title>. <source>Blood</source> (<year>2017</year>) <volume>130</volume>(<issue>26</issue>):<page-range>2848&#x2013;59</page-range>. doi: <pub-id pub-id-type="doi">10.1182/blood-2017-05-784942</pub-id>
</citation>
</ref>
<ref id="B125">
<label>125</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pratz</surname> <given-names>KW</given-names>
</name>
<name>
<surname>Koh</surname> <given-names>BD</given-names>
</name>
<name>
<surname>Patel</surname> <given-names>AG</given-names>
</name>
<name>
<surname>Flatten</surname> <given-names>KS</given-names>
</name>
<name>
<surname>Poh</surname> <given-names>W</given-names>
</name>
<name>
<surname>Herman</surname> <given-names>JG</given-names>
</name>
<etal/>
</person-group>. <article-title>Poly (ADP-ribose) polymerase inhibitor hypersensitivity in aggressive myeloproliferative neoplasms</article-title>. <source>Clin Cancer Res</source> (<year>2016</year>) <volume>22</volume>(<issue>15</issue>):<page-range>3894&#x2013;902</page-range>. doi: <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-15-2351</pub-id>
</citation>
</ref>
<ref id="B126">
<label>126</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fischer</surname> <given-names>U</given-names>
</name>
<name>
<surname>Forster</surname> <given-names>M</given-names>
</name>
<name>
<surname>Rinaldi</surname> <given-names>A</given-names>
</name>
<name>
<surname>Risch</surname> <given-names>T</given-names>
</name>
<name>
<surname>Sungalee</surname> <given-names>S</given-names>
</name>
<name>
<surname>Warnatz</surname> <given-names>H-J</given-names>
</name>
<etal/>
</person-group>. <article-title>Genomics and drug profiling of fatal TCF3-HLF&#x2013;positive acute lymphoblastic leukemia identifies recurrent mutation patterns and therapeutic options</article-title>. <source>Nat Genet</source> (<year>2015</year>) <volume>47</volume>:<fpage>1020</fpage>. doi: <pub-id pub-id-type="doi">10.1038/ng.3362</pub-id>
</citation>
</ref>
<ref id="B127">
<label>127</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Piao</surname> <given-names>J</given-names>
</name>
<name>
<surname>Takai</surname> <given-names>S</given-names>
</name>
<name>
<surname>Kamiya</surname> <given-names>T</given-names>
</name>
<name>
<surname>Inukai</surname> <given-names>T</given-names>
</name>
<name>
<surname>Sugita</surname> <given-names>K</given-names>
</name>
<name>
<surname>Ohyashiki</surname> <given-names>K</given-names>
</name>
<etal/>
</person-group>. <article-title>Poly (ADP-ribose) polymerase inhibitors selectively induce cytotoxicity in TCF3-HLF-positive leukemic cells</article-title>. <source>Cancer Lett</source> (<year>2017</year>) <volume>386</volume>:<page-range>131&#x2013;40</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.canlet.2016.11.021</pub-id>
</citation>
</ref>
<ref id="B128">
<label>128</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Falzacappa</surname> <given-names>MVV</given-names>
</name>
<name>
<surname>Ronchini</surname> <given-names>C</given-names>
</name>
<name>
<surname>Faretta</surname> <given-names>M</given-names>
</name>
<name>
<surname>Iacobucci</surname> <given-names>I</given-names>
</name>
<name>
<surname>Di Ror&#xe0;</surname> <given-names>AGL</given-names>
</name>
<name>
<surname>Martinelli</surname> <given-names>G</given-names>
</name>
<etal/>
</person-group>. <article-title>The combination of the PARP inhibitor rucaparib and 5FU is an effective strategy for treating acute leukemias</article-title>. <source>Mol Cancer Ther</source> (<year>2015</year>) <volume>14</volume>(<issue>4</issue>):<page-range>889&#x2013;98</page-range>. doi: <pub-id pub-id-type="doi">10.1158/1535-7163.MCT-14-0276</pub-id>
</citation>
</ref>
<ref id="B129">
<label>129</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Meng</surname> <given-names>S</given-names>
</name>
<name>
<surname>Matrone</surname> <given-names>G</given-names>
</name>
<name>
<surname>Lv</surname> <given-names>J</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>K</given-names>
</name>
<name>
<surname>Wong</surname> <given-names>WT</given-names>
</name>
<name>
<surname>Cooke</surname> <given-names>JP</given-names>
</name>
</person-group>. <article-title>LIM domain only 2 regulates endothelial proliferation, angiogenesis, and tissue regeneration</article-title>. <source>J Am Heart Assoc</source> (<year>2016</year>) <volume>5</volume>(<issue>10</issue>):<elocation-id>e004117</elocation-id>. doi: <pub-id pub-id-type="doi">10.1161/JAHA.116.004117</pub-id>
</citation>
</ref>
<ref id="B130">
<label>130</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Parvin</surname> <given-names>S</given-names>
</name>
<name>
<surname>Ramirez-Labrada</surname> <given-names>A</given-names>
</name>
<name>
<surname>Aumann</surname> <given-names>S</given-names>
</name>
<name>
<surname>Lu</surname> <given-names>X</given-names>
</name>
<name>
<surname>Weich</surname> <given-names>N</given-names>
</name>
<name>
<surname>Santiago</surname> <given-names>G</given-names>
</name>
<etal/>
</person-group>. <article-title>LMO2 confers synthetic lethality to PARP inhibition in DLBCL</article-title>. <source>Cancer Cell</source> (<year>2019</year>) <volume>36</volume>(<issue>3</issue>):<fpage>237</fpage>&#x2013;<lpage>49.e6</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.ccell.2019.07.007</pub-id>
</citation>
</ref>
<ref id="B131">
<label>131</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Boehm</surname> <given-names>T</given-names>
</name>
<name>
<surname>Foroni</surname> <given-names>L</given-names>
</name>
<name>
<surname>Kaneko</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Perutz</surname> <given-names>MF</given-names>
</name>
<name>
<surname>Rabbitts</surname> <given-names>TH</given-names>
</name>
</person-group>. <article-title>The rhombotin family of cysteine-rich LIM-domain oncogenes: distinct members are involved in T-cell translocations to human chromosomes 11p15 and 11p13</article-title>. <source>Proc Natl Acad Sci</source> (<year>1991</year>) <volume>88</volume>(<issue>10</issue>):<page-range>4367&#x2013;71</page-range>. doi: <pub-id pub-id-type="doi">10.1073/pnas.88.10.4367</pub-id>
</citation>
</ref>
<ref id="B132">
<label>132</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hirose</surname> <given-names>K</given-names>
</name>
<name>
<surname>Inukai</surname> <given-names>T</given-names>
</name>
<name>
<surname>Kikuchi</surname> <given-names>J</given-names>
</name>
<name>
<surname>Furukawa</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Ikawa</surname> <given-names>T</given-names>
</name>
<name>
<surname>Kawamoto</surname> <given-names>H</given-names>
</name>
<etal/>
</person-group>. <article-title>Aberrant induction of LMO2 by the E2A-HLF chimeric transcription factor and its implication in leukemogenesis of B-precursor ALL with t (17,19)</article-title>. <source>Blood</source> (<year>2010</year>) <volume>116</volume>(<issue>6</issue>):<page-range>962&#x2013;70</page-range>. doi: <pub-id pub-id-type="doi">10.1182/blood-2009-09-244673</pub-id>
</citation>
</ref>
<ref id="B133">
<label>133</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Horvat</surname> <given-names>L</given-names>
</name>
<name>
<surname>Antica</surname> <given-names>M</given-names>
</name>
<name>
<surname>Matuli&#x107;</surname> <given-names>M</given-names>
</name>
</person-group>. <article-title>Effect of notch and PARP pathways' Inhibition in leukemic cells</article-title>. <source>Cells</source> (<year>2018</year>) <volume>7</volume>(<issue>6</issue>):<fpage>58</fpage>. doi: <pub-id pub-id-type="doi">10.3390/cells7060058</pub-id>
</citation>
</ref>
<ref id="B134">
<label>134</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Caracciolo</surname> <given-names>D</given-names>
</name>
<name>
<surname>Scionti</surname> <given-names>F</given-names>
</name>
<name>
<surname>Juli</surname> <given-names>G</given-names>
</name>
<name>
<surname>Altomare</surname> <given-names>E</given-names>
</name>
<name>
<surname>Golino</surname> <given-names>G</given-names>
</name>
<name>
<surname>Todoerti</surname> <given-names>K</given-names>
</name>
<etal/>
</person-group>. <article-title>Exploiting MYC-induced PARPness to target genomic instability in multiple myeloma</article-title>. <source>Haematologica</source> (<year>2020</year>), <elocation-id>haematol.2019.240713</elocation-id>. doi: <pub-id pub-id-type="doi">10.3324/haematol.2019.240713</pub-id>
</citation>
</ref>
<ref id="B135">
<label>135</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pawlyn</surname> <given-names>C</given-names>
</name>
<name>
<surname>Loehr</surname> <given-names>A</given-names>
</name>
<name>
<surname>Ashby</surname> <given-names>C</given-names>
</name>
<name>
<surname>Tytarenko</surname> <given-names>R</given-names>
</name>
<name>
<surname>Deshpande</surname> <given-names>S</given-names>
</name>
<name>
<surname>Sun</surname> <given-names>J</given-names>
</name>
<etal/>
</person-group>. <article-title>Loss of heterozygosity as a marker of homologous repair deficiency in multiple myeloma: a role for PARP inhibition</article-title>? <source>Leukemia</source> (<year>2018</year>) <volume>32</volume>(<issue>7</issue>):<page-range>1561&#x2013;6</page-range>. doi: <pub-id pub-id-type="doi">10.1038/s41375-018-0017-0</pub-id>
</citation>
</ref>
<ref id="B136">
<label>136</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Neri</surname> <given-names>P</given-names>
</name>
<name>
<surname>Ren</surname> <given-names>L</given-names>
</name>
<name>
<surname>Gratton</surname> <given-names>K</given-names>
</name>
<name>
<surname>Stebner</surname> <given-names>E</given-names>
</name>
<name>
<surname>Johnson</surname> <given-names>J</given-names>
</name>
<name>
<surname>Klimowicz</surname> <given-names>A</given-names>
</name>
<etal/>
</person-group>. <article-title>Bortezomib-induced &#x201c;BRCAness&#x201d; sensitizes multiple myeloma cells to PARP inhibitors</article-title>. <source>Blood</source> (<year>2011</year>) <volume>118</volume>(<issue>24</issue>):<page-range>6368&#x2013;79</page-range>. doi: <pub-id pub-id-type="doi">10.1182/blood-2011-06-363911</pub-id>
</citation>
</ref>
<ref id="B137">
<label>137</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nong</surname> <given-names>L</given-names>
</name>
<name>
<surname>Mathews</surname> <given-names>L</given-names>
</name>
<name>
<surname>Meads</surname> <given-names>MB</given-names>
</name>
<name>
<surname>Dalton</surname> <given-names>W</given-names>
</name>
<name>
<surname>Shain</surname> <given-names>KH</given-names>
</name>
</person-group>. <article-title>Rational drug design: proteasome inhibitor mediated down-regulation of the FA/BRCA pathway is synergistic with PARP inhibition in myeloma cell lines</article-title>. <source>Blood</source> (<year>2011</year>) <volume>118</volume>(<issue>21</issue>):<page-range>2922&#x2013;</page-range>. doi: <pub-id pub-id-type="doi">10.1182/blood.V118.21.2922.2922</pub-id>
</citation>
</ref>
<ref id="B138">
<label>138</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xu</surname> <given-names>A</given-names>
</name>
<name>
<surname>Mazumder</surname> <given-names>A</given-names>
</name>
<name>
<surname>Borowiec</surname> <given-names>J</given-names>
</name>
</person-group>. <article-title>Cell line-dependent synergy between the PARP inhibitor veliparib and the proteasome inhibitor bortezomib in the killing of myeloma cells</article-title>. <source>Blood</source> (<year>2015</year>) <volume>126</volume>:<page-range>5556&#x2013;</page-range>. doi: <pub-id pub-id-type="doi">10.1182/blood.V126.23.5556.5556</pub-id>
</citation>
</ref>
<ref id="B139">
<label>139</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yarde</surname> <given-names>DN</given-names>
</name>
<name>
<surname>Oliveira</surname> <given-names>V</given-names>
</name>
<name>
<surname>Mathews</surname> <given-names>L</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>X</given-names>
</name>
<name>
<surname>Villagra</surname> <given-names>A</given-names>
</name>
<name>
<surname>Boulware</surname> <given-names>D</given-names>
</name>
<etal/>
</person-group>. <article-title>Targeting the fanconi anemia/BRCA pathway circumvents drug resistance in multiple myeloma</article-title>. <source>Cancer Res</source> (<year>2009</year>) <volume>69</volume>(<issue>24</issue>):<page-range>9367&#x2013;75</page-range>. doi: <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-09-2616</pub-id>
</citation>
</ref>
<ref id="B140">
<label>140</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xiong</surname> <given-names>T</given-names>
</name>
<name>
<surname>Wei</surname> <given-names>H</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>X</given-names>
</name>
<name>
<surname>Xiao</surname> <given-names>H</given-names>
</name>
</person-group>. <article-title>PJ34, a poly(ADP-ribose) polymerase (PARP) inhibitor, reverses melphalan-resistance and inhibits repair of DNA double-strand breaks by targeting the FA/BRCA pathway in multidrug resistant multiple myeloma cell line RPMI8226/R</article-title>. <source>Int J Oncol</source> (<year>2015</year>) <volume>46</volume>(<issue>1</issue>):<page-range>223&#x2013;32</page-range>. doi: <pub-id pub-id-type="doi">10.3892/ijo.2014.2726</pub-id>
</citation>
</ref>
<ref id="B141">
<label>141</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huang</surname> <given-names>H</given-names>
</name>
<name>
<surname>Cao</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Wei</surname> <given-names>W</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>W</given-names>
</name>
<name>
<surname>Lu</surname> <given-names>S-Y</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>Y-B</given-names>
</name>
<etal/>
</person-group>. <article-title>Targeting poly (ADP-ribose) polymerase partially contributes to bufalin-induced cell death in multiple myeloma cells</article-title>. <source>PloS One</source> (<year>2013</year>) <volume>8</volume>(<issue>6</issue>):<elocation-id>e66130</elocation-id>. doi: <pub-id pub-id-type="doi">10.1371/journal.pone.0066130</pub-id>
</citation>
</ref>
<ref id="B142">
<label>142</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xiong</surname> <given-names>T</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>X</given-names>
</name>
<name>
<surname>Wei</surname> <given-names>H</given-names>
</name>
<name>
<surname>Xiao</surname> <given-names>H</given-names>
</name>
</person-group>. <article-title>Influence of PJ34 on the genotoxicity induced by melphalan in human multiple myeloma cells</article-title>. <source>Arch Med Sci</source> (<year>2015</year>) <volume>11</volume>(<issue>2</issue>):<page-range>301&#x2013;6</page-range>. doi: <pub-id pub-id-type="doi">10.5114/aoms.2014.43164</pub-id>
</citation>
</ref>
<ref id="B143">
<label>143</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Patel</surname> <given-names>PR</given-names>
</name>
<name>
<surname>Oh</surname> <given-names>A</given-names>
</name>
<name>
<surname>Senyuk</surname> <given-names>V</given-names>
</name>
<name>
<surname>Mahmud</surname> <given-names>D</given-names>
</name>
<name>
<surname>Mahmud</surname> <given-names>N</given-names>
</name>
<name>
<surname>Rondelli</surname> <given-names>D</given-names>
</name>
</person-group>. <article-title>Inhibition of PARP and DNA-PK lead to synergistic cytotoxicity with melphalan in multiple myeloma</article-title>. <source>Biol Blood Marrow Transplant</source> (<year>2017</year>) <volume>23</volume>(<issue>3</issue>):<fpage>S269</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.bbmt.2016.12.434</pub-id>
</citation>
</ref>
<ref id="B144">
<label>144</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Alagpulinsa</surname> <given-names>DA</given-names>
</name>
<name>
<surname>Ayyadevara</surname> <given-names>S</given-names>
</name>
<name>
<surname>Yaccoby</surname> <given-names>S</given-names>
</name>
<name>
<surname>Shmookler Reis</surname> <given-names>RJ</given-names>
</name>
</person-group>. <article-title>A cyclin-dependent kinase inhibitor, dinaciclib, impairs homologous recombination and sensitizes multiple myeloma cells to PARP inhibition</article-title>. <source>Mol Cancer Ther</source> (<year>2016</year>) <volume>15</volume>(<issue>2</issue>):<page-range>241&#x2013;50</page-range>. doi: <pub-id pub-id-type="doi">10.1158/1535-7163.MCT-15-0660</pub-id>
</citation>
</ref>
<ref id="B145">
<label>145</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kumar</surname> <given-names>SK</given-names>
</name>
<name>
<surname>LaPlant</surname> <given-names>B</given-names>
</name>
<name>
<surname>Chng</surname> <given-names>WJ</given-names>
</name>
<name>
<surname>Zonder</surname> <given-names>J</given-names>
</name>
<name>
<surname>Callander</surname> <given-names>N</given-names>
</name>
<name>
<surname>Fonseca</surname> <given-names>R</given-names>
</name>
<etal/>
</person-group>. <article-title>Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma</article-title>. <source>Blood</source> (<year>2015</year>) <volume>125</volume>(<issue>3</issue>):<page-range>443&#x2013;8</page-range>. doi: <pub-id pub-id-type="doi">10.1182/blood-2014-05-573741</pub-id>
</citation>
</ref>
<ref id="B146">
<label>146</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Radhakrishnan</surname> <given-names>SK</given-names>
</name>
<name>
<surname>Bebb</surname> <given-names>DG</given-names>
</name>
<name>
<surname>Lees-Miller</surname> <given-names>SP</given-names>
</name>
</person-group>. <article-title>Targeting ataxia-telangiectasia mutated deficient Malignancies with poly ADP ribose polymerase inhibitors</article-title>. <source>Trans Cancer Res</source> (<year>2013</year>) <volume>2</volume>(<issue>3</issue>):<page-range>155&#x2013;62</page-range>.</citation>
</ref>
<ref id="B147">
<label>147</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Weston</surname> <given-names>VJ</given-names>
</name>
<name>
<surname>Oldreive</surname> <given-names>CE</given-names>
</name>
<name>
<surname>Skowronska</surname> <given-names>A</given-names>
</name>
<name>
<surname>Oscier</surname> <given-names>DG</given-names>
</name>
<name>
<surname>Pratt</surname> <given-names>G</given-names>
</name>
<name>
<surname>Dyer</surname> <given-names>MJ</given-names>
</name>
<etal/>
</person-group>. <article-title>The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in <italic>vitro</italic> and <italic>in vivo</italic>
</article-title>. <source>Blood</source> (<year>2010</year>) <volume>116</volume>(<issue>22</issue>):<page-range>4578&#x2013;87</page-range>. doi: <pub-id pub-id-type="doi">10.1182/blood-2010-01-265769</pub-id>
</citation>
</ref>
<ref id="B148">
<label>148</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Knittel</surname> <given-names>G</given-names>
</name>
<name>
<surname>Rehk&#xe4;mper</surname> <given-names>T</given-names>
</name>
<name>
<surname>Korovkina</surname> <given-names>D</given-names>
</name>
<name>
<surname>Liedgens</surname> <given-names>P</given-names>
</name>
<name>
<surname>Fritz</surname> <given-names>C</given-names>
</name>
<name>
<surname>Torgovnick</surname> <given-names>A</given-names>
</name>
<etal/>
</person-group>. <article-title>Two mouse models reveal an actionable PARP1 dependence in aggressive chronic lymphocytic leukemia</article-title>. <source>Nat Commun</source> (<year>2017</year>) <volume>8</volume>(<issue>1</issue>):<fpage>153</fpage>.</citation>
</ref>
<ref id="B149">
<label>149</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Herriott</surname> <given-names>A</given-names>
</name>
<name>
<surname>Tudhope</surname> <given-names>SJ</given-names>
</name>
<name>
<surname>Junge</surname> <given-names>G</given-names>
</name>
<name>
<surname>Rodrigues</surname> <given-names>N</given-names>
</name>
<name>
<surname>Patterson</surname> <given-names>MJ</given-names>
</name>
<name>
<surname>Woodhouse</surname> <given-names>L</given-names>
</name>
<etal/>
</person-group>. <article-title>PARP1 expression, activity and ex vivo sensitivity to the PARP inhibitor, talazoparib (BMN 673), in chronic lymphocytic leukaemia</article-title>. <source>Oncotarget</source> (<year>2015</year>) <volume>6</volume>(<issue>41</issue>). doi: <pub-id pub-id-type="doi">10.18632/oncotarget.6287</pub-id>
</citation>
</ref>
<ref id="B150">
<label>150</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Williamson</surname> <given-names>CT</given-names>
</name>
<name>
<surname>Muzik</surname> <given-names>H</given-names>
</name>
<name>
<surname>Turhan</surname> <given-names>AG</given-names>
</name>
<name>
<surname>Zam&#xf2;</surname> <given-names>A</given-names>
</name>
<name>
<surname>O'Connor</surname> <given-names>MJ</given-names>
</name>
<name>
<surname>Bebb</surname> <given-names>DG</given-names>
</name>
<etal/>
</person-group>. <article-title>ATM deficiency sensitizes mantle cell lymphoma cells to poly(ADP-ribose) polymerase-1 inhibitors</article-title>. <source>Mol Cancer Ther</source> (<year>2010</year>) <volume>9</volume>(<issue>2</issue>):<page-range>347&#x2013;57</page-range>. doi: <pub-id pub-id-type="doi">10.1158/1535-7163.MCT-09-0872</pub-id>
</citation>
</ref>
<ref id="B151">
<label>151</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Williamson</surname> <given-names>C</given-names>
</name>
<name>
<surname>Kubota</surname> <given-names>E</given-names>
</name>
<name>
<surname>Hamill</surname> <given-names>J</given-names>
</name>
<name>
<surname>Klimowicz</surname> <given-names>A</given-names>
</name>
<name>
<surname>Ye</surname> <given-names>R</given-names>
</name>
<name>
<surname>Muzik</surname> <given-names>H</given-names>
</name>
<etal/>
</person-group>. <article-title>Enhanced cytotoxicity of PARP inhibition in mantle cell lymphoma harbouring mutations in both ATM and p53</article-title>. <source>EMBO Mol Med</source> (<year>2012</year>) <volume>4</volume>:<page-range>515&#x2013;27</page-range>. doi: <pub-id pub-id-type="doi">10.1002/emmm.201200229</pub-id>
</citation>
</ref>
<ref id="B152">
<label>152</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rule</surname> <given-names>S</given-names>
</name>
</person-group>. <article-title>The modern approach to mantle cell lymphoma</article-title>. <source>Hematol Oncol</source> (<year>2019</year>) <volume>37</volume>(<issue>S1</issue>):<page-range>66&#x2013;9</page-range>. doi: <pub-id pub-id-type="doi">10.1002/hon.2596</pub-id>
</citation>
</ref>
<ref id="B153">
<label>153</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Curtis</surname> <given-names>A</given-names>
</name>
<name>
<surname>Rueter</surname> <given-names>J</given-names>
</name>
<name>
<surname>Rajan</surname> <given-names>S</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>R</given-names>
</name>
<name>
<surname>Shopland</surname> <given-names>L</given-names>
</name>
</person-group>. <article-title>Additive and synergistic inhibition of mantle cell lymphoma cell growth by combining olaparib with ibrutinib</article-title>. <source>J Cell Biochem</source> (<year>2018</year>) <volume>119</volume>(<issue>7</issue>):<page-range>5843&#x2013;51</page-range>. doi: <pub-id pub-id-type="doi">10.1002/jcb.26773</pub-id>
</citation>
</ref>
<ref id="B154">
<label>154</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>de Jong</surname> <given-names>MRW</given-names>
</name>
<name>
<surname>Visser</surname> <given-names>L</given-names>
</name>
<name>
<surname>Huls</surname> <given-names>G</given-names>
</name>
<name>
<surname>Diepstra</surname> <given-names>A</given-names>
</name>
<name>
<surname>van Vugt</surname> <given-names>M</given-names>
</name>
<name>
<surname>Ammatuna</surname> <given-names>E</given-names>
</name>
<etal/>
</person-group>. <article-title>Identification of relevant drugable targets in diffuse large B-cell lymphoma using a genome-wide unbiased CD20 guilt-by association approach</article-title>. <source>PloS One</source> (<year>2018</year>) <volume>13</volume>(<issue>2</issue>):<elocation-id>e0193098</elocation-id>. doi: <pub-id pub-id-type="doi">10.1371/journal.pone.0193098</pub-id>
</citation>
</ref>
<ref id="B155">
<label>155</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Alizadeh</surname> <given-names>AA</given-names>
</name>
<name>
<surname>Gentles</surname> <given-names>AJ</given-names>
</name>
<name>
<surname>Lossos</surname> <given-names>IS</given-names>
</name>
<name>
<surname>Levy</surname> <given-names>R</given-names>
</name>
</person-group>. <article-title>Molecular outcome prediction in diffuse large-B-cell lymphoma</article-title>. <source>N Engl J Med</source> (<year>2009</year>) <volume>360</volume>(<issue>26</issue>):<page-range>2794&#x2013;5</page-range>. doi: <pub-id pub-id-type="doi">10.1056/NEJMc0902616</pub-id>
</citation>
</ref>
<ref id="B156">
<label>156</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nieto</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Popat</surname> <given-names>U</given-names>
</name>
<name>
<surname>Anderlini</surname> <given-names>P</given-names>
</name>
<name>
<surname>Valdez</surname> <given-names>B</given-names>
</name>
<name>
<surname>Andersson</surname> <given-names>B</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>P</given-names>
</name>
<etal/>
</person-group>. <article-title>Autologous stem cell transplantation for refractory or poor-risk relapsed Hodgkin's lymphoma: effect of the specific high-dose chemotherapy regimen on outcome</article-title>. <source>Biol Blood marrow Transplant</source> (<year>2013</year>) <volume>19</volume>(<issue>3</issue>):<page-range>410&#x2013;7</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.bbmt.2012.10.029</pub-id>
</citation>
</ref>
<ref id="B157">
<label>157</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Valdez</surname> <given-names>BC</given-names>
</name>
<name>
<surname>Li</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Murray</surname> <given-names>D</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Nieto</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Champlin</surname> <given-names>RE</given-names>
</name>
<etal/>
</person-group>. <article-title>The PARP inhibitor olaparib enhances the cytotoxicity of combined gemcitabine, busulfan and melphalan in lymphoma cells</article-title>. <source>Leuk Lymphoma</source> (<year>2017</year>) <volume>58</volume>(<issue>11</issue>):<page-range>2705&#x2013;16</page-range>. doi: <pub-id pub-id-type="doi">10.1080/10428194.2017.1306647</pub-id>
</citation>
</ref>
<ref id="B158">
<label>158</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>van Bussel</surname> <given-names>MTJ</given-names>
</name>
<name>
<surname>Awada</surname> <given-names>A</given-names>
</name>
<name>
<surname>de Jonge</surname> <given-names>MJA</given-names>
</name>
<name>
<surname>Mau-S&#xf8;rensen</surname> <given-names>M</given-names>
</name>
<name>
<surname>Nielsen</surname> <given-names>D</given-names>
</name>
<name>
<surname>Sch&#xf6;ffski</surname> <given-names>P</given-names>
</name>
<etal/>
</person-group>. <article-title>A first-in-man phase 1 study of the DNA-dependent protein kinase inhibitor peposertib (formerly M3814) in patients with advanced solid tumours</article-title>. <source>Br J Cancer</source> (<year>2021</year>) <volume>124</volume>(<issue>4</issue>):<page-range>728&#x2013;35</page-range>. doi: <pub-id pub-id-type="doi">10.1038/s41416-020-01151-6</pub-id>
</citation>
</ref>
<ref id="B159">
<label>159</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Webster</surname> <given-names>JA</given-names>
</name>
<name>
<surname>Tibes</surname> <given-names>R</given-names>
</name>
<name>
<surname>Morris</surname> <given-names>L</given-names>
</name>
<name>
<surname>Blackford</surname> <given-names>AL</given-names>
</name>
<name>
<surname>Litzow</surname> <given-names>M</given-names>
</name>
<name>
<surname>Patnaik</surname> <given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>Randomized phase II trial of cytosine arabinoside with and without the CHK1 inhibitor MK-8776 in relapsed and refractory acute myeloid leukemia</article-title>. <source>Leukemia Res</source> (<year>2017</year>) <volume>61</volume>:<page-range>108&#x2013;16</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.leukres.2017.09.005</pub-id>
</citation>
</ref>
<ref id="B160">
<label>160</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gopal</surname> <given-names>AK</given-names>
</name>
<name>
<surname>Popat</surname> <given-names>R</given-names>
</name>
<name>
<surname>Mattison</surname> <given-names>RJ</given-names>
</name>
<name>
<surname>Menne</surname> <given-names>T</given-names>
</name>
<name>
<surname>Bloor</surname> <given-names>A</given-names>
</name>
<name>
<surname>Gaymes</surname> <given-names>T</given-names>
</name>
<etal/>
</person-group>. <article-title>A Phase I trial of talazoparib in patients with advanced hematologic Malignancies</article-title>. <source>Int J Hematol Oncol</source> (<year>2021</year>) <volume>10</volume>(<issue>3</issue>):<fpage>Ijh35</fpage>.</citation>
</ref>
<ref id="B161">
<label>161</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Neri</surname> <given-names>P</given-names>
</name>
<name>
<surname>Duggan</surname> <given-names>P</given-names>
</name>
<name>
<surname>Gratton</surname> <given-names>K</given-names>
</name>
<name>
<surname>Ren</surname> <given-names>L</given-names>
</name>
<name>
<surname>Johnson</surname> <given-names>J</given-names>
</name>
<name>
<surname>Slaby</surname> <given-names>J</given-names>
</name>
<etal/>
</person-group>. <article-title>Phase I study of the PARP1-2 inhibitor veliparib in combination with bortezomib in patients with relapsed or refractory multiple myeloma</article-title>. <source>Blood</source> (<year>2012</year>) <volume>120</volume>:<page-range>1862&#x2013;</page-range>. doi: <pub-id pub-id-type="doi">10.1182/blood.V120.21.1862.1862</pub-id>
</citation>
</ref>
<ref id="B162">
<label>162</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kummar</surname> <given-names>S</given-names>
</name>
<name>
<surname>Kinders</surname> <given-names>R</given-names>
</name>
<name>
<surname>Gutierrez</surname> <given-names>ME</given-names>
</name>
<name>
<surname>Rubinstein</surname> <given-names>L</given-names>
</name>
<name>
<surname>Parchment</surname> <given-names>RE</given-names>
</name>
<name>
<surname>Phillips</surname> <given-names>LR</given-names>
</name>
<etal/>
</person-group>. <article-title>Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced Malignancies</article-title>. <source>J Clin Oncol</source> (<year>2009</year>) <volume>27</volume>(<issue>16</issue>):<page-range>2705&#x2013;11</page-range>. doi: <pub-id pub-id-type="doi">10.1200/JCO.2008.19.7681</pub-id>
</citation>
</ref>
<ref id="B163">
<label>163</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kummar</surname> <given-names>S</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>A</given-names>
</name>
<name>
<surname>Ji</surname> <given-names>J</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Reid</surname> <given-names>JM</given-names>
</name>
<name>
<surname>Ames</surname> <given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas</article-title>. <source>Cancer Res</source> (<year>2011</year>) <volume>71</volume>(<issue>17</issue>):<page-range>5626&#x2013;34</page-range>. doi: <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-11-1227</pub-id>
</citation>
</ref>
<ref id="B164">
<label>164</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Soumerai</surname> <given-names>JD</given-names>
</name>
<name>
<surname>Zelenetz</surname> <given-names>AD</given-names>
</name>
<name>
<surname>Moskowitz</surname> <given-names>CH</given-names>
</name>
<name>
<surname>Palomba</surname> <given-names>ML</given-names>
</name>
<name>
<surname>Hamlin</surname> <given-names>PA</given-names>
</name>
<name>
<surname>Noy</surname> <given-names>A</given-names>
</name>
<etal/>
</person-group>. <article-title>The PARP inhibitor veliparib can be safely added to bendamustine and rituximab and has preliminary evidence of activity in B-cell lymphoma</article-title>. <source>Clin Cancer Res</source> (<year>2017</year>) <volume>23</volume>(<issue>15</issue>):<page-range>4119&#x2013;26</page-range>. doi: <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-16-3068</pub-id>
</citation>
</ref>
<ref id="B165">
<label>165</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yap</surname> <given-names>TA</given-names>
</name>
<name>
<surname>Plummer</surname> <given-names>R</given-names>
</name>
<name>
<surname>Azad</surname> <given-names>NS</given-names>
</name>
<name>
<surname>Helleday</surname> <given-names>T</given-names>
</name>
</person-group>. <article-title>The DNA damaging revolution: PARP inhibitors and beyond</article-title>. <source>Am Soc Clin Oncol Educ Book</source> (<year>2019</year>) <volume>39)</volume>:<page-range>185&#x2013;95</page-range>. doi: <pub-id pub-id-type="doi">10.1200/EDBK_238473</pub-id>
</citation>
</ref>
<ref id="B166">
<label>166</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kummar</surname> <given-names>S</given-names>
</name>
<name>
<surname>Ji</surname> <given-names>J</given-names>
</name>
<name>
<surname>Morgan</surname> <given-names>R</given-names>
</name>
<name>
<surname>Lenz</surname> <given-names>H-J</given-names>
</name>
<name>
<surname>Puhalla</surname> <given-names>SL</given-names>
</name>
<name>
<surname>Belani</surname> <given-names>CP</given-names>
</name>
<etal/>
</person-group>. <article-title>A phase I study of veliparib in combination with metronomic cyclophosphamide in adults with refractory solid tumors and lymphomas</article-title>. <source>Clin Cancer Res</source> (<year>2012</year>) <volume>18</volume>(<issue>6</issue>):<page-range>1726&#x2013;34</page-range>. doi: <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-11-2821</pub-id>
</citation>
</ref>
<ref id="B167">
<label>167</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pratt</surname> <given-names>G</given-names>
</name>
<name>
<surname>Yap</surname> <given-names>C</given-names>
</name>
<name>
<surname>Oldreive</surname> <given-names>C</given-names>
</name>
<name>
<surname>Slade</surname> <given-names>D</given-names>
</name>
<name>
<surname>Bishop</surname> <given-names>R</given-names>
</name>
<name>
<surname>Griffiths</surname> <given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>A multi-centre phase I trial of the PARP inhibitor olaparib in patients with relapsed chronic lymphocytic leukaemia, T-prolymphocytic leukaemia or mantle cell lymphoma</article-title>. <source>Br J haematol</source> (<year>2018</year>) <volume>182</volume>(<issue>3</issue>):<page-range>429&#x2013;33</page-range>. doi: <pub-id pub-id-type="doi">10.1111/bjh.14793</pub-id>
</citation>
</ref>
<ref id="B168">
<label>168</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hills</surname> <given-names>RK</given-names>
</name>
<name>
<surname>Castaigne</surname> <given-names>S</given-names>
</name>
<name>
<surname>Appelbaum</surname> <given-names>FR</given-names>
</name>
<name>
<surname>Delaunay</surname> <given-names>J</given-names>
</name>
<name>
<surname>Petersdorf</surname> <given-names>S</given-names>
</name>
<name>
<surname>Othus</surname> <given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials</article-title>. <source>Lancet Oncol</source> (<year>2014</year>) <volume>15</volume>(<issue>9</issue>):<page-range>986&#x2013;96</page-range>. doi: <pub-id pub-id-type="doi">10.1016/S1470-2045(14)70281-5</pub-id>
</citation>
</ref>
<ref id="B169">
<label>169</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Karp</surname> <given-names>JE</given-names>
</name>
<name>
<surname>Thomas</surname> <given-names>BM</given-names>
</name>
<name>
<surname>Greer</surname> <given-names>JM</given-names>
</name>
<name>
<surname>Sorge</surname> <given-names>C</given-names>
</name>
<name>
<surname>Gore</surname> <given-names>SD</given-names>
</name>
<name>
<surname>Pratz</surname> <given-names>KW</given-names>
</name>
<etal/>
</person-group>. <article-title>Phase I and pharmacologic trial of cytosine arabinoside with the selective checkpoint 1 inhibitor sch 900776 in refractory acute leukemias</article-title>. <source>Clin Cancer Res</source> (<year>2012</year>) <volume>18</volume>(<issue>24</issue>):<page-range>6723&#x2013;31</page-range>. doi: <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-12-2442</pub-id>
</citation>
</ref>
<ref id="B170">
<label>170</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Munster</surname> <given-names>P</given-names>
</name>
<name>
<surname>Mita</surname> <given-names>M</given-names>
</name>
<name>
<surname>Mahipal</surname> <given-names>A</given-names>
</name>
<name>
<surname>Nemunaitis</surname> <given-names>J</given-names>
</name>
<name>
<surname>Massard</surname> <given-names>C</given-names>
</name>
<name>
<surname>Mikkelsen</surname> <given-names>T</given-names>
</name>
<etal/>
</person-group>. <article-title>First-in-human phase I study of A dual mTOR kinase and DNA-PK inhibitor (CC-115) in advanced Malignancy</article-title>. <source>Cancer Manage Res</source> (<year>2019</year>) <volume>11</volume>:<page-range>10463&#x2013;76</page-range>. doi: <pub-id pub-id-type="doi">10.2147/CMAR.S208720</pub-id>
</citation>
</ref>
<ref id="B171">
<label>171</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ruhe</surname> <given-names>M</given-names>
</name>
<name>
<surname>Rabe</surname> <given-names>D</given-names>
</name>
<name>
<surname>Jurischka</surname> <given-names>C</given-names>
</name>
<name>
<surname>Schr&#xf6;der</surname> <given-names>J</given-names>
</name>
<name>
<surname>Schierack</surname> <given-names>P</given-names>
</name>
<name>
<surname>Deckert</surname> <given-names>PM</given-names>
</name>
<etal/>
</person-group>. <article-title>Molecular biomarkers of DNA damage in diffuse large-cell lymphoma&#x2014;a review</article-title>. <source>J Lab Precis Med</source> (<year>2019</year>) <volume>4</volume>. doi: <pub-id pub-id-type="doi">10.21037/jlpm.2019.01.01</pub-id>
</citation>
</ref>
<ref id="B172">
<label>172</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sundar</surname> <given-names>R</given-names>
</name>
<name>
<surname>Brown</surname> <given-names>J</given-names>
</name>
<name>
<surname>Ingles Russo</surname> <given-names>A</given-names>
</name>
<name>
<surname>Yap</surname> <given-names>TA</given-names>
</name>
</person-group>. <article-title>Targeting ATR in cancer medicine</article-title>. <source>Curr problems cancer</source> (<year>2017</year>) <volume>41</volume>(<issue>4</issue>):<page-range>302&#x2013;15</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.currproblcancer.2017.05.002</pub-id>
</citation>
</ref>
<ref id="B173">
<label>173</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>de Mel</surname> <given-names>S</given-names>
</name>
<name>
<surname>Rashid</surname> <given-names>MBM</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>XY</given-names>
</name>
<name>
<surname>Goh</surname> <given-names>J</given-names>
</name>
<name>
<surname>Lee</surname> <given-names>CT</given-names>
</name>
<name>
<surname>Poon</surname> <given-names>LM</given-names>
</name>
<etal/>
</person-group>. <article-title>Application of an ex-vivo drug sensitivity platform towards achieving complete remission in a refractory T-cell lymphoma</article-title>. <source>Blood Cancer J</source> (<year>2020</year>) <volume>10</volume>(<issue>1</issue>):<fpage>9</fpage>. doi: <pub-id pub-id-type="doi">10.1038/s41408-020-0276-7</pub-id>
</citation>
</ref>
<ref id="B174">
<label>174</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rashid</surname> <given-names>M</given-names>
</name>
<name>
<surname>Toh</surname> <given-names>TB</given-names>
</name>
<name>
<surname>Hooi</surname> <given-names>L</given-names>
</name>
<name>
<surname>Silva</surname> <given-names>A</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Tan</surname> <given-names>PF</given-names>
</name>
<etal/>
</person-group>. <article-title>Optimizing drug combinations against multiple myeloma using a quadratic phenotypic optimization platform (QPOP)</article-title>. <source>Sci Trans Med</source> (<year>2018</year>) <volume>10</volume>(<issue>453</issue>). doi: <pub-id pub-id-type="doi">10.1126/scitranslmed.aan0941</pub-id>
</citation>
</ref>
<ref id="B175">
<label>175</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Goh</surname> <given-names>J</given-names>
</name>
<name>
<surname>De Mel</surname> <given-names>S</given-names>
</name>
<name>
<surname>Hoppe</surname> <given-names>MM</given-names>
</name>
<name>
<surname>Mohd Abdul Rashid</surname> <given-names>MB</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>XY</given-names>
</name>
<name>
<surname>Jaynes</surname> <given-names>P</given-names>
</name>
<etal/>
</person-group>. <article-title>An ex vivo platform to guide drug combination treatment in relapsed/refractory lymphoma</article-title>. <source>Sci Trans Med</source> (<year>2022</year>) <volume>14</volume>(<issue>667</issue>):<elocation-id>eabn7824</elocation-id>. doi: <pub-id pub-id-type="doi">10.1126/scitranslmed.abn7824</pub-id>
</citation>
</ref>
<ref id="B176">
<label>176</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kawano</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Moschetta</surname> <given-names>M</given-names>
</name>
<name>
<surname>Manier</surname> <given-names>S</given-names>
</name>
<name>
<surname>Glavey</surname> <given-names>S</given-names>
</name>
<name>
<surname>G&#xf6;rg&#xfc;n</surname> <given-names>GT</given-names>
</name>
<name>
<surname>Roccaro</surname> <given-names>AM</given-names>
</name>
<etal/>
</person-group>. <article-title>Targeting the bone marrow microenvironment in multiple myeloma</article-title>. <source>Immunol Rev</source> (<year>2015</year>) <volume>263</volume>(<issue>1</issue>):<page-range>160&#x2013;72</page-range>. doi: <pub-id pub-id-type="doi">10.1111/imr.12233</pub-id>
</citation>
</ref>
<ref id="B177">
<label>177</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname> <given-names>A</given-names>
</name>
<name>
<surname>Yi</surname> <given-names>M</given-names>
</name>
<name>
<surname>Qin</surname> <given-names>S</given-names>
</name>
<name>
<surname>Chu</surname> <given-names>Q</given-names>
</name>
<name>
<surname>Luo</surname> <given-names>S</given-names>
</name>
<name>
<surname>Wu</surname> <given-names>K</given-names>
</name>
</person-group>. <article-title>Prospects for combining immune checkpoint blockade with PARP inhibition</article-title>. <source>J Hematol Oncol</source> (<year>2019</year>) <volume>12</volume>(<issue>1</issue>):<fpage>98</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s13045-019-0784-8</pub-id>
</citation>
</ref>
</ref-list>
</back>
</article>